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MULTIPLE SCLEROSIS AND CIS
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS), in most cases characterized by relapses of neurological dysfunction and accumu-
lation of disability.1 
More than 150 years ago, Carswell, Cruveilhier and Charcot already described the patho-
logical and clinical features of MS.2 Yet, the exact cause of MS is still unrevealed. 
The disease mostly affects young women, 70% of patients have an age of onset between 
20-40 years.3 MS also occurs in children,4 around 3-5% of MS patients have the first 
attack during childhood.4, 5
The first generally recognized criteria for MS were established in 1954 by Allison and 
Millar.6, 7 Ten years later, Schumacher described the ‘clinically definite’ form of MS 
(CDMS), defined as: clinical evidence of demyelination in two different neurological 
localizations at two different time points.8 After the Schumacher criteria, several 
revisions were proposed.7 When using pathologically confirmed cases, the criteria for 
CDMS proposed by Poser et al in 1983 are shown to be the most sensitive.9, 10 Currently, 
the McDonald 2017 criteria are used to diagnose MS. However, the Poser criteria for 
CDMS are still often used in MS research as study endpoint.
The first manifestation of MS is called a clinically isolated syndrome (CIS), a subacute epi-
sode of focal neurological symptoms resulting from inflammatory demyelination of the 
optic nerve, spinal cord, cerebrum, cerebellum or brain stem.3 The disease course after CIS 
is highly heterogeneous, most patients will have subsequent relapses after this first mani-
festation (relapsing remitting MS (RRMS)), however, one third will remain monophasic.11 
Figure 1.  Disease course for the majority of RRMS patients. 
The first attack of demyelination (CIS) is followed by a relapsing disease course (RRMS), followed by the progressive 
phase of the disease (SPMS) (Reference: Fox RJ and Cohen JA, Cleve Clin J of Med 2001; 68: 157-171) 
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The majority of RRMS patients will reach a progressive phase of MS; secondary progressive 
MS (SPMS), characterized by irreversible disability progression that is independent of 
relapses. 12 In this progressive phase, neurodegeneration is more prominent. The transition 
from RRMS to SPMS usually occurs after approximately 20 years of disease duration.13
In ten to fifteen percent of patients, MS starts with a progressive onset and no relapses, 
these patients have primary progressive MS (PPMS). This thesis focusses on the early 
presentation of relapse-onset MS. Therefore PPMS is not discussed in this thesis. Figure 1 
shows the clinical course, MRI activity and disease burden in RRMS patients. 
There is a growing number of disease-modifying therapies (DMT) available that can be 
administered after the first manifestation of MS (CIS), in patients with a high risk of 
future disease activity. These therapies are immunomodulatory and taken early in the 
disease course, delay a second relapse and have a potential to prevent future disability.3, 14-18 
Unfortunately, these therapies do have serious adverse effects.19-21 To prevent unneces-
sary treatment of patients with a benign disease course, it is important to identify these 
patients early. Markers for disease stratification, predicting long-term prognosis and 
predicting treatment response are crucial to provide more individualized care.22 
Apart from the important role of risk stratification in the choice for early treatment in 
patients with a future active disease course, prognostic factors are also essential when 
counselling patients about the prognosis of this life-changing heterogeneous disease. 
CURRENT DIAGNOSTIC TOOLS
In clinical practice, magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) 
analyses are routinely used to estimate the risk for MS.
Magnetic resonance imaging (MRI)
MRI of the brain and spinal cord is the most important tool in the diagnostic work-up 
in patients with a suspicion of CIS and MS. For MS diagnosis two conditions should be 
present, the first is dissemination in space (DIS), and the second is dissemination in 
time (DIT). The goal of the use of MRI is not only to demonstrate DIS and DIT but also 
to exclude alternative diagnoses.23 MS lesions are typically visible on MRI in the white 
matter: periventricular, juxtacortical, infratentorial, and in the spinal cord, these lesions 
are hyper intense on T2-weighted MRI sequences and characteristically ovoid shaped.24 
Figure 2 shows the typical localizations for MS lesions.
The long-term risk for CDMS when T2 lesions are present on MRI at time of the first 
attack is 60-80%. When these lesions are absent, this risk is 20-25%.11, 25 Both localization 
and number of lesions affect the risk of MS. Patients with T2 lesions in the brainstem 
have a higher MS risk than patients with only supratentorial lesions.26 Also lesions in 
the corpus callosum predict CDMS diagnosis in patients with CIS.27
Some studies have shown that not only white matter lesions but also grey matter atrophy 
and brain volume loss, which are signs of axonal loss, were predictive for MS diagnosis.28, 29 
However, another recent study did not find an association between brain volume loss and 
the risk of CDMS in CIS patients.30 
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Figure 2.  Typical MS lesions on brain MRI: A periventricular, B juxtacortical, C infratentorial, D spinal cord
T1-hypointense lesions, which is another sign of axonal loss, are highly predictive for 
CDMS diagnosis in children with CIS,31 but in adults the predictive value is low.32 
Figure 3a shows examples of T1-hypointense lesions. 
Figure 3. a  T1-hypointense lesions       b  gadolinium enhancing lesion on brain MRI
McDonald criteria
The first MRI criteria for MS, established in 2001, were the first version of the McDonald 
criteria.33 In the following years multiple updates of these criteria are introduced.34-36 The 
criteria are simplified and according to the update in 2010, MS could even be diagnosed 
at time of CIS when asymptomatic contrast enhancing lesions were seen simultaneously 
with non-enhancing lesions (DIT).35 Figure 3b shows a contrast enhancing lesion on 
brain MRI. The criteria for DIS could be fulfilled when the MRI scan shows at least one 
clinically silent lesion in two separate characteristic localizations of demyelination. 
The latest revisions to the McDonald criteria were proposed in 2017. These new criteria 
allow an MS diagnosis when the MRI meets the criteria for DIS and unique oligoclonal 
bands (OCB) are present in CSF, even when there is no evidence of DIT on the MRI scan. 
Furthermore, not only asymptomatic lesions but also symptomatic lesions can be used to 
A B C D
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demonstrate DIS and DIT on MRI.36 An important note comes with these criteria: they can 
be applied only when the clinical features are characteristic of MS and other diagnoses 
are excluded. The MRI scan of patients with other disorders, for example neuromyelitis 
optica, neurosarcoidosis or CNS lymphoma, can mimic the MRI features used in the MS 
criteria.3 Table 1 shows the McDonald 2017 criteria for MS. These newly proposed criteria 
are validated in this thesis.
In some cases white matter abnormalities fulfilling the MRI criteria for MS are found as a 
random finding in people without typical MS symptoms. This is called radiologically isolated 
syndrome (RIS).37, 38 Multiple studies have shown that these people have a chance of 30-40% 
during a follow-up time of 2-5 years to experience a clinical attack, and therefore be diag-
nosed with MS.37, 39, 40 Hence, this RIS patient group could be considered as at high risk for MS. 
McDonald 2017
DIS a) Objective clinical evidence of ≥2 lesions, or objective clinical evidence of 
 1 lesion with reasonable historical evidence of a prior attack involving a 
 different CNS site
b) MRI: ≥1 T2 lesions in at least 2 of 4 MS-typical regions of the CNS: 
 Periventricular, (Juxta)cortical, Infratentorial, Spinal cord
DIT a) ≥2 attacks separated by a period of at least month
b) MRI: Simultaneous presence of gadolinium-enhancing and non-enhancing lesions at 
any time
c) MRI: A new T2 and/or gadolinium-enhancing lesion on follow-up MRI, 
 irrespective of its timing with reference to a baseline scan
d) Demonstration of CSF-specific OCBs (as substitute for demonstration of DIT)
Table 1.  Overview of diagnostic criteria (2017) for DIS and DIT, based on the 2017 revisions to the McDonald crite-
ria.36 MS diagnosis is met when fulfilling DIS criteria (by fulfilling a or b) and DIT criteria (by fulfilling a, b, c or d).
Abbreviations: CNS, central nervous system; CSF, cerebrospinal fluid; OCB, oligoclonal bands
Cerebrospinal fluid 
Unique oligoclonal bands in CSF are a sign of a chronic humoral immune reaction in the 
CNS.41 There is a variety of methods to establish OCBs, but a worldwide consensus is to 
use isoelectric focussing as the correct and standard method to determine OCBs.42 
Oligoclonal bands are not only found in MS. Processes triggering a B-cell response in 
other neuroimmunological ailments such as neurosarcoidosis, SLE or Behcet’s disease 
may also lead to unique OCBs in CSF.41 However, the negative predictive value of OCB for 
MS diagnosis is high, around 90% of patients with MS do have OCBs in CSF.41, 43
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Multiple studies have shown that OCB positivity in CIS patients predicts CDMS diagnosis 
and disability,43 even when corrected for MRI measurements.14, 44, 45 In patients with no T2 
lesions on MRI, it is shown that presence of OCB increases the risk for CDMS from 4 to 
23%.46 An other study showed that 50% of MS patients who were initially negative for 
OCB converted to positive OCB during follow-up.47 A large study in CIS patients found 
that the specificity of the 2010 DIS criteria increased from 81% to 88% when adding OCB 
to the criteria.48 These results imply that MRI and OCB do complement each other.49  
This is the reason why OCB in CSF are included in the most recent criteria for MS.36 When 
OCB are not present in CSF the diagnosis MS should be critically reconsidered. 
Visual evoked potentials (VEP)
Visual evoked potentials are used to identify dysfunction of the optic nerve. VEP did 
not or only moderately improve diagnostic accuracy for MS diagnosis.50-52 Therefore the 
diagnostic criteria for MS do not include VEP. However, VEP could be useful to diagnose 
optic neuritis. 
Optical coherence tomography (OCT)
Optical Coherence Tomography is used to measure retinal thickness. This non-
invasive technique produces two-dimensional images using low-coherence light.53 
In MS, the retinal nerve fibre layer (RNFL) is of particular interest. Since the retina is 
not myelinated, myelin is not interfering with OCT measurements. RNFL thickness is 
negatively correlated with disability and is found to be associated with brain atrophy.54, 
55 Therefore OCT is useful for assessing neuro axonal degeneration. Another extensive 
study showed that a thinner RNFL in eyes with no history of optic neuritis doubled the 
risk of disability worsening in the first 3 years and this risk was almost 4 times higher in 
the 4th and 5th year of follow-up.56 
PATHOPHYSIOLOGY: NEURO-INFLAMMATION VERSUS NEURODEGENERATION
The exact pathophysiological processes leading to multiple sclerosis pathology have 
not yet been completely elucidated. Complex mechanisms with neuro-inflammatory 
and neurodegenerative components have been implicated.57 Several studies have shown 
the crucial role for the adaptive immune system in the pathogenesis of MS.58, 59 In many 
aspects the disease resembles other so called autoimmune diseases such as rheumatoid 
arthritis, type I diabetes and psoriasis. Furthermore, inflammatory genes are associated 
with MS risk and about two third of these genes show overlap with other autoimmune 
ailments.60
Nevertheless, any autoimmune ailment has its target tissue that may be more 
vulnerable to immune attacks than healthy individuals. Also the enormous differences 
in disease course between individual MS patients may be related to differences in 
vulnerability of their brain and/or spinal cord tissue. It is likely that different immune 
responses play distinct roles in the early versus the progressive phase of the disease.59, 61 
However, it is unclear whether inflammation and neurodegeneration are primary or 
13
1
General introduction
secondary processes and how these factors interplay over the disease course. 
Current therapies for MS are immunomodulating, and relapses are the main target of 
these MS therapies.21 Yet, axonal damage is considered one of the major causes of per-
sisting neurological disability.62 The progressive phase of the disease makes that there 
is a controversy regarding the importance of relapses, nonetheless relapses early in the 
disease course do effect later disability and relapses are the main reason for disability in 
the early disease course.63
GENETIC, BIOLOGICAL AND ENVIRONMENTAL FACTORS
Genetic, biological and environmental factors play rolls in the risk for MS. These factors 
and their relation to MS risk are discussed below.
Latitudinal gradient
The prevalence of MS is unevenly distributed across populations around the world.64 
MS is more common in high-income countries in temperate zones such as Western 
Europe, North America, and Australia. In low-income countries in tropical zones the 
prevalence of MS is lower.65 66 The risk of MS seems to be higher in areas further from the 
equator. The uneven distribution of MS reflects differences in both genetic predisposition 
and environmental risk factors.66 However, there are some controversies about this 
latitudinal gradient theory. Some studies claim that the latitudinal gradient might be 
decreasing.64, 67, 68 These results could be due to genetic factors, but also behavioural 
factors could be of influence.66, 69 These controversies could further be the effect of 
the increased migration of people around the world. Yet, several studies revealed that 
migration from areas with a low MS risk to areas with a high MS prevalence leads to a 
higher risk of MS and that migrating from a high risk area to a low risk area results in a 
reduced risk of MS.70-74 It has been shown that the second generation of migrants have 
almost the same MS risk as people in the new country of residence.70, 71 A recent study 
showed that disability progression in North Africans living in France is more severe than 
disease progression in Caucasian patients living in France or North Africans living in 
North Africa. Resulting in a shorter time to reach higher EDSS scores, a higher relapse 
rate, and, especially in the second generation, a lower age of onset.75 These results argue 
for the fact that the individual risk of MS seems to be mainly set during childhood and 
is importantly influenced by environmental factors.76
Genetics
The latitude theory pleads for a major influence of environmental factors for MS risk. 
However, genetic factors play an important role as well. Studies in MS patients and 
their families showed that 20% of MS patients have family members with MS.77 The fact 
that the recurrence risk for siblings of MS patients is higher than the risk in the general 
population and that the concordance in monozygotic twins is higher than in dizygotic 
twins (25% vs 3%) points to a genetic contribution to the MS risk.78-80 It seems unlikely that 
shared environmental factors are of influence on the MS risk in close biological relatives 
14
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of MS patients because adoptees of MS patients do not have a higher risk of MS.81
The main genetic locus of MS risk is the human leukocyte antigen (HLA) class II region 
(the classic HLA-DRB1*1501 allele).82 Up to now over 200 non-HLA MS risk loci, all 
associated with a small risk of MS, are identified.83 These loci mainly lie in genes with 
immunological functions.60 MS risk seems to be modified by genetic and environmental 
factors and interactions between the two seems to be of influence here.84
Gender
The incidence and prevalence of MS has been increasing in the past decades. This 
increase is partly due to longer survival, but changes in lifestyle also seem to play an 
important role, particularly in women.64, 85 The female/male ratio for MS has been 
increasing in the last decades.86, 87 This gender effect mainly occurs early in the disease 
course, women have a higher relative risk of CIS,88 but most studies did not find a 
difference between female and male CIS patients for the risk of developing MS.14, 88 
A large study containing data from 18885 patients from 25 countries found a higher 
relapse rate in female patients compared to male patients.89 However, male patients 
seem to accumulate disability faster than female patients.90 In PPMS this difference in 
disability accumulation was not seen. The increasing female/male risk ratio for CIS can 
perhaps be explained by changes in lifestyle factors amongst women. There have been 
important lifestyle changes in past decades, for example in time spent outdoors, eating 
and drinking behaviour, smoking and obesity, but also life in areas with air pollution.64 
Some changes have been more specific to females, such as birth control and hormonal 
changes leading to lower age at menarche. 
Age
The disease course of MS is influenced by age of onset. Several studies showed that 
patients who are younger at time of CIS have a higher risk for conversion to CDMS.14, 44
A younger age of onset is also associated with good response to DMT.22 
Patient age has been shown a more important determinant of decline in relapse 
incidence and the secondary progressive phase than disease duration.89 Furthermore, 
relapse rate in the relapsing remitting phase of MS does not seem to influence the age 
of progression to SPMS.91
Environmental and clinical factors
Multiple environmental factors are associated with MS risk. These factors modulate 
disease presentation and therapeutic responsiveness.92, 93 The most important environ-
mental factors that influence the risk of MS are discussed here.  
Vitamin D
An explanation for the above mentioned latitude theory might be the higher load of 
UV radiation and therefore higher levels of vitamin D in people who live around the 
15
1
General introduction
equator. Lack of UVB radiation has been shown to be associated with MS prevalence and 
lesion load on MRI.94-96 Many studies found an association between low vitamin D levels 
and MS risk, both in the general population and in CIS patients.97-100 Several studies 
showed that vitamin D measured before the first symptoms of MS is associated with a 
future MS diagnosis. A population based study in Denmark found that a low concentration 
neonatal vitamin D measured in dried blood spots samples is associated with an in-
creased risk of MS.101 A German study showed that in the 24 months before CIS, vitamin 
D levels were lower than in healthy controls who did not develop CIS.102 Furthermore, a 
low vitamin D early in the disease course has been found to be a strong risk factor for 
long-term disease activity and disability and is associated with a higher relapse rate.99, 
103, 104 Genes involved in the vitamin D metabolism have been detected as risk factors for 
MS.60 The main mechanism of action of vitamin D is immunomodulatory,105 vitamin D 
supplementation showed multiple immunomodulatory effects.106, 107 However, it is not 
exactly clear how vitamin D influences MS.
Pregnancy and hormonal factors
Pregnancy is suggested to be protective against MS disease activity,108 with a reduced 
risk of MS during pregnancy.109 Also the relapse rate seems to be lower especially during 
the third trimester of pregnancy, but after delivery an increase in relapse rate and an 
increase in number of MRI lesions is seen.108, 110 In animal-models anti-inflammatory 
effects of female sex hormones are observed.111 Yet, a randomised controlled trial and a 
cross-over study in women with RRMS did not show a lower relapse rate in the patient 
group who received a pregnancy-specific form of oestrogen compared to the placebo 
group.112, 113 Another finding that argues against a major role for female sex hormones in 
the protection against MS is that oral contraceptives in the general population do not 
seem to correlate with a decreased risk of MS.114-116 However, one of the above mentioned 
studies showed a lower load of gadolinium-enhancing lesions in patients who were 
treated with estradiol.113 How pregnancy results in reduced neuroinflammatory activity 
in patients with RRMS remains a question to be solved. 
Smoking 
Several studies provided evidence that smoking results in an increased risk of MS.117, 118 
Smoking influenced the MS risk regardless of age of exposure. Both intensity and du-
ration of smoking was associated with the risk of MS.118 Not only cigarette smoking but 
also waterpipe smoking and passive smoking contributed to the risk of MS.119, 120 
Furthermore, it has been shown that smoking worsens the clinical course in MS 
patients and that smoking shortens the time to the secondary progressive phase of 
the disease.121-123 Multiple studies showed that the negative effects slowly decrease 
after smoking cessation, this is independent of the number of pack years.118, 121, 122 A 
Swedish population-based study found that patients who used moist snuff (a form of 
smokeless tobacco) were at lower risk for MS compared to patients who had never used 
moist snuff. This risk reduction was even seen in the tobacco smoking population. This 
indicates that nicotine is not causing the negative effect of smoking, and that nicotine 
16
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probably even causes immune-modulating effects that could protect against MS.124
There are conflicting results about the association between smoking and MS risk in CIS 
patients. Only a few studies are available in CIS patients and these studies are hampered 
by methodologic issues.125-129 The association of smoking and MS risk in CIS patients are 
described in this thesis.
Alcohol
More conflicting results are found on the effects of alcohol use on MS risk. Some studies 
suggest that moderate alcohol consumption has a protective effect on MS progression, 
and even reduces the harmful effect of smoking.130, 131 But there are also studies showing 
that cessation of alcohol consumption could improve MS related disability.132 However, 
a large cohort study and a meta-analysis of 10 studies did not show an association 
between alcohol consumption and MS risk.133, 134 These conflicting results indicate that it 
is unclear whether alcohol consumption has a protecting or adverse effect on MS.
Hygiene hypothesis
One of the explanations why the increasing incidence of MS mainly occurs in high-
income countries is a phenomenon that is called the ‘hygiene hypothesis’.135, 136 Advances 
in sanitation cause less exposure to infections in childhood, which may result in a 
higher prevalence of allergic and autoimmune diseases such as MS when encountering 
infections in adolescence.136 
EBV virus
Presence of EBV antibodies is observed in almost 100% of MS patients.137 Also a high EBV 
antibody titre is associated with risk of MS.138 Several studies showed that EBV antibodies 
were increased already in the years before the first symptoms.102, 138 In young adult patients 
primary EBV infection manifests in 25-70% as infectious mononucleosis, a clinical mani-
festation of a primary EBV infection.139 Patients who have had infectious mononucleosis 
showed a more than two times higher risk of MS.140 In both MS and control brain samples 
EBV infection was present. However, a higher number of EBV proteins has been shown in 
chronic and active MS plaques compared to controls. 141 It is of note that the prevalence of 
EBV in the general population is high (94%).137 However, encountering the EBV virus seems 
essential for MS development.140 These results suggest that EBV vaccination would be a po-
tential option to prevent MS.142 Yet, another possibility is that a shared genetic background 
contributes to the association between infectious mononucleosis and MS.143, 144 
Obesity
A large study in 238.371 women found that a BMI of more than 30 kg/m2 at the age of 
18 years increased the risk of MS with a factor two compared to women with a BMI 
between 18.5 and 21 kg/m2. In this kind of studies confounders such as smoking, vitamin 
D, and female sex hormones should be taken into account. In the mentioned study the 
17
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findings were corrected for age, latitude of residence, ethnicity, and smoking.145 Multiple 
studies confirmed these results in female and in male patients.146, 147
Two studies showed that obesity in childhood increased the risk of both paediatric- and 
adult-onset MS and CIS.148, 149 On the other hand, more recent studies found that rather 
adolescent obesity and not childhood obesity increased MS risk.150, 151 Furthermore, 
obesity seems to interact with established MS genetic risk loci. A significant interaction 
is shown between a BMI higher than 27 and carrying 1 or 2 risk alleles of HLA-A*02.152 
Also a recent study in two datasets found that a higher genetically induced BMI (using a 
weighted genetic risk score to predict BMI) predicted greater susceptibility to MS, which 
implies a causal effect of increased BMI on MS risk and an overlap in genetic pathways 
for obesity and MS.153 Regarding treatment response, overweight MS patients showed 
more disease activity while treated with first-line treatment interferon beta than MS 
patients with a normal weight, implying an effect of BMI on interferon beta treatment 
response.154 All these studies found a link between obesity and MS risk, however, it is not 
known if obesity predicts MS diagnosis in CIS patients. Since the prevalence of obesity is 
increasing, this may be one of the reasons that MS prevalence is increasing as well. 
Salt intake
The main cause of the obesity epidemic is probably the Western diet, which contains 
increasing amounts of sugar, fat and salt. It has been shown that Th17 cells are more 
pathogenic under high-salt conditions, showing an upregulation of pro-inflammatory 
cytokines. The same study showed that a high-salt diet in mice led to a more aggres-
sive course of EAE (the animal model of MS).155 However, these mice received very high 
amounts of salt, the equivalent in humans would be 68 grams a day, this is 11 times the 
advised amount of salt.
Multiple studies showed contradictory results concerning the relation between high 
salt intake and multiple sclerosis. A study in 2015 showed higher relapse rates and more 
new lesions on MRI scan in MS patients with medium and high salt intake.156 
However, more recent studies revealed no influence of salt intake on MS risk in the 
general population nor in CIS patients.157, 158 Also two paediatric studies, both performed 
in 2016, did not show an influence of high salt intake on MS diagnosis or on time to 
the next relapse.159, 160 These recent results plead against the former theories about the 
negative effect of salt on MS disease course. 
Stress
There are discordant results concerning the correlation between stress and MS risk.161 
Most studies show that stressful life events are associated with MS risk and a higher 
relapse rate and that stress can bring back previous symptoms.162-164
However, in a nationwide Danish cohort study no evidence was found for a causal asso-
ciation between well-defined severe stressful life events and MS risk.165
Of note is that in this kind of research multiple quality issues arise, such as selection 
and blinding problems, correction for psychosocial factors and a large heterogeneity in 
stress measurements.164
18
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BIOMARKERS
Finding new biomarkers is an important topic in MS research. There is a need for 
biomarkers early in the disease course to help diagnosing MS accurately as early 
as possible and prevent unnecessary treatment, but also for disease stratification, 
predicting long-term prognosis and predicting and monitoring treatment response.166, 
167 These markers are crucial to provide more individualized care. Up to now multiple 
biomarkers are identified and have the potential to become clinically useful.168 A few of 
the biomarkers that are validated for predicting MS in CIS patients are discussed below. 
Chitinase 3 like 1 (CHI3L1) in CSF
Chitinase 3 like 1 was first identified using a proteomic approach.169 Increased CHI3L1 
levels has been associated with a future MS diagnosis in patients with CIS. This finding 
is validated in independent cohorts of CIS patients.170, 171 CHI3L1 was not only a predictor 
for MS diagnosis but also a risk factor for future disability.170, 172 
Neurofilament light chain (NfL) in serum and CSF
A promising biomarker for axonal damage is neurofilament light chain (NfL).173 High NfL 
levels in CSF are associated with MS diagnosis in CIS and RIS patients.174, 175 Also serum 
NfL levels were higher in CIS and MS patients compared to healthy controls and associ-
ated with disability.176-178 Serum is a more accessible body fluid than CSF. The correlation 
between CSF and serum NfL makes serum NfL a promising biomarker to monitor axonal 
damage longitudinally.
CXCL13
CXCL13 is a chemokine that is involved in B-cell maturation and migration.179 High 
CXCL13 levels in CSF are associated with MS diagnosis in CIS patients, relapses and OCBs 
in CSF. 180, 181
Kappa and lambda free light chains (KFLC and LFLC)
In case of intrathecal B cell activity, plasma cells secrete free light chains. Kappa free 
light chains CSF-serum ratios were higher in CIS and MS patients than in controls.182 
Moreover, a lower KFLC/LFLC CSF ratio was associated with a future CDMS diagnosis in 
CIS patients.183 whether KFLC is superior to OCB in terms of sensitivity and specificity is 
not clear.182, 184  
MULTIPLE SCLEROSIS IN CHILDHOOD
As has been mentioned before, MS also occurs in children. Around 3-5% of MS patients 
have the first attack during childhood.4, 5 The differential diagnosis in children with 
suspected MS is more extensive than in adults.185, 186 Children with MS tend to have 
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a higher relapse rate, with more severe attacks than adults with MS.187, 188 Another 
sign of higher inflammatory activity is a higher lesion load on MRI in children than 
in adults.189, 190 Despite this more inflammatory disease course, disease progression is 
slower in children. A possible hypothesis for this is that the developing CNS of children 
has more plasticity to recover.191 Although progression in childhood-onset multiple 
sclerosis takes longer, a stage of irreversible disability is reached at a younger age.191, 
192 Furthermore, PPMS in children is rare.4 Because of these differences it is debated 
whether adulthood onset MS and childhood onset MS reflects the same disease.193 The 
criteria for childhood onset MS are revised in 2012 based on the McDonald 2010 crite-
ria for MS in adulthood. These criteria are developed by the International Paediatric 
MS Study Group (IPMSSG).194 In this thesis we compared the clinical features at onset, 
time to MS diagnosis, relapse rate, and disability between childhood-onset and adult-
hood-onset CIS and MS. 
PROUD STUDIES
From the Rotterdam MS centre ErasMS, two prospective studies in patients who are 
followed after a first attack of demyelination are coordinated: the PROUD (Predicting 
the Outcome of a Demyelinating event) study and the PROUD-kids study. Patients 
are included in Erasmus MC and several collaborating regional hospitals. Both studies 
have the same prospective study design, giving the opportunity to find markers 
for predicting long-term prognosis and treatment response to provide a more 
individualized care.22  The first cohort consists of adult CIS patients and the second 
cohort consists of children with a first attack of acquired demyelinating syndromes 
(ADS). This gives the unique opportunity to compare disease course, biomarkers and 
clinical factors between paediatric and adult patients with a first attack of possible 
MS. Patients are included within six months after a first attack of demyelination if they 
or their families signed an informed consent form. Neurological examination, blood 
samples, a lumbar puncture (if clinically indicated) and MRI scans are performed at 
baseline. All patients are included at time of the first attack of demyelination and after 
that reassessed regularly. The studies described in this thesis are executed within these 
two patient cohorts.195-200 
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SCOPE OF THIS THESIS
The first attack of MS often occurs in young adults in the prime of their lives. Especially 
in this young patient group, adequate counselling about their prognosis is important. 
Furthermore, the increasing amount of available immunomodulatory therapies that 
could be administered even before MS diagnosis emphasizes the need for better pre-
diction at an early phase of this heterogeneous disease. Adequately predicting disease 
activity is essential to prevent unnecessary treatment of patients with a benign disease 
course. This thesis focuses on defining prognostic factors for better prediction of clinical 
disease activity in adults with CIS and in children with a first attack of ADS.
The first part of this thesis describes prognostic factors in adult patients with CIS.  
In chapter 2, the new McDonald 2017 criteria are evaluated and compared to the former 
2010 McDonald criteria by applying both criteria to our prospective CIS cohort.
Fatigue is a common symptom in patients with MS and CIS. However, not much is 
known about the course of fatigue after a first attack of demyelination. Chapter 3 des-
cribes the course of fatigue after CIS. In chapter 4, the predictive value of the immuno-
logical biomarker soluble CD27 (sCD27) for CDMS in CIS patients is evaluated. Chapter 5 
zooms in on distinct effector phenotypes of Th17 cells as key regulators of MS onset. We 
evaluated the correlation of these cells with disease activity in CIS and MS and examined 
the association with natalizumab treatment response. 
Smoking is a well-established factor that influences disease course of patients with MS. 
However, there are conflicting results about the association of smoking and MS risk 
in CIS patients. In chapter 6, we aimed to determine the risk of CDMS in smoking and 
non-smoking patients at time of CIS.
The second part of this thesis focuses on the search of prognostic markers for disease 
course in children with ADS. We compared our prospective cohort of children with ADS 
to our prospective cohort of adult CIS patients. 
In chapter 7, we compared multiple clinical parameters, time to MS diagnosis and 
relapse rate between adults and children after CIS. The above described biomarker 
sCD27 is in chapter 8 evaluated in children with ADS. Another promising biomarker 
is neurofilament light chain (NfL), a marker for axonal damage. It is shown that NfL 
in CSF predicts MS diagnosis in adult patients with CIS, in children this was not yet 
investigated. In chapter 9, we compared NfL levels between paediatric and adult CIS 
patients and explored the predictive value of NfL levels for CDMS diagnosis. Finally, the 
key findings of this thesis and implications for future research are summarized and 
discussed in chapter 10.
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ABSTRACT
Importance: Recently, the International Panel on Diagnosis of Multiple Sclerosis revised 
the McDonald 2010 criteria for the diagnosis of multiple sclerosis (MS). The new criteria 
are easier to apply and could lead to more and earlier diagnoses. It is important to vali-
date these criteria globally for their accuracy in clinical practice. 
Objective: To evaluate the diagnostic accuracy of the 2017 criteria versus the 2010 crite-
ria to predict clinically definite MS (CDMS) in patients with a typical clinically isolated 
syndrome (CIS).
Design, setting and patients: 251 Patients fulfilled the inclusion criteria. 13 Patients 
received another diagnosis early in the diagnostic process and therefore were exclu-
ded from the analyses. 9 CIS patients declined to participate in the study. This left 229 
patients who were included between March 2006 and August 2016 in this prospective 
CIS cohort. Patients underwent a baseline MRI scan within three months after onset of 
symptoms and, if clinically required, a lumbar puncture was performed.
Main outcome and measures: Sensitivity, specificity, accuracy, positive and negative pre-
dictive value were calculated after 1, 3 and 5 years for the 2017 versus the 2010 criteria. 
Results: Among the 229 CIS patients, 167 were female (73%). The mean (SD) age was 33.5 
(8.2) years. Hundred and thirteen patients (49%) were diagnosed with CDMS during 
a mean (SD) follow-up time of 65.3 (30.9) months. Sensitivity for the 2017 criteria was 
higher than for the 2010 criteria (68%; 95% CI, 57-77%, vs 36%; 95%CI, 27-47%; p<0.001), 
but specificity was lower (61%; 95% CI, 50-71% vs 85%; 95%CI, 76-92%; p<0.001). 
Using the 2017 criteria more MS diagnoses could be made at baseline (97 (54%; 95%CI, 
47-61%) vs 46 (26%; 95%CI, 20-32%) p<0.001). In the group with at least 5 years of 
follow-up, 33% of patients who were diagnosed with MS using the 2017 criteria did not 
experience a second attack during follow-up versus 23% when using the 2010 criteria.
Conclusion and relevance: The 2017 revised McDonald criteria are more sensitive but 
less specific for a second attack than the previous 2010 criteria. The trade-off is that it 
leads to a higher number of MS diagnoses in patients with a less active disease course. 
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) with substantial heterogeneity in severity and prognosis.1
In 85% of patients, MS starts with a clinically isolated syndrome (CIS), a first clinical 
episode of CNS demyelination.2 CIS can remain a single event, but can also be followed 
by the relapsing disease MS. MS is diagnosed based on clinical or MRI evidence of dis-
semination in space (DIS) and time (DIT). The diagnostic criteria for MS evolved over the 
years to diagnose MS earlier and more easily.3-6
Up to now, MS can be diagnosed when a typical CIS is followed by a new clinical event 
or when there are new lesions on T2 weighted images on a follow-up MRI scan. Since 
the McDonald 2010 criteria, MS can also be diagnosed based on a single baseline MRI 
scan showing asymptomatic contrast enhancing lesions.6
Disease-modifying therapies (DMTs) can be administered early in the disease course, 
even at time of CIS. DMTs can delay a second attack after CIS,7-9 and have potential to 
prevent future disability.10, 11 However, DMTs have side effects. To select patients for early 
treatment, it is important to predict accurately who will develop a relapsing disease 
course and who will not.12 Accurate diagnostic criteria are therefore essential. 
Recently, new diagnostic criteria have been proposed for MS in patients with a typical 
CIS.13 These criteria are easier to apply than the McDonald 2010 criteria (Table 1). The 
most important addition is that the new criteria allow MS diagnosis when the MRI scan 
meets criteria for DIS and unique oligoclonal bands (OCB) are present in CSF, even in ab-
sence of DIT on the MRI scan. The other major difference is that not only asymptomatic 
but also symptomatic lesions can be used to demonstrate DIS and DIT on MRI. Further-
more, cortical lesions can be used to demonstrate dissemination in space.13
These revisions will presumably lead to a higher number of MS diagnoses at time of 
CIS. However, the revised criteria may be accompanied by a higher rate of false positive 
diagnosis. Therefore, it is of great importance to apply these criteria to available cohorts 
of CIS patients and validate their accuracy in clinical practice.  
We aimed to evaluate the diagnostic accuracy of these novel criteria.
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KEY POINTS
Question What is the diagnostic accuracy of the 2017 criteria versus the 2010 criteria 
to predict clinically definite MS (CDMS) in patients with a typical clinically isolated 
syndrome (CIS)?
Findings This study included 229 patients with a clinically isolated syndrome. The 
sensitivity of the revised McDonald 2017 criteria was higher than for the 2010 
criteria, and specificity was lower for the 2017 criteria.
Meaning The 2017 revision of the McDonald MS criteria leads to a higher number 
of MS diagnoses in patients with a less active disease course.
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McDonald 2010 McDonald 2017
DIS a) Objective clinical evidence of ≥2 
lesions, or objective clinical evidence 
of 1 lesion with reasonable historical 
evidence of a prior attack involving 
a different CNS site
b) ≥1 T2 lesion in at least 2 of 4 MS-
 typical regions of the CNS:
 Periventricular
 Juxtacortical
 Infratentorial
 Spinal cord
 (symptomatic lesions in patients 
with brainstem or spinal cord 
 syndrome are excluded)
a) Objective clinical evidence of ≥2 
lesions, or objective clinical evidence 
of 1 lesion with reasonable historical 
evidence of a prior attack involving 
 a different CNS site
b) ≥1 T2 lesion in at least 2 of 4 MS-
 typical regions of the CNS:
 Periventricular
 (Juxta)cortical
 Infratentorial
 Spinal cord
DIT a) ≥2 attacks separated by a period of 
at least 1 month
b) Simultaneous presence of 
 asymptomatic gadolinium-
 enhancing and non-enhancing 
lesions at any time
c) A new T2 and/or gadolinium-
 enhancing lesion on follow-up MRI, 
irrespective of its timing with refe-
rence to a baseline scan
a) ≥2 attacks separated by a period of 
at least 1 month
b) Simultaneous presence of 
 gadolinium-enhancing and non-
enhancing lesions at any time
c) A new T2 and/or gadolinium-
 enhancing lesion on follow-up MRI, 
irrespective of its timing with refe-
rence to a baseline scan
d) Demonstration of CSF-specific OCBs 
(as substitute for demonstration of 
DIT)
Table 1.  McDonald 2010 and 2017 criteria
Overview of diagnostic criteria (2010 and 2017) for DIS and DIT. Based on the 2010 revisions to the McDonald 
criteria and 2017 revisions to the McDonald criteria. 
Abbreviations: DIS, dissemination in space; DIT, dissemination in time; CNS, central nervous system; 
MRI, magnetic resonance imaging; CSF, cerebrospinal fluid; OCB, oligoclonal bands.
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METHODS
Study participants 
Patients with a suspected first episode of MS were included in our prospective cohort 
of CIS patients (Predicting the Outcome of a Demyelinating event, PROUD study), 
an multicentre study in Erasmus MC in Rotterdam, a tertiary referral centre for MS 
patients (MS Centre ErasMS) in collaboration with several regional hospitals. Patients 
were between 18 and 50 years of age and were included between March 2006 and Au-
gust 2016, within 3 months after onset of clinical symptoms, and with at least 1 year 
of follow-up. Patients were assessed at baseline and reassessed annually. No patients 
with a previous history of neurological symptoms suggestive for CNS demyelination 
were included. Patients underwent baseline MRI and routine laboratory tests to rule 
out other possible diagnoses. When an alternative diagnosis was made, the patient 
was excluded from analyses. 
Standard protocol approvals and patient consents
The study protocol was approved by the Ethics Committee of Erasmus MC Rotterdam 
and of the other participating centres. All patients provided written informed consent.
Definitions
A relapse was defined as new symptoms of neurological dysfunction or subacute wor-
sening of existing symptoms after 30 days of improvement or stable disease and no 
evidence of an alternative diagnosis.14 Symptoms had to exist for longer than 24 hours 
and not be preceded by fever. Exacerbations were confirmed by neurological exami-
nation. CDMS was defined as clinical dissemination in space and time as described by 
Poser et al.3 
Procedures
MRI scans were performed on a 1.5T magnet with a standard head coil (Philips, Best, 
The Netherlands, or General Electric, Milwaukee, WI, USA). Images were obtained in the 
axial plane and the following pulse sequences were used: T1-weighted conventional 
spin-echo(SE), SE proton-density-weighted (PDW), T2 weighted SE, and/or fluid-attenuated 
inversion recovery (FLAIR) sequence, with 2-5mm images. 
Patient selection
All baseline MRI scans were scored for DIS using the McDonald 2010 criteria and the 
2017 revisions to the McDonald criteria (n=229). To evaluate the 2010 and 2017 criteria 
for DIT and DIS+DIT, we selected patients who had a baseline MRI scan that included T1 
images after gadolinium administration or scans that did not show any T2 hyper intense 
lesions (n=180). 
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We performed sub-analyses for patients of whom we had data on OCB (n=124), patients 
with baseline spinal cord MRI available (n=79), and patients who were not treated with DMT 
before CDMS diagnosis (n=135).
Statistical analyses
For statistical analyses we used SPSS software, version 24.0 (SPSS Inc) and GraphPad 
Prism5. Patients who fulfilled the diagnostic criteria at time of the first attack and were 
diagnosed with CDMS during follow-up were considered as true positives (TP). False 
positives (FP) were defined as fulfilling the diagnostic criteria for MS at baseline but 
not diagnosed with CDMS during follow-up. Patients who did not fulfil the diagnostic 
criteria and who were not diagnosed with CDMS during follow-up were considered as 
true negatives (TN) and patients who did not fulfil the diagnostic criteria at baseline 
but were diagnosed with CDMS were considered as false negatives (FN). 
The following ratios were calculated:
Sensitivity: [TP / (TP+FN)] x100
Specificity: [TN / (TN+FP)] x100
Positive predictive value (PPV): [TP / (TP+FP)] x100
Negative predictive value (NPV): [TN / (TN+FN)] x100
Accuracy: [(TP + TN)/(TP + TN + FP + FN)] x100
Ratios were calculated with a 95% confidence interval (CI), for DIS, DIT (with and 
without oligoclonal bands) and MS diagnoses on baseline MRI scans using the 2010 and 
2017 McDonald criteria after 1, 3 and 5 years of follow-up. We compared sensitivity and 
specificity between the 2010 and 2017 criteria using McNemar’s test. 
For group comparison of continuous parametric variables, we used 2-tailed t test and for 
non-parametric data Mann-Whitney U test. For categorical data, we applied Chi-square. 
Time to diagnosis using the 2010 and 2017 criteria and time to CDMS were analyzed 
using Kaplan-Meier curves and compared using log-rank test. Hazard ratios for time 
to CDMS were calculated using COX proportional hazard regression analysis. Patients 
without a second attack during follow-up were considered as censored observations. 
P-values less than 0.05 were considered significant. 
RESULTS
Patient characteristics
In total 251 patients fulfilled the inclusion criteria, 13 patients were diagnosed with other 
diagnoses than MS, all <3 months of follow-up (neuromyelitis optica, spinal cord tumor, 
chronic relapsing inflammatory optic neuropathy, meningioma, vascular, sarcoidosis, 
vitamin B12 deficiency, psychogenic). Nine patients declined to participate in the study. 
After these exclusions, 229 CIS patients were eligible for analysis. All patients had at 
least 1 year follow-up time. 
One hundred thirteen patients (49%) were diagnosed with CDMS during a mean (SD) 
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follow-up of 65.3 (30.9) months. Median (IQR) time to CDMS diagnosis was 23.4 (10.2-
45.3) months. Fifty-five patients (24%) were treated with DMT before CDMS diagnosis. 
The median (IQR) time between onset of symptoms and baseline MRI scan was 3.7 weeks 
(1.6-6.3). One hundred eighty (79%) had MRI scans with post-gadolinium images available or 
scans that did not show any abnormalities. Baseline spinal cord MRI was performed in 107 
patients (47%), of whom 78 (73%) had spinal cord symptoms. In 148 patients(65%) oligoclo-
nal bands were assessed. Table 2 shows the baseline characteristics of the included patients. 
Characteristic CIS-patients     
(n=229)
CDMS                
(n=113)
Monophasic    
(n=116)
p-valuea 
Female sex, no. (%) 167 (72.9) 85 (75.2) 82 (70.7) 0.44
Ageb, mean (SD), years 33.5 (8.2) 32.2 (7.7) 34.8 (8.4) 0.01
Follow-up time, mean (SD), months 65.3 (30.9) 73.1 (29.3) 57.6 (30.5) <0.01
Clinical syndrome type, no. (%)
-optic nerve 88 (38.4) 41 (36.3) 47 (40.5) 0.51
-brainstem 44 (19.2) 29 (25.7) 15 (12.9) 0.01
-spinal cord 79 (34.5) 37 (32.7) 42 (36.2) 0.94
-cerebral hemispheres 39 (17.0) 21 (18.6) 18 (15.5) 0.54 
-cerebellar 14 (6.1) 9 (8.0) 5 (4.3) 0.25
DMT at time of CIS no. (%) 55 (24.0) 35 (31.0) 20 (17.2) 0.02
OCB, (> 1 band), (n=148) (%) 111 (75.0) 65 (83.3) 46 (65.7) 0.01
Time to baseline MRI, median (IQR) 4.0 (1.7-6.9) 4.3 (2.0-7.5) 3.6 (1.6-6.3) 0.14
MS 2010 criteria, no. (%) 46 (20.1) 33 (29.2) 13 (11.2) <0.01
MS 2017 criteria, no. (%) 110 (48.0) 73 (64.6) 37 (31.9) <0.01
Table 2.  Patient characteristics
a P value calculated between CDMS and Monophasic
b Age at symptom onset
Abbreviations: CIS, clinically isolated syndrome; CDMS, clinically definite multiple sclerosis; SD, standard 
deviation; DMT, disease-modifying therapies; OCB, oligoclonal bands; MRI, magnetic resonance imaging; 
IQR, interquartile range.
DIS and DIT criteria at baseline
The 2010 criteria for DIS were fulfilled for 124 of 229 patients (54%). Of them 74 (60%) 
experienced a second relapse (CDMS) during follow-up. One hundred forty-nine patients 
(65%) fulfilled the 2017 criteria for DIS and 89 (60%) were diagnosed with CDMS.
To evaluate the 2010 and 2017 criteria for DIT we selected patients who had a baseline 
MRI scan including post-gadolinium T1 images (n=180). 
The 2010 criteria for DIT were fulfilled for 46 of 180 patients (26%). Thirty-three of these 
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patients (72%) were diagnosed with CDMS. Hundred and twenty-six of 180 patients 
(70%) fulfilled DIT according to the 2017 criteria. Of them 76 (60%) experienced a second 
attack. Table 3 shows sensitivity, specificity, and accuracy with 95%CI for DIS and DIT 
according to the 2010 and 2017 criteria. 
Table 3.  Test characteristics for the 2010 and 2017 McDonald criteria
Abbreviations: DIS, dissemination in space; DIT, dissemination in time; 95%CI, 95% confidence interval; PPV, posi-
tive predictive value; NPV, negative predictive value
2010 vs 2017 revised criteria
Using the McDonald 2010 criteria, 46 of 180 patients with CIS (26%; 95%CI, 20-32%) 
were diagnosed with MS at baseline. When using the 2017 criteria, 51 more patients are 
diagnosed with MS at baseline: 97 patients (54%; 95%CI, 47-61%) (p<0.001). Thirty-three 
of 46 patients with MS (72%) using the 2010 criteria and 62 of 97 patients with MS (64%) 
using the 2017 criteria had a second attack during follow-up. Resulting in a sensitivity 
of 36%; 95%CI, 27-47%; (2010) vs 68%; 95%CI, 57-77% (2017) (p<0.001) and a specificity of 
85%; 95%CI, 76-92%; (2010) vs 61%; 95%CI, 50-71% (2017) (p<0.001). Table 3 shows sensiti-
vity, specificity, and accuracy for the 2010 and 2017 criteria.
For patients with at least five years follow-up (n=88), 14 of 22 patients (64%) diagnosed 
with MS using the 2010 criteria had a second attack before year five, for the 2017 criteria 
26 of 48 (54%). 
This implies that 22 of 48 patients (46%), with at least 5 year follow-up and diagnosed 
with MS at baseline using the 2017 criteria were not yet diagnosed with CDMS after five 
years. For the 2010 criteria this were 8 of 22 patients (36%). For the total follow-up time 
in the group with at least 5 year follow-up, these numbers were 16 of 48 (33%) (2017) and 
5 of 22 (23%) (2010). Sensitivity, specificity, PPV, NPV and accuracy at one, two, five years 
and for the total follow-up time for DIS, DIT for the 2010 and 2017 criteria are shown in 
Supplementary Table 1. 
DIS (n=229) DIT (n=180) DIS+DIT (n=180)
2010
Sensitivity (95%CI) 66 (56-74) 36 (27-47) 36 (27-47)
Specificity (95%CI) 57 (47-66) 85 (76-92) 85 (76-92)
Accuracy (95%CI) 61 (55-67) 61 (54-68) 61 (54-68)
Hazard ratio (95%CI) 2.0 (1.3-2.9) 1.9 (1.2-2.9) 1.9 (1.2-2.9)
2017
Sensitivity (95%CI) 79 (70-86) 84 (74-90) 68 (57-77)
Specificity (95%CI) 48 (39-58) 44 (34-55) 61 (50-71)
Accuracy (95%CI) 63 (57-70) 64 (57-71) 64 (57-71)
Hazard ratio (95%CI) 2.7 (1.7-4.2) 2.6 (1.5-4.6) 2.0 (1.3-3.1)
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Figure 1 shows the survival curves for CDMS according to the poser criteria,3 the 
McDonald 2010 and the revised 2017 criteria. MS diagnosis is made earlier using the 
2017 compared to the 2010 criteria (p<0.001). Table 3 shows the hazard ratios for DIS, DIT 
and DIS+DIT for the 2010 and 2017 criteria. 
Figure 1.  Time from CIS to CDMS, McDonald 2010, and 2017 MS
Survival curves for time from clinically isolated syndrome to multiple sclerosis for CDMS, the 2010 and revised 
2017 criteria. Abbreviations: CDMS, clinically definite MS
Contribution of OCB and symptomatic enhancing lesions separately
Using the new 2017 criteria, twice as many patients could be diagnosed with MS at 
baseline compared to the 2010 criteria (97 vs 46 patients). In 32 (63%) of these extra 
MS diagnoses the diagnosis could be made based on DIT fulfilment with OCB in CSF. Of 
these 32 patients, 47% was not diagnosed with CDMS during follow-up. The other major 
difference between the criteria is that not only asymptomatic but also symptomatic 
lesions can be used to demonstrate DIS and DIT on MRI. This led to the other 19 (37%) 
more MS diagnosis at baseline. Of these patients, 31% had no second attack.
Sub-analyses
For all sub-analyses we selected patients who had a baseline MRI scan that included T1 
images after gadolinium administration (n=180). 
No. at risk
2017 criteria 180 62 39 24 10 3
2010 criteria 180 96 65 38 12 3
CDMS 180 128 81 46 16 5
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Patients with known OCB status were selected for the first sub-analysis (n=124, 69%). 
Sensitivity for the 2010 versus the 2017 criteria was respectively: 32% (95% CI, 21-45%) 
and 70% (95% CI, 57-80%) (p<0.001). The specificity was: 75% (95% CI, 55-89%) vs 53% 
(95% CI, 40-67%) (p<0.001). In 79 of 180 patients (44%), a baseline spinal cord MRI was 
performed. Here sensitivity for the 2010 criteria was 29% (95% CI, 16-45%) and for the 
2017 criteria: 72% (95% CI, 58-86%) (p<0.001). The specificity was 84% (95% CI, 67-93%) 
vs 49% (95% CI, 32-65%) (p<0.001)
Because DMT could have postponed a second attack, we performed another sub-analysis 
excluding the patients treated with DMT before CDMS diagnosis, leaving 135 of 180 
patients (75%) eligible for analyses. Here sensitivity for the 2010 criteria was 27% (95% 
CI, 17-40%) and for the 2017 criteria: 58% (95% CI, 45-70%) (p<0.001). Specificity was 90% 
(95% CI, 81-96%) vs 73% (95% CI, 61-82%) (p<0.001)
DISCUSSION
We evaluated the accuracy of the 2017 revisions of the McDonald criteria versus the 
McDonald 2010 criteria to predict CDMS at the moment of a first demyelinating attack. 
The criteria for DIS and DIT used in the 2010 and 2017 criteria were applied to a prospec-
tive cohort of 229 CIS patients during a mean follow-up of 5.4 years. 
We observed higher sensitivity for the 2017 criteria than for the 2010 criteria (68% vs 
36%). However, as expected, specificity for the 2017 criteria was lower (61% vs 85%). The 
accuracy did not differ significantly (accuracy: 61% (2010) and 64% (2017)). Accuracy of 
the McDonald 2010 criteria was similar to earlier studies validating the 2010 criteria in 
CIS cohorts.15-18 
High sensitivity of diagnostic criteria is important to allow earlier initiation of DMT, 
which has been shown beneficial for disease outcome.7, 9, 10 On the other hand, incorrect 
diagnoses and unnecessary treatment should be avoided. In our data, specificity of the 
2017 criteria was significantly lower than for the 2010 criteria. Earlier data showed that 
the previous McDonald criteria lead to a higher number of MS diagnoses in patients 
who will not have a second attack.19 When new less strict criteria are introduced, the 
Will Roger’s phenomenon could be observed.20 This refers to the statistical observation 
that when a boundary on a scale is moved to the left, the outcome for both patient 
groups improves. More CIS patients will be moved to the MS group, therefore the MS 
group will probably have a more favourable outcome with a lower attack frequency. This 
makes comparisons between different time periods in MS research challenging, since 
the overall prognosis for MS patients is getting better. 
With these new MS criteria, MS diagnosis includes a single CIS attack without sub-
sequent clinical disease activity and therefore comes even closer to the group with 
radiologically isolated syndrome (RIS). Patients with RIS cannot be diagnosed with MS 
using the current criteria. Since DMTs can delay a second attack in patients with CIS and 
have a potential to prevent future disability, the discussion comes closer to whether RIS 
patients who are at high risk for future attacks and already have cognitive problems21 
should also be diagnosed with MS and be treated with DMT. 
We found that after five years of follow-up the number of patients fulfilling the criteria, 
but with no second attack was higher for the 2017 than for the 2010 criteria 
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(46% vs 36%). However, in the period after these five years of follow-up, eight more 
patients were diagnosed with CDMS. Of them six fulfilled the 2017 criteria at baseline, 
and three fulfilled the 2010 criteria. This shows that a longer follow-up will probably 
lead to a higher positive predictive value of the criteria.
Another potential explanation for the high number of patients that fulfilled the 
criteria but did not experience a second event is treatment with DMT before CDMS 
diagnosis. This could have postponed or prevented a second attack and therefore 
lowered the specificity of the criteria. We did not exclude patients who used DMT 
before CDMS diagnosis, this could have introduced selection bias. Instead of exclusion, 
we performed a separate analysis with the group that did not receive DMT before 
second attack. In this sub-analysis the specificity increased for both criteria. But after 
at least five years of follow-up, even in this untreated group, 4 of 15 (27%) patients 
who fulfilled the 2010 criteria and 11 of 33 (33%) patients who fulfilled the 2017 criteria 
did not experience a second attack. 
Sixty-three % Of the extra MS diagnoses using the new diagnostic 2017 criteria were 
made based on OCB in CSF, 47% of these patients did not experience a second attack. 
The other 37% of new MS diagnoses could be made based on demonstrating DIS or 
DIT with asymptomatic enhancing lesions on MRI, 31% of these did not experience a 
second attack. Especially inclusion of OCB in the 2017 criteria seems to contribute to 
the lower specificity.
There are some limitations to this study. Although there was a sufficient follow-up to 
draw conclusions (mean FU-time: 5.4 years), the range is rather wide (SD: 2.6 years). The 
possibility remains that after further follow-up, additional patients will have a second 
attack. However, total number of patients in this study was large enough to allow sub-
analyses for different minimum follow-up times and this demonstrated maintenance of 
accuracy together with a limited decrease of sensitivity (Supplementary Table 1). 
Secondly, not all patients underwent a baseline spinal cord MRI scan and lumbar punc-
ture. Though it is known to increase sensitivity,22, 23 it is not common clinical practice to 
include spinal cord MRI in the routine diagnostic work-up when there are no spinal cord 
symptoms. Also a lumbar puncture was not always clinically required and we did not 
have ethical permission for obtaining CSF for research purposes alone. Therefore, the 
decision to perform a lumbar puncture or a spinal cord MRI was not random. To avoid 
selection bias, we did not exclude the patients who did not have CSF or spinal cord MRI 
data available. In this way, our findings are more applicable to the general clinical prac-
tice. However, we did perform sub-analyses and specificity and sensitivity did not differ 
from the total group. 
Thirdly, though applied in most studies on MS criteria for CIS patients,24-26 the use of 
sensitivity, specificity, NPV and PPV is somewhat problematic. They imply reference to 
a gold standard. Obviously, in this patient group we do not have neuropathological 
information. Earlier studies used pathologically confirmed CDMS cases to demonstrate 
that the highest rate of correct diagnoses could be made when using the Poser CDMS 
criteria.27, 28 Therefore we accepted the use of CDMS as a proxy to pathological evidence 
to confirm MS diagnosis. 
Lastly, in the 2017 criteria, cortical lesions are added as an extra parameter to show DIS. 
Advanced MRI techniques are required to visualize cortical lesions. These techniques are 
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hardly available in routine clinical practice,13 therefore at present, we cannot study the 
contribution of this parameter. A recent study, in which the MAGNIMS 2016 MRI crite-
ria were validated in a large retrospective CIS cohort, showed that inclusion of cortical 
lesions did not affect DIS criteria performance.23, 25
In conclusion, the 2017 revisions to the McDonald criteria are more sensitive than the 
previous 2010 criteria. Therefore, the new diagnostic criteria will probably increase the 
proportion of MS diagnoses. However, the specificity is significantly lower when applied 
to our cohort of CIS patients, leading to a higher number of MS diagnoses with a less 
active disease course, at least in the first years after onset.
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ABSTRACT
Background: Fatigue is reported by more than 75% of of multiple sclerosis (MS) patients. 
In an earlier study we showed that fatigue is not only a common symptom in patients 
at time of clinically isolated syndrome (CIS; fatigued 46%), but also predicts subsequent 
diagnosis of clinically definite MS (CDMS). The course of fatigue after CIS is unknown. 
Objective: We aimed to explore the long-term course of fatigue after CIS. 
Methods: In this study, 235 CIS patients, aged 18-50 years, were prospectively followed. 
Patients filled in the Krupp’s Fatigue Severity Scale (FSS) and the Hospital Anxiety and 
Depression Scale (HADS) at baseline and annually. After reaching CDMS diagnosis, EDSS 
(Expanded Disability Status Scale) was obtained annually. Mixed-effects models were 
used to analyse longitudinal FSS measurements.
Results: Fatigue at baseline was an independent predictor for CDMS diagnosis (hazard 
ratio (HR): 2.6, 95% confidence interval (CI): 1.6-4.4). The evolution of FSS was the same 
in CIS patients who remained monophasic and patients who were diagnosed with 
CDMS during follow-up. However, FSS increased by 0.86 units after reaching CDMS diag-
nosis (p=0.01). After this increase, the FSS course remained unaltered (p=0.44).
Conclusion: Fatigue, which is often present at time of CIS, probably persists over time 
and increases after a second attack. 
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INTRODUCTION
Fatigue is a common symptom in MS, reported by more than 75% of patients,1-3 and is 
described as the most debilitating symptom by 15-40% of MS patients.4 In MS fatigue is 
defined as 'a subjective lack of physical and/or mental energy, perceived by the individual 
or caregiver to interfere with usual and desired activities'5
The pathophysiological mechanisms of MS-related fatigue are not yet fully understood. 
Fatigue can result from MS-related symptoms such as sleep deprivation, MS-
related neuro-psychiatric disorders such as depression and anxiety, and side effects of 
medication (secondary fatigue),6,7 but fatigue can also be the direct result of MS-related 
pathophysiological processes such as inflammation, demyelination, and axonal loss 
(primary fatigue).6,7 Several studies also indicated an independent relation between 
inflammation and fatigue.8,9 In a previous study we showed that fatigue was present 
in 46% of patients at time of the first attack, independent of the neuroanatomical 
localization of this first attack, with a severity similar to fatigue in patients with MS.10 
This indicates that the MS-related fatigue presents itself already early in the disease 
at the moment of the first symptoms, not related to the attack itself. Few relatively 
short-term studies in patients diagnosed with MS suggested that fatigue persists over 
time. Those studies had a maximum follow-up of 3 years.1,11-14 The long-term course of 
fatigue after clinically isolated syndrome (CIS) is not known. The aim of this study was 
to explore the course of fatigue, during follow-up after CIS. The second aim was to study 
the association between fatigue at time of CIS and disability after a second clinical attack.
METHODS
Patients
All patients with CIS, a suspected first episode of MS, who visited Erasmus Medical 
Centre (EMC) University Hospital in Rotterdam, a tertiary referral centre for multiple 
sclerosis, or one of the collaborating regional hospitals, were enrolled in this study. All 
the patients were included and followed between July 2006 and December 2015 in the 
multicentre prospective observational study on Predicting the Outcome of a Demyeli-
nating event (PROUD study). Study protocols have been described previously.10 Patients 
were between 18 and 50 years of age, and were included in the study within six months 
after the onset of CIS. At baseline patients underwent an MRI scan and routine labora-
tory tests to rule out alternative diagnoses.15 Patients with alternative diagnoses and 
patients who suffered from life-threatening comorbidities (i.e. malignancies, acquired 
immunodeficiency syndrome (AIDS)) were excluded. Patients with comorbidities likely 
to cause fatigue, other than depression, were excluded from the analyses. After inclusion 
patients were reassessed annually.
Definitions
An exacerbation was defined as new symptoms or subacute worsening of existing 
symptoms after 30 days of improvement or stable disease and no evidence of alternative 
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diagnosis.16 To be regarded as exacerbation, symptoms had to exist for longer than 24 
hours and not to be preceded by fever.17 All exacerbations were confirmed by neurolo-
gical examination. Clinically definite multiple sclerosis (CDMS) was defined as clinical 
dissemination in space and time as described by Poser et al.17 Disability was measured 
using the Expanded Disability Status Scale (EDSS).18 After a diagnosis of CDMS, EDSS 
was obtained at annual reassessments by a trained physician. In case of an exacerba-
tion, the physicians made sure that an EDSS was obtained at least three months after 
the exacerbation.
Questionnaires 
Krupp’s Fatigue Severity Scale (FSS) was used to assess fatigue.19 This self-administered 
questionnaire is validated for use in patients with MS.19-21 FSS consists of nine questions 
with seven possible answers for each question, ranging from strong disagreement to 
strong agreement. The FSS score ranges from one to nine; fatigue is defined as an FSS of 
5.0 or higher.22 
Hospital Anxiety and Depression Scale (HADS) was used to measure anxiety and 
depression.23 This is also a self-administered questionnaire, that has been validated in 
MS patients.24 It contains seven items measuring symptoms of anxiety and seven items 
measuring symptoms of depression. For both anxiety and depression a score of 11 points 
or higher (out of 21 points) was considered as being anxious or depressed. HADS was 
obtained at the same time as FSS to correct for depression and anxiety, as fatigue is 
associated with these factors.25,26 FSS and HADS were obtained at baseline and annually.
Standard protocol approvals and patient consent
This study was approved by the Medical Ethics Committee of Erasmus MC Rotterdam. 
Written informed consent was obtained from all patients. 
Data analysis
Statistical analyses were done using SPSS version 21 (SPSS Inc., Chicago, Illinois, USA) 
for Windows, R statistical software version 3.2.4 and GraphPad Prism5 (GraphPad, San 
Diego, USA) for Windows. We compared continuous data using a two-tailed t-test 
(for age, follow-up time, Time CIS to baseline FSS, FSS and HADS-A at baseline) or a 
Mann-Whitney U-test (for HADS-D and IgG index) if the data were not normally distri-
buted. Chi-square or Fisher’s exact test were applied to analyse categorical data (gender, 
ethnicity, immunomodulating therapy (IMT), dichotomized FSS, clinical syndrome type, 
oligoclonal bands (OCB) and MRI features). Time to CDMS was calculated from the onset 
of the first symptoms to the second clinical attack (confirmed by a neurological exami-
nation). Patients who did not experience a second attack were considered as censored 
observations. Survival data were analysed using Kaplan Meier survival analyses with 
Log-rank test, univariable, and multivariable Cox proportional hazard regression models. 
To analyse the longitudinal FSS measurements and to evaluate the association between 
baseline FSS and EDSS during follow-up, we used mixed effects models. To model the 
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time effect flexibly we utilized natural cubic splines with two internal knots placed at 
the 33.3% and 66.6% percentiles of the observed follow-up times. In the linear mixed 
model used to analyse the longitudinal FSS measurements we corrected our findings for 
ethnicity, gender, anatomical localization of the first symptoms, age at time of CIS, and 
HADS. To analyse the change in evolution of FSS after CDMS diagnosis we included an 
interaction term between CDMS at time of questionnaire and the nonlinear time. In the 
model where we analysed EDSS (as continuous variable) we corrected for localization 
of the first symptoms. To analyse the correlation between FSS at baseline and evolution 
of EDSS during follow-up after CDMS we included the interaction term between FSS 
at baseline and time. For both analyses the model with random intercept and random 
slopes were deemed the most appropriate based on likelihood ratio tests between 
nested random-effects structures. Different F-tests were used to evaluate whether the 
time effect was nonlinear, whether FSS altered after being diagnosed with CDMS, and 
whether EDSS was dependent on the baseline FSS. 
RESULTS
Patient characteristics
At time of the analyses, 281 patients were enrolled in the study. In total, 46 patients 
were excluded from further analysis because of alternative diagnoses (n=12), 
comorbidities other than depression, that are likely to cause fatigue (Crohn’s disease 
(n=1), ulcerative colitis (n=1), hypothyroidism (n=7), pan-hypopituitarism (n=1), newly 
diagnosed diabetes mellitus (n=1)), and missing data on the questionnaires (n=23). 
After exclusions, 235 patients were left for the analyses. A total of 825 questionnaires 
were obtained (median number of questionnaires per person is: 3.0 (interquartile 
range (IQR): 2.0-5.0)). During the mean follow-up of 51.9 months, 89 patients (37.9%) 
were diagnosed with CDMS. Fifteen of 825 questionnaires were obtained within three 
months after CDMS diagnosis. Fifty-nine patients received IMT before CDMS diagnosis. 
Patient characteristics are shown in Table 1. CIS patients are stratified into CDMS and 
monophasic.
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Characteristic All patients
n=235 (100%)
CDMS
n=89 (37.9%)
Monophasic
n=146 (62.1%)
p-value a
Gender, female n (%) 178 (75.7) 74 (83.1) 104 (71.2) 0.04 
Age (years) mean (SD) b 34.2 (8.3) 33.6 (8.1) 34.5 (8.4) ns (0.38)
Caucasian ethnicity, n (%) 187 (79.6) 76 (85.4) 111 (76.0) ns (0.08)
Follow-up time (months), mean (SD) 51.9 (29.5) 65.1 (25.0) 43.9 (29.1) p<0.01 
Time CIS to baseline FSS (weeks), mean (SD) 12.8 (8.6) 12.3 (6.9) 13.2 (9.6) ns (0.50)
Time CIS to CDMS (months), median (IQR) na 19.0 (8.4-42.3) na na
Immunomodulating therapy, n (%) 101 (43.0) 74 (83.1) 27 (18.5) <0.01
Immunomodulating therapy at time of CIS, n (%) 59 (25.1) 32 (36.0) 27 (18.5) <0.01
Questionnaires at baseline
FSS, mean (SD) 4.2 (1.8) 4.8 (1.8) 3.8 (1.7) <0.01
FSS ≥ 5.0, n (%) 83 (35.3) 47 (52.8) 36 (24.7) <0.01
HADS-A, mean (SD) 7.1 (4.1) 7.6 (4.4) 6.7 (3.9) ns (0.14)
HADS-D, median (IQR) 4.0 (1.3-7.0) 4.0 (2.0-8.0) 3.0 (1.0-6.0) <0.01
Presenting phenotype at CIS 
-Optic neuritis 
-Brainstem 
-Spinal cord
-Cerebellum 
-Cerebral hemispheres
-Multifocal
94 (40.0) 
25 (10.6)
62 (26.4) 
3 (1.3)
21 (8.9)
30 (12.8)
29 (32.6)
15 (16.9)
23 (25.8)
0 (0.0)
8 (9.0)
14 (15.7)
65 (44.5)
10 (6.8)
39 (26.7)
3 (2.1)
13 (8.9)
16 (11.0)  
ns (0.07) 
ns (0.06) 
ns (0.88) 
ns (0.29) 
ns (0.98) 
ns (0.29)
CSF findings at baseline
Positive OCB, n (%)   (n=142) 115 (81.0%) 57 (93.4%) 58 (71.6%) <0.01
IgG index, median (IQR)   (n=137) 0.83 (0.57-1.30) 1.00 (0.62-1.39) 0.78 (0.56-1.11) 0.03
Features baseline MRI scan
≥ 9 T2 lesions on T2-weighted images, n (%) 90 (38.3) 48 (53.9) 42 (28.8) <0.01
Gadolinium-enhancing lesions, n (%)   (n=158) 65 (41.1) 31 (48.4) 34 (36.2) ns (0.12)
Table 1.  Patient characteristics
a p-value calculated between CDMS and monophasic. b Age at time of CIS
Abbreviations: CIS, clinically isolated syndrome; CDMS, patients who are diagnosed with CDMS during follow-up 
after CIS defined by Poser criteria; Monophasic, not diagnosed with CDMS; ns, not significant; na, not applicable; 
HADS-A, HADS-anxiety; HADS-D, HADS-depression; OCB, oligoclonal bands; Ig Immunoglobulin
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Fatigue predicts CDMS diagnosis
Fatigue at baseline was associated with a shorter time to CDMS diagnosis (HR: 2.5, 
95% CI 1.5-3.9; p<0.001) using a univariable Cox regression model. After adjustments 
(sex, age, ethnicity, localization of symptoms, anxiety, depression, number of T2 
lesions, gadolinium enhancement at baseline MRI and IMT before CDMS diagnosis), 
multivariable COX analysis showed that fatigue at time of CIS was associated with 
CDMS diagnosis both as a dichotomous variable (HR 2.7, 95% CI 1.6-4.4; p<0.001) and 
as continuous variable (HR 1.4, 95% CI 1.2-1.6; p<0.001). Kaplan-Meier curves for time to 
CDMS in fatigued and non-fatigued patients are shown in Figure 1. 
There were no differences between FSS scores in patients who received IMT versus 
patients who did not receive IMT in the CDMS group (mean FSS, respectively 4.6 vs 4.4; 
p=0.19) and in the monophasic CIS group (mean FSS, respectively 3.8 vs 3.4; p=0.26). 
Patients who were diagnosed with CDMS during follow-up showed higher scores on the 
depression scale (HADS-D) compared to patients who remained monophasic (median: 
4.0 vs 3.0 p<0.01). However, the hazard ratio per point elevation in HADS-D was small 
(HR: 1.075, 95% CI 1.02-1.14; p=0.01). 
From 112 patients, we knew the level of education. There was no difference in baseline 
FSS between patients with the lowest (n=65) and highest (n=47) level of education. Level 
of education did not correlate with CDMS diagnosis during follow-up in this cohort.
Figure 1.  Time to CDMS
Kaplan-Meier curves for time to 
CDMS. Patients were stratified at 
fatigued (FSS≥5) vs non-fatigued 
FSS<5), (log-rank test, p<0.01)
Longitudinal follow-up of fatigue
FSS at time of CIS did not differ between male and female patients (male vs female, 
mean FSS 3.90 vs 4.31 (p=0.18)). However, during follow-up female patients had a 0.68 
units higher FSS than males (mixed effects model analysis: estimated main effect for 
female:0.68 (p<0.01)). There was no significant difference in FSS between Caucasian and 
non-Caucasian patients at baseline (Caucasian vs non-Caucasian, mean baseline FSS: 
Fatigue after a first attack of suspected MS
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4.20 vs 4.30 (p=0.76)) and during follow-up (estimated main effect for non-Caucasian: 
0.23 (p=0.27)). Age at time of CIS did not correlate with FSS at baseline (Pearson’s rho: 
0.02 (p=0.78) nor during follow-up (estimated main effect per year older: 0.01 (p=0.30)).
Anatomical localization of the first presenting symptom did not influence the FSS at 
baseline (optic neuritis vs other localization, mean baseline FSS: 3.93 vs 4.40 (p=0.10) 
nor during follow-up (estimated main effect for optic neuritis: 0.17 (p=0.38). The mean 
time between first neurological symptoms and baseline FSS was 12.8 weeks (SD: 8.6), no 
correlation between this time and baseline FSS score was found. 
An increase of >1 point in FSS was seen in 25% of patients who remained CIS during 
follow-up. In the patients who were diagnosed with CDMS 30% showed an increase of 
>1 point in FSS, this difference was not significant (p=0.34). 
The longitudinal evolution of FSS in time was nonlinear (p<0.01). Therefore we utilized a 
mixed effects model with natural cubic splines. The evolution of FSS was not altered after 
CDMS diagnosis (p=0.44 for interaction between the nonlinear effect for time and CDMS 
diagnosis ). However, there was a significant increase of FSS by 0.86 units after CDMS diag-
nosis (estimated main effect for FSS at time of CDMS: 0.86 (p=0.01)). After this increase in 
FSS the FSS course remained unaltered, comparable to the course of FSS in monophasic CIS 
patients. These results were adjusted for ethnicity, gender, anatomical localization of first 
symptoms, age at time of CIS, and HADS. The evolution of FSS for monophasic CIS patients 
and CIS patients diagnosed with CDMS during follow-up are shown in Figure 2A and 2B, 
Figure 2B depicts the FSS evolution for CIS patients with two years between CIS and CDMS. 
The figures for CIS patients with different times between CIS and CDMS look similar, with 
the sole difference that the increase in FSS takes place at time of CDMS diagnosis. 
Figure 2  Follow-up FSS in males and 
females
Time 0 refers to study entry. 
A. FSS evolution in patients who are 
not diagnosed with CDMS during 
follow-up.
B. FSS evolution in patients who 
are diagnosed with CDMS during 
follow-up. The illustration depicts 
the model for CDMS diagnosis at 
year 2. For patients with other times 
to CDMS diagnosis, the figure looks 
similar with the increase in fatigue 
at time of CDMS diagnosis 
A
B
57
Fatigue after a first attack of suspected MS
3
EDSS 
When patients were diagnosed with CDMS (n=89), EDSS was obtained annually. There 
is a trend towards a 0.9 units higher EDSS during follow-up in patients with FSS ≥5.0 at 
time of CIS, compared to patients with FSS <5.0 (mixed effects model analysis: estima-
ted fixed effect for FSS≥5.0: 0.90 (p=0.10)). Those results were adjusted for localization 
of the first symptoms. Patients who changed >1 point in FSS score during follow-up did 
not show higher EDSS scores during follow-up than patients who did not change >1 
point in FSS score.
DISCUSSION
In this study we explored the course of fatigue after CIS. The first part of the study 
replicates our earlier observation that a higher FSS at time of CIS, unrelated to disability 
or time between first neurological symptoms and baseline FSS, predicts a subsequent 
diagnosis of CDMS.10 Patients with a future diagnosis of CDMS already had a higher 
FSS at time of CIS than patients who remained monophasic during follow-up. Here we 
showed that after the second attack (and thus after CDMS diagnosis), the FSS increased 
even more. 
We found that fatigue is predictive for a shorter time to CDMS diagnosis. There is some 
evidence that a shorter time to CDMS diagnosis might correlate with a more severe 
disease course with more disability.27 Cavallari et al. found that fatigue in patients with 
MS was predictive for disease worsening.28 Therefore we tested whether fatigue present 
even earlier in the disease also predicts future disability. In a mixed-effects model, with 
correction for localization of CIS, we did not find a correlation between fatigue at time 
of CIS (FSS ≥5.0) and EDSS during follow-up. However, we did find a trend towards a 
0.9-point higher EDSS score during follow-up in patients who were fatigued at baseline; 
a 0.9-point increase in EDSS might be clinically relevant.  
A strength of our study was the large sample size, almost twice as large as our previous 
cohort (235 vs 127).10 Earlier studies looked at the course of fatigue in patients who were 
already diagnosed with MS with a much shorter follow-up of 1 to a maximum of 3 years 
with various results in the persistency of fatigue.1, 11-13, 29, 30 To our knowledge, this is the first 
study that examined fatigue annually after onset of CIS with a long follow-up (mean: 4.3 
years). Since we had a large sample size we could adjust our findings for multiple factors 
including HADS. Anxiety and depression are known confounders and were associated 
with FSS, therefore the analyses were adjusted for these factors.25, 26,31
Although part of the patients received IMT, it did not influence the results, because FSS 
did not differ between those who used IMT and those who did not. This is in line with 
previous literature.12,32 Fifty-nine patients received IMT prior to CDMS diagnosis, which 
may have postponed CDMS diagnosis. Therefore our results may even be an underesti-
mation. However, in the multivariable COX model we corrected for IMT prior to CDMS 
diagnosis. 
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One explanation for the observed increase in FSS score after CDMS diagnosis could be 
that this increase is related to the second attack itself, however, only a small proportion 
of questionnaires was obtained in a short period after the second attack (15 of 825 
questionnaires within three months); this indicates that it is more likely that the 
observed increase in FSS is the MS-related fatigue and not the attack related fatigue.
The FSS is a self-administered questionnaire, and easy to fill in. Although it is a subjective 
scale, it is as efficient as other scales measuring fatigue.33 Its validity has been proven in 
MS; hence it has been used widely in MS studies. Because of its short length and simpli-
city we had a preference for specifically this scale in order to limit the withdrawal due to 
repetitive annual measurement of fatigue.
In this study less than 40% of CIS patients experienced a second attack during a mean 
follow-up time of more than 4 years. Using the newest diagnostic criteria,34 a part of the 
remaining 60% of patients, having a less active disease, would be diagnosed with MS. 
This underlines that not only predictors for MS diagnosis are important but also predic-
tors for disease activity and disability.
There were a few limitations to our study. First, because patients were included over a 
long period of time, there was a wide range in follow-up, resulting in different numbers 
of completed questionnaires per patient. To overcome this problem a mixed-effects 
model was used which allowed us to correct for different follow-up times and use all 
available questionnaires in the analyses. Second, we did not measure EDSS scores at the 
moment of CIS; therefore, we could not adjust for baseline EDSS. All EDSS scores were 
obtained at least 3 months after an attack because we did not want a resent relapse 
influencing the EDSS score. However, although we could not adjust for baseline EDSS, 
we did adjust for localization of CIS. 
We did not have reliable information on level of education for all patients. However, in a 
subgroup of 112 patients we had this information. In this subgroup the results were not 
altered after adding level of education to the COX regression model.
Last, since we did not perform a follow-up MRI scan regularly, we used the Poser criteria 
for defining CDMS diagnosis.17 In this way, we did show an effect on a second attack, this 
might be clinically more relevant, than showing an effect on MRI. 
In summary, using a large prospective cohort of CIS patients, we show that fatigue at 
time of CIS predicts a subsequent CDMS diagnosis. Our findings indicate that fatigue 
exists early in the disease course of MS, probably will remain present during the further 
follow-up, and increases after CDMS diagnosis. Despite the long follow-up, we did not 
find an association between presence of fatigue at the moment of the first symptoms 
and future disability. However, we did find a trend towards a higher EDSS in patients 
who were fatigued at baseline. It would be interesting to follow our cohort to see 
whether, with a longer follow-up, the correlation of fatigue at first attack and disability 
during follow-up will reach significance. Fatigue can interfere with a person’s ability to 
function at home and work, our advice for clinical practise is to give proper attention to 
symptoms and management of fatigue already early in the disease course.
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ABSTRACT
Importance: There is a growing number of therapies that could be administered after 
the first symptom of CNS demyelination. These drugs can delay multiple sclerosis (MS) 
diagnosis and slow down future disability. However, treatment of patients with benign 
course may not be needed, therefore there is a need for biomarkers to predict long-term 
prognosis in patients with clinically isolated syndrome (CIS).
Objective: To investigate whether the T-cell activation marker soluble CD27 (sCD27), 
measured in cerebrospinal fluid (CSF) of patients at time of a first attack, predicts a sub-
sequent diagnosis of MS and is associated with a higher relapse rate.
Design, setting and patients: This prospective study included 77 patients with CIS 
between March 2002 and May 2015 in a tertiary referral centre for multiple sclerosis, 
in collaboration with several regional hospitals. Patients with CIS underwent a lumbar 
puncture and MRI scan within 6 months after first onset of symptoms. 
Main Outcome and Measures: Soluble CD27 levels were determined in cerebrospinal 
fluid using a commercially available Enzyme-Linked Immuno Sorbent Assay (ELISA). Cox 
regression analyses was used to calculate univariate and multivariable hazard ratios for 
MS diagnosis. Association between sCD27 levels and relapse rate was assessed using a 
negative binomial regression model.
Results: Among 77 patients with CIS, 50 were female (79.5%), and mean (SD) age was 
32.7 (7.4) years. Mean (SD) age in the control individuals was 33.4 (9.5) years, and 20 were 
female (66.7%). Patients with CIS had higher CSF sCD27 levels than control individuals 
(geometric mean (95% CI): 31.3 U/mL (24.0-40.9) vs 4.67 U/mL (2.9-7.5); p<0.001). During 
a mean follow-up of 54.8 (±35.1) months 39 of 77 (50.6%) patients were diagnosed with 
MS. In a model adjusted for MRI and CSF measurements, sCD27 levels were associated 
with a diagnosis of MS (hazard ratio: 2.4 per 100 U/mL increase in sCD27 levels 95% 
CI, 1.27-4.53; p=0.007). Additionally, MS patients with high sCD27 levels (>31.4 U/mL 
(median)) at time of CIS had a 5.5 times higher annualized relapse rate than patients 
with low sCD27 levels (annualized relapse rate: 0.06 vs 0.33; p=0.02).
Conclusion and relevance: Soluble CD27 in cerebrospinal fluid of CIS patients predicts 
MS diagnosis and a high relapse rate. Therefore, sCD27 is an activation molecule directly 
related to the immunopathology of the disease, and is a potential clinical marker to 
help in treatment decisions after a first attack of suspected MS.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS (central nervous 
system) with large heterogeneity in severity and prognosis.1 There is a growing number 
of therapies that could be administered after the first symptom of CNS demyelination 
(clinically isolated syndrome (CIS)), even before MS diagnosis. Disease-modifying therapies 
(DMTs) delay MS diagnosis, and have a potential to prevent future disability.2-7 However, 
these therapies have side effects, therefore, treating CIS patients who will not reach MS 
diagnosis should be prevented. This underscores the need for biomarkers to predict long-
term prognosis at an early phase of the disease.8,9 
Many studies have shown the crucial role for T cells and B cells in the pathogenesis of
MS.10-13 T cells activated by the TCR/CD3 complex release a soluble form of CD27 (sCD27).14 
CD27 and sCD27 co-stimulate maturing of T cells, and induce activation and proliferation 
of T and B cells.15,16 Increased sCD27 levels have been reported in various autoimmune 
diseases such as systemic lupus erythematosus, rheumatoid arthritis,17-20 and MS.21,20 Soluble 
CD27 is considered a biomarker of active intrathecal T-cell-mediated inflammation. For 
distinguishing MS from non-inflammatory diseases sCD27 showed a higher discriminatory 
power than common humoral markers for active intrathecal inflammation as IgG index or 
presence of oligoclonal bands (OCB).22 Soluble CD27 levels in serum did not discriminate 
normal individuals from patients with MS.21 It is not known if CSF sCD27 levels at time of CIS 
have a predictive value for disease course. The aim of this study was to examine whether 
CSF sCD27 levels in CIS patients, predict MS diagnosis and relapse rate.23
METHODS
Study participants
For this study, data were prospectively collected between March 2002 and May 2015 from 
patients with a first episode of demyelinating disease who visited the neurological clinic 
of Erasmus MC University Hospital in Rotterdam, a tertiary referral centre for patients 
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KEY POINTS
Question: What is the value of soluble CD27 in predicting long-term prognosis in 
patients with clinically isolated syndrome?
Findings: In this prospective study that included 77 patients with clinically 
isolated syndrome, soluble CD27 was independently associated with MS 
diagnosis. Additionally, soluble CD27 was associated with a 5.5-fold higher 
annualized relapse rate.
Meaning: Soluble CD27 in cerebrospinal fluid of patients with clinically isolated 
syndrome could be used to predict which patients will have an active disease 
course at the time of a first attack.
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with MS, in collaboration with several regional hospitals. Patients with CIS were eligible 
for this study if they were between 18-50 years of age. Patients with alternative diag-
noses and patients who suffered from life-threatening comorbidities (i.e. malignancies, 
acquired immunodeficiency syndrome (AIDS)) were excluded from analysis. At baseline 
patients underwent an MRI-scan with gadolinium and routine laboratory tests to rule 
out alternative diagnoses.24 If a lumbar puncture was performed, extra CSF was collec-
ted for the study. CSF samples were aliquoted and stored at -80 degrees. For this study 
we included patients with a CSF sample collected within 6 months after onset of CIS 
and at least 6 months follow-up after CIS. After inclusion, patients were reassessed 
at least annually at the neurology outpatient department. For control group, we used 
CSF from symptomatic controls (SCs), patients with neurological symptoms, but have 
no objective clinical findings to define a specific neurological disease, as defined by 
Teunissen et al.25 Control group patients underwent a lumbar puncture at the neurology 
department of Erasmus MC between January 2002 and April 2014 for reasons other 
than neuroinflammatory diseases. Those were acute headache with no subarachnoid 
hemorrhage, no idiopathic intracranial hypertension and no inflammation (n=15), exclu-
sion of neurosyphilis (n=7), and other (e.g. muscle pain, sensory disturbances without 
CNS pathology) (n=8). 
Standard protocol approvals, registrations, and patient consents
The study protocol was approved by the Ethics Committee of the Erasmus MC University 
Hospital. All prospectively included patients provided written informed consent.
Definitions
An exacerbation of MS was defined as per acute worsening of existing symptoms or 
new symptoms after 30 days of improvement or stable disease and no evidence of alter-
native diagnosis. To be regarded as exacerbation, symptoms should exist for more than 
24h and not be preceded by fever. All exacerbations were confirmed by neurological 
examination.26 The diagnosis of MS in all patients was made according to the McDonald 
criteria (revised in 2010) based on a second clinical relapse or the baseline MRI scan.27 
All patients underwent a baseline MRI scan with gadolinium. A follow-up MRI scan was 
not performed regularly, therefore we did not take the follow-up MRI scan into account 
when defining MS diagnosis. Patients with monophasic CIS did not fulfill McDonald 
criteria (revised in 2010) criteria during follow-up. Disability was measured using the 
Expanded Disability Status Scale (EDSS).28 When patients experienced a second attack, 
EDSS was performed annually. EDSS scores performed within 3 months after exacerbation 
were not used in the analyses. Follow-up was calculated by subtracting CIS date from 
the last visit date. 
Sample preparation and sCD27 ELISA
Collected CSF samples were immediately centrifuged for 10 minutes at 3000 rpm to 
separate the supernatant from cells and cellular elements. After centrifugation, CSF was 
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aliquoted and stored at -80 °C until use for this study.29 Routine CSF diagnostics inclu-
ding IgG index, OCBs, cell count and total protein was performed. Soluble CD27 levels 
were measured twice for each sample using the commercially available enzyme-linked-
immunosorbent assay (ELISA) kit (PeliKine compact human sCD27 kit; Sanquin)14 The 
ELISA was performed according to the manufacturer’s instructions. Concentrations were 
expressed in U/mL by reference to a standard curve supplied with the ELISA kit. The ana-
lysts who performed the experiments were blinded for the clinical diagnosis of patients. 
The detection limit of the ELISA was 5 U/ml. 
Statistical analysis
Statistical analyses were done using SPSS 21.0 (SPSS Inc., Chicago, Illinois, USA) for 
Windows and Graphpad Prism5 (GraphPad, San Diego, USA) for Windows. To assess 
normality of data distribution, we performed the Kolmogorov-Smirnov test. The 
distribution of sCD27 was nonparametric and after log transformation the data were 
normally distributed. Therefore, geometric means were calculated. For group com-
parison of continuous variables, we applied two-tailed t-test (age, follow-up, sCD27) 
or nonparametric Mann-Whitney U test (IgG index, time between CIS and lumbar 
puncture (LP)). Nominal data comparison between groups was done using Chi-square 
or Fisher’s exact test (gender, clinically isolated syndrome type, treatment before MS 
diagnosis, OCB). Time to MS was calculated from onset of first symptoms to MS diag-
nosis (McDonald criteria, revised in 2010).27 Patients who were not diagnosed with MS 
during follow-up were considered as censored observations. Cox proportional hazard 
regression analysis was used to calculate univariate and multivariable hazard ratios. 
The proportional hazard assumption was tested by including time dependent cova-
riate in the model. Odds ratios for MS in the subgroup with >0 subclinical T2 lesions 
on the MRI scan were calculated using binary logistic regression. Annualized relapse 
rate (ARR) was compared between groups using a negative binomial regression model 
with the natural logarithm of number of follow-up years after a second clinical attack 
as offset. This offset corrects for the difference in follow-up between included patients. 
Because of overdispersion of data, we did not use a Poisson regression model. P-values 
<0.05 were considered significant.
RESULTS
Patient characteristics
Inclusion criteria for this study were met by 77 patients with CIS. The mean follow-up 
time for the total CIS group was 52.4 months (SD ±34.5). The median time from CIS to 
MS diagnosis (McDonald criteria, revised in 2010) (n=39) was 7.8 months (IQR: 2.0-41.9). 
Nine patients (11.4%) received DMT (Glatiramer acetate (n=3) or interferon-beta (n=6)) 
in the period between CIS and MS diagnosis. No patients were treated with DMT at time 
of lumbar puncture. Thirty symptomatic controls were age and gender matched. Patient 
and control characteristics are shown in Table 1. Patients with CIS were further stratified 
into MS and monophasic.
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Soluble CD27 levels are higher in CIS patients than in symptomatic control individuals
We first compared sCD27 levels in CSF between CIS patients and controls. After log 
transformation sCD27 levels were normally distributed. Soluble CD27 levels were signifi-
cantly higher in CIS patients than in controls. The geometric mean (95% CI) was respec-
tively 31.3 U/mL (24.0-40.9) vs 4.7 U/mL (2.9-7.5); p<0.01. (Figure 1A)
Soluble CD27 levels are associated with MS diagnosis
Next, we compared CIS patients who were diagnosed with MS (n=39) (mean follow-up time: 
52.4 months (SD ±34.5)) to patients who remained CIS (n=38) during follow-up. Soluble CD27 
levels were significantly increased in CIS patients with a future MS diagnosis (geometric 
mean (95%CI) respectively 42.0 U/mL (29.1-50.6) vs 23.2 U/mL (15.8-33.9); p=0.03. (Figure 1B)
Figure 1.  Comparison of CSF sCD27 levels
A. Comparison of CSF sCD27 levels between CIS versus controls. B. Comparison of CSF sCD27 levels between 
monophasic CIS versus MS. Horizontal lines with error bars indicate geometric mean with 95% CI
High sCD27 levels are associated with shorter time to MS
We stratified data by sCD27 levels using the median sCD27 level (31.4 U/ml) of CIS 
patients as cut-off. In Figure 2, we show that CIS patients with high levels sCD27 had 
a shorter time to MS diagnosis than patients with low sCD27 levels (log-rank test: 
p=0.02). After adjustments (≥9 T2 lesions, contrast enhancement on baseline MRI-scan, 
presence of OCB and IgG index), multivariable Cox regression analyses showed that 
sCD27 is an independent predictive factor for time to MS diagnosis. The HR was 2.4 per 
100 U/mL increase of sCD27 (p=0.007).
A B
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We performed a sub-analysis where we excluded monophasic CIS patients with less 
than two years of follow-up (n=12). The HR in univariate and multivariable Cox analyses 
remained significant (HR: 2.3 per 100 U/mL; p=0.009).
Nine patients (11.8 %) received DMT before MS diagnosis. Seven of nine patients (77.8%) 
had sCD27 levels higher than 2 times the maximum level of the control group. Four of 
them (44.4%) were diagnosed with MS. The log-rank test for time to MS diagnosis was 
more significant when we excluded these nine patients with DMT before MS diagnosis 
(p=0.004). The corrected HR for MS diagnosis was 2.4 per 100 U/mL increase of sCD27 
(p=0.007).
Figure 2.  Time from CIS to 
MS in patients with high 
and low sCD27 levels         
Kaplan-Meier curve for 
time from CIS to MS 
for patients with and 
without high sCD27 levels 
(log-rank test p=0.02).  
Cut-off value: median: 
31.4 U/mL
Annualized relapse rate is higher in patients with high sCD27 levels at time of CIS
The total number of relapses in patients who experienced a second clinical attack (n=31) 
was 26 in a total of 120.9 person-years at risk. The group with high sCD27 levels at time 
of CIS (n=18, using the median sCD27 level in CIS patients as cut-off (31.4 U/mL)) had a 
5.5 times higher ARR during follow-up after the second attack, estimated by negative 
binomial regression analysis with log link, corrected for follow-up time (ARR: 0.06 vs 
0.33; p=0.02). Other possible factors effecting ARR, such as contrast enhancement, 
dissemination in space (McDonald criteria, revised in 2010), more than 9 T2 lesions on 
the first MRI scan, unique OCBs in CSF and proportion of time on DMT, did not have 
significant influence on ARR. However, IgG index was significantly correlated with ARR. 
One point elevation in IgG index was associated with 3.7 times higher ARR (p<0.01). 
Soluble CD27 titer did not correlate with EDSS later in the disease course (data not 
shown). We collected EDSS scores of 24 of 31 patients with a second attack. During 
follow-up only 3 patients reached an EDSS score of 4 or more. Of these, all had high 
sCD27 levels (greater than median of 46.3 U/mL). 
low sCD27 (n) 39 32 25 19 16 19
high sCD27 (n) 38 22 17 12 11 7
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High sCD27 levels at time of CIS are associated with OCB and IgG index 
There was a positive correlation between IgG index and sCD27 in CSF at time of CIS 
(Spearman’s rho: 0.68; p<0.01). CIS patients with more than one unique OCB in CSF (n=54) 
had significantly higher sCD27 levels than CIS patients with no OCBs (n=19) (p<0.01). 
(Figure 3)
Figure 3.  Soluble CD27 levels in CIS patients, CSF and MRI measurements
Horizontal lines with error bars indicate geometric mean and 95% CI
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High sCD27 levels at time of CIS are associated with MRI abnormalities
Patients with more than 9 T2 lesions on the baseline MRI scan (n=24) had higher sCD27 
levels (geometric mean, 52.3 U/mL vs 24.8 U/mL; p=0.009). Patients with no subclinical 
T2 lesion on the brain MRI at time of CIS (n=14) had lower sCD27 levels than patients 
with at least one subclinical T2 lesion (geometric mean: 14.8 vs 37.0; p=0.008). In a 
sub-analysis we selected patients with at least one subclinical T2 lesion (n=63). Within 
this group the odds ratio of high sCD27 (using the median sCD27 level in CIS patients as 
cut-off (31.4 U/mL)) for MS diagnosis was 3.0; p=0.037. In the same subgroup the odds 
ratio for presence of oligoclonal bands did not reach significance (OR: 2.9; p=0.09)
Contrast enhancement on the MRI scan at time of CIS was not associated with sCD27 
levels. (Figure 3.)
DISCUSSION
The rationale behind this study is based on the observation that CSF levels of sCD27 
are significantly elevated in MS versus symptomatic controls.21,22,30 We reasoned that 
a MS-associated biomarker could perhaps predict disease course at first attack, in 
analogy with MS-related MRI abnormalities that can predict future definite MS.27,31,32 
Indeed we demonstrate here that high sCD27 predicts a subsequent diagnosis of MS, 
and is associated with higher attack frequency after diagnosis. 21 of 77 CIS patients 
(27%) had sCD27 levels below the maximum level of controls. These patients clearly 
had a less active disease course. 
Soluble CD27 is a stable molecule, the immune assay is quite reproducible and per-
formed consistently in the literature.21,22,30 It carries some extra attraction as this T-cell 
activation marker appears directly related to the core of immunopathology in MS.10,11,33 
It is of note that Bielekova et al. have found a clear relation between sCD27 levels and 
the presence of intrathecal T cells.22 Amongst an impressive set of CSF inflammatory 
parameters, sCD27 performed best in identifying local inflammation and appeared 
correlated with progression. It seems not farfetched to suggest that higher T-cell acti-
vation is related to higher lesion load and a more active disease course. 
The number of T2 lesions on brain MRI at time of CIS is currently the most predictive 
tool for MS diagnosis. A larger number of T2 lesions result in a shorter time to MS diag-
nosis. Also unique OCBs in CSF are predictive for a second attack in CIS patients.3
In a multivariable analysis we found that the association of sCD27 with future MS 
diagnosis remained after adjustment for known predictive factors such as OCB, IgG 
index, and MRI abnormalities (more than nine T2 lesions, and contrast enhancement 
on baseline MRI-scan). 
In line with previous studies, we observed a correlation between sCD27 and IgG index.21,22,26 
(Figure 3) Whether there is a direct role for sCD27 released by T cells on IgG production 
by B cells is speculative, but such a functional effect has been shown in vitro by Dang et 
al.34 They showed that the binding of sCD27 to the CD27 ligand CD70 on memory B cells, 
stimulates those B cells to differentiate into IgG secreting plasma cells.20,34 
At time of lumbar puncture none of the patients were treated with DMT in this study 
cohort. Nine patients (11.8 %) received DMT before MS diagnosis. Excluding these 
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nine patients from the survival analyses does not have major effects on our results. 
Although the log-rank test for time to MS diagnosis is more significant when we 
exclude the patients with DMT before MS diagnosis. 
In a subgroup of patients with at least one subclinical T2 lesion, high sCD27 was 
associated with MS diagnosis. The sample size was too small for analyses in more 
subgroups. In combination with MRI findings, sCD27 quantification could be helpful in 
decision making for starting immunomodulatory therapy because sCD27 is a marker 
for neuro-inflammation and predicts MS diagnosis and subsequent relapse rate. 
There are some limitations of this study. First, the follow-up time has a wide range. To 
address this problem, we corrected for follow-up in the statistical analysis. We also did 
a sub-analysis in which we excluded monophasic CIS patients with less than 2 years 
follow-up. The HR in univariate and multivariable Cox analyses remained significant. 
Second, all patients underwent a baseline MRI scan with gadolinium, but a follow-up 
MRI scan was not performed uniformly according to a strict protocol. Therefore, we did 
not take the follow-up MRI scan in account when defining patients with MS but used 
the classical Poser criteria based on clinical manifestations. Third, though the sample 
size was sufficient for multivariable analysis, validation in a bigger cohort is required. 
CONCLUSIONS
This study demonstrates that sCD27 levels in CSF of CIS patients helps to predict MS 
diagnosis and a high relapse rate. Therefore, CSF sCD27 could be an activation marker 
directly related to the immunopathology of the disease with potential value for selec-
ting patients with higher subsequent disease activity.
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ABSTRACT
Interleukin-17-expressing CD4+ T helper 17 (Th17) cells are considered as critical regu-
lators of multiple sclerosis disease activity. However, depending on the species and 
pro-inflammatory milieu, Th17 cells are functionally heterogeneous, consisting of subpo-
pulations that differentially produce interleukin-17, interferon-gamma and granulocyte 
macrophage colony-stimulating factor. In the current study, we zoomed in on distinct 
effector phenotypes of human Th17 cells and their correlation with disease activity in 
multiple sclerosis patients. Th memory populations single- and double-positive for C-C 
chemokine receptor 6 (CCR6) and CXC chemokine receptor 3 (CXCR3) were functionally 
assessed in blood and/or cerebrospinal fluid from a total of 59 clinically isolated syndro-
me, 35 untreated and 24 natalizumab-treated relapsing-remitting multiple sclerosis, as 
well as 9 end-stage multiple sclerosis patients. Within the clinically isolated syndrome 
group, 23 patients obtained a second attack within 1 year and 26 patients did not expe-
rience subsequent attacks during a follow-up of more than 5 years. Low frequencies of 
T helper 1 (Th1)-like Th17 (CCR6+CXCR3+), and not Th17 (CCR6+CXCR3-) effector memory 
populations in blood strongly associated with a rapid diagnosis of clinically definite 
multiple sclerosis. In cerebrospinal fluid of clinically isolated syndrome and relapsing-
remitting multiple sclerosis patients, Th1-like Th17 effector memory cells were abundant 
and showed increased production of interferon-gamma and granulocyte macrophage 
colony-stimulating factor compared to paired CCR6+ and CCR6- CD8+ T-cell populations 
and their blood equivalents after short-term culturing. Their local enrichment was 
confirmed ex vivo using cerebrospinal fluid and brain single-cell suspensions. Across 
all pro-inflammatory Th cells analyzed in relapsing-remitting multiple sclerosis blood, 
Th1-like Th17 subpopulation T helper 17.1 (Th17.1; CCR6+CXCR3+CCR4-) expressed the 
highest very late antigen-4 levels and selectively accumulated in natalizumab-treated 
patients who remained free of clinical relapses. This was not found in patients who 
experienced relapses during natalizumab treatment. The enhanced potential of Th17.1 
cells to infiltrate the central nervous system was supported by their predominance 
in cerebrospinal fluid of early multiple sclerosis patients and their preferential 
transmigration across human brain endothelial layers. These findings reveal a dominant 
contribution of Th1-like Th17 subpopulations, in particular Th17.1 cells, to clinical disease 
activity and provide a strong rationale for more specific and earlier use of T cell-targeted 
therapy in multiple sclerosis.
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INTRODUCTION
Multiple sclerosis (MS) is mediated by effector T cells trafficking from the periphery into 
the central nervous system to trigger local inflammation, demyelination and neuro-
degeneration.1 Although current T cell-directed treatment attenuates disease activity, it 
often causes serious complications and does not prevent disease progression in MS.2 To 
improve treatment efficacy and risk management, more in-depth insight into human 
effector T cells during MS onset is warranted. In the earliest clinical presentation of MS, 
clinically isolated syndrome (CIS), increased peripheral CD4+ T cell activation is linked to 
the occurrence of a second attack.3 However, substantial knowledge has been gained 
about specific human T helper (Th) functions, and the exact nature of the pro-inflam-
matory Th subsets involved in MS is incompletely understood.   
Both Th1 and Th17 cells are known to be encephalitogenic, but use distinct transmigrati-
on routes to enter the central nervous system. In experimental autoimmune encephalo-
myelitis, Th1 cells preferentially migrate into the spinal cord, while Th17 cells mainly 
infiltrate the brain.4 This is facilitated by their differential expression of pro-inflam-
matory cytokines, chemokine receptors and integrins.5-7 Interleukin-17 (IL-17) and C-C 
chemokine receptor 6 (CCR6) are key determinants for Th17 transmigration across the 
blood-brain barrier.7, 8 IL-17 is generally considered as the signature cytokine produced by 
CCR6-positive Th17 cells. However, this greatly underestimates Th17 effector function, since 
subpopulations also (co-)produce interferon-gamma (IFN-γ) and granulocyte macrophage 
colony-stimulating factor (GM-CSF). Next to IL-17, also IFN-γ and GM-CSF are strongly pro-
duced by myelin-specific CCR6-positive Th cells in MS.9 Th17 polyfunctionality is differently 
regulated between species, as reflected by the antagonistic regulation of IL-17 and GM-CSF 
expression in human compared to murine Th cells.10-12 Particularly GM-CSF produced by Th 
cells is implicated as a critical mediator of MS onset.13, 14 
The surface expression of another chemokine receptor, CXCR3, defines Th17 cells with 
Th1-like features.15 CCR6 and CXCR3 expression on CD4+ T cells is controlled by transcription 
factors RORγt and T-bet, respectively, which were originally associated with IL-17/IFN-γ 
double-production.15 However, recent findings demonstrate more heterogeneous IL-17, 
IFN-γ and GM-CSF expression profiles in Th17 cells, depending on the inflammatory milieu.16 
Besides CCR6 and CXCR3, also the presence of the α4β1 integrin very late antigen-4 (VLA-4), 
which is abundant on Th17 cells in MS cerebrospinal fluid,17 determines T-cell transmigra-
tion capacities. Anti-VLA-4 monoclonal antibody natalizumab is currently one of the most 
effective therapies in MS, but relapses are still encountered after one year in about one-
third of treated patients.18 Understanding which distinct pro-inflammatory Th subsets are 
targeted by natalizumab will help to better predict treatment response in MS.19
Here, blood and cerebrospinal fluid samples from CIS and both untreated and natali-
zumab-treated relapsing-remitting MS (RRMS) patients were assessed for distribution, 
memory phenotype, activation and pro-inflammatory capacity of Th17 subsets. We 
reveal that IFN-γ-/GM-CSF-producing (CCR6+CXCR3+), but not IL-17-producing (CCR6+
CXCR3-) Th17 effector cells are key regulators of MS onset. A Th1-like Th17 subpopulation 
termed Th17.1 (CCR6+CXCR3+CCR4-) is selectively targeted by natalizumab in MS patients 
who remained free of clinical relapses. This work supports the design and early use of 
therapeutic strategies against Th17.1 cells to prevent relapses in MS.
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MATERIALS AND METHODS
Patients
Characteristics of patients and controls in the screening cohorts are summarized in Table 1. 
Main experimental results were confirmed using additional cohorts (Supplementary 
Table 1). All CIS and RRMS patients as well as controls were included at Erasmus MC 
(Rotterdam, The Netherlands), which is a national tertiary referral centre for MS patients 
(MS Centre ErasMS). All primary material was collected between 2007 and 2017. 
For blood analyses, we selected 23 CIS patients who did not experience a second clinical 
attack for at least 5 years of follow-up (CIS-CIS) and 26 CIS patients who were diagnosed 
with clinically definite MS (CDMS) within 1 year after CIS (CIS-CDMS) from our prospec-
tive cohort. None of these patients were treated with disease-modifying therapies be-
fore or at time of sampling. CIS was defined as a first clinical attack of demyelination in 
the central nervous system.20 CDMS diagnosis was made when a patient experienced two 
attacks with clinical evidence of two separate lesions according to the Poser criteria.21 A 
relapse was defined as sub-acute worsening of existing symptoms, or new symptoms 
after at least 30 days of improvement or stable disease.22 Fatigue scores were acquired 
at time of the first attack using the self-administered Krupp’s Fatigue Severity Scale 
(FSS), as shown previously.23 Anti-EBNA1 IgG levels were determined in plasma using a 
well-validated chemiluminescent assay and analyzer (Liaison XL; both Diasorin, Saluggia, 
Italy) according to manufacturers’ instructions at our local referral centre for virus diag-
nostics (Erasmus MC).   
RRMS patients were diagnosed according to the McDonald 2010 criteria.24 Blood Th 
cell analyses were performed for 31 treatment-naive RRMS patients, as well as for 24 
RRMS patients before start and after both 6 and 12 months of natalizumab therapy. The 
median time between the last clinical attack and first administration of natalizumab 
was 2.8 months (IQR: 1.7-6.3). Seventeen of these patients (70.8%) were treated with 
disease-modifying therapy before initiation of natalizumab (14 with interferon (IFN)-β, 
1 with both dimethylfumarate and fingolimod, 1 with glatiramer acetate and 1 with 
mitoxantron). 
Cerebrospinal fluid with and without paired blood samples were obtained from 14 
early-stage MS patients (ErasMS) and 9 late-stage MS patients (Netherlands Brain Bank, 
Amsterdam). In the early-stage MS group, 10 patients were CIS at the time of lumbar 
puncture and 4 patients were diagnosed with RRMS within 6 months before sampling. 
The median time between sampling and the last clinical attack was 2.8 months 
(IQR: 1.3-5.8). Additional autopsied brain tissues were obtained from 5 late-stage MS 
patients and 2 non-demented controls (Netherlands Brain Bank). All study protocols 
were approved by the medical ethics committee of the Erasmus MC (Rotterdam) and 
VUmc (Amsterdam, The Netherlands). Written informed consent was obtained from all 
included patients and controls.
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Blood, ex vivo
Cohort HC CIS-CIS CIS-CDMS RRMS, no Txg RRMS, Nat Txg
Patients, n 19 16 16 18 17a
Gender, female n (%) 16 (84) 11 (69) 13 (81) 15 (83) 12 (71)
Age (years), median (IQR)b 45 (35-49) 36 (27-40) 33 (28-37) 46 (37-50) 38 (30-46)c
Follow-up time (years), median (IQR) na 6.8 (6.2-7.3) 4.1 (3.1-5.7) na na
Disease duration (months), median (IQR)d na 2.0 (1.3-3.1) 2.0 (1.2-3.0) 120 (48-193) 92 (48-160)c
≥9 T2 lesions at baseline, n (%) na 3 (19) 10 (63) na na
CSF/brain, ex vivo CSF, TCC
Cohorte Early MS Late MS Late NDC Early MS Late MS
Patients, n (paired blood) 4 (4) 5 (5) 2 (2) 10 (4) 7 (7)f
Gender, female n (%) 2 (50) 5 (100) 1 (50) 10 (100) 5 (71)
Age in years, median (IQR)b 32 (18-41) 62 (44-72) 78 (NA) 33 (23-38) 70 (60-82)
Follow-up time (years), median (IQR) 0.3 (0.3-0.5) na na 1.5 (0.6-5.5) na
Disease duration (months), median (IQR)d 3.8 (2.7-5.2) na na 3.8 (1.0-22.4) na
PMD (hours), median (IQR) na 8.5 (8.4-9.2) 6.1 (NA) na 8.6 (8.3-9.3)
pH CSF, median (IQR) na 6.3 (6.3-6.7) 6.5 (NA) na 6.5 (6.3-6.7)
Table 1.  Characteristics of patients and controls in screening cohorts
aFourteen patients were included for in-depth analysis of Th17 subpopulations in blood. For three patients, 
Th subsets were only used for analysis of pro-inflammatory cytokine expression. 
bAt time of sampling
cAt time of pretreatment sampling
dTime from CIS diagnosis to sampling
eSamples obtained from either CIS and RRMS patients (‘early’) or deceased MS patients and NDC (‘late’)
fThree patients were also used for ex vivo CSF/brain T-cell analysis
gRRMS according to the McDonald 2010 criteria
Abbreviations: CDMS, clinically definite MS; CIS, clinically isolated syndrome; CSF, cerebrospinal fluid; 
IQR, interquartile range; na, not applicable or available; Nat, natalizumab; NDC, non-demented control; 
PMD, post-mortem delay; RRMS, relapsing-remitting MS; TCC, T-cell culture; Tx, treatment
Mononuclear cell isolation from blood, cerebrospinal fluid and brain tissue 
Blood from patients and matched controls was collected using Vacutainer CPT tubes (BD 
Biosciences, Erembodegem, Belgium) containing sodium heparin. Peripheral blood mo-
nonuclear cells were isolated according to manufacturer’s instructions. After centrifu-
gation, cells were taken up in RPMI1640 (Lonza, Verviers, Belgium) containing 40% fetal 
calf serum (FCS) and 20% dimethyl sulfoxide (Sigma-Aldrich, Saint-Louis, MO) and stored 
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in liquid nitrogen until further use. Surplus cerebrospinal fluid of early-stage MS patients 
was obtained through lumbar puncture for diagnostic purposes. Blood and cerebrospinal 
fluid samples from late-stage MS patients were acquired post-mortem through heart 
puncture and ventricle drainage, respectively. Collection tubes with cerebrospinal fluid 
were centrifuged for 10 min at 500g. Paired blood and blood from buffy coats were diluted 
in PBS, after which mononuclear cells were isolated by density gradient centrifugation 
using Ficoll-Paque Plus (GE Healthcare, Freiburg, Germany). Cerebrospinal fluid and blood 
mononuclear cell fractions were resuspended in RPMI 1640 containing with 10% heat 
inactivated human AB serum (Sanquin, Rotterdam, The Netherlands) and 1% Pen/Strep 
(Lonza) and left to rest at 37oC until further use. Brain tissue samples were processed and 
single-cell suspensions were obtained as recently published.25 
Short-term cerebrospinal fluid and blood T-cell cultures
Short-term culturing of cerebrospinal fluid-derived T cells was required to obtain suffi-
cient cell numbers for FACS sorting and intracellular cytokine staining of the Th subsets 
of interest. Cerebrospinal fluid and blood T cells were cultured as previously described.26 
In short, mononuclear cell fractions were treated for 13 to 15 days with γ-irradiated 
feeder cells (10x106 PBMC and 1x106 EBV- B-cell lines HAL-02 and RS-411), phytohemag-
glutinin-L (1 ng/ml; Sigma-Aldrich), IL-2 (25 U/ml; Erasmus MC) and IL-15 (12.5 ng/µl; 
Miltenyi Biotec, Leiden, The Netherlands) in RPMI1640 containing L-glutamine (Lonza), 
1% Pen/Strep and 10% heat-inactivated human AB serum. IL-2 and IL-15 were added 
every 3 to 4 days. Post-mortem cerebrospinal fluid samples were re-stimulated using 
the same protocol. 
Antibodies and flow cytometry
Multicolor flow cytometric analysis was performed using the following fluorochrome-
labeled monoclonal anti-human antibodies: CD3 BV785 (SK7), CD8 FITC (SK1), CD45RA 
APC-H7 (HI100), HLA-DR FITC and BB515 (G46-6), VLA-4 BV711 and APC (9F10), CD45RO 
PerCP-Cy5.5 (UCHL1), CD25 BV605 and APC-R700 (2A3), CD226 BB515 (DX11), MCAM 
PerCP-Cy5.5 (P1H12), PSGL-1 APC (KPL-1), GM-CSF BV421 and PE-CF594 (BVD2-21C11; all BD 
Biosciences), CD4 BV510 (OKT4), CD38 BV711 and PerCP-Cy5.5 (HIT2), CXCR3 BV421, PE-Cy7 
and APC (G025H7), CCR6 PE (G034E3), CCR7 PE-CF594 (150503), CCR4 PE-Cy7 and PE-Dazzle 
(L291H4), CD161 BV605 (HP-3G10), IFN-γ BV421 and BV711 (4S.B3), and IL-17A APC (BL168; 
all Biolegend, London, UK). Cells were stained for 30 min at 4oC, measured with an 
LSRII-Fortessa flow cytometer and analyzed using FACSDiva 6.1.2 software (both BD 
Biosciences). Th1, Th17 and Th1-like Th17 cells were defined based on markers CCR6 and 
CXCR3 with and without the use of CCR4. For analyses without CCR4, total CD4+ T cells 
were subdivided into CCR6-CXCR3+ (Th1), CCR6+CXCR3- (Th17) and CCR6+CXCR3+ (Th1-like 
Th17) subsets. In each Th subset, the proportion of effector memory (CCR7-CD45RA-) and 
central memory (CCR7-CD45RA+) cells was analyzed. CCR4 was used 
as a marker to discriminate CCR6-CXCR3+CCR4- (Th1), CCR6+CXCR3-CCR4+ (Th17), 
CCR6+CXCR3+CCR4- (Th17.1) and CCR6+CXCR3+CCR4+ (Th17 double-positive, DP) 
subpopulations.27 
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Intracellular cytokine staining
Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-), Th1-like Th17 (CCR6+CXCR3+), as well as CCR6- and 
CCR6+ CD8+ T cells were sorted from blood and cerebrospinal fluid T-cell memory pools 
(CD3+CD25-/int CD45RO+CD45RA-) using a BD FACSAriaTM III cell sorter. Prior to isolation of 
Th memory subsets from buffy coats, CD4+ cells were purified from the mononuclear 
cell fraction using CD4 microbeads and the autoMACS Pro Separator (both Miltenyi Bio-
tec). Cells were stimulated with phorbol 12-myristate 13-acetate (PMA; 1:2000) and iono-
mycin (1:500; both Sigma-Aldrich) for 5 h. GolgiStop (1:1500; BD Biosciences) was added 
during the last 2.5 h of stimulation. Stimulated cells were fixed and permeabilized using 
the BD Cytofix/CytopermTM kit (BD Biosciences) according to the provided protocol, and 
stained for IFN-γ, GM-CSF and IL-17A within the same tube. 
RNA isolation and quantitative PCR
Sorted T-cell subsets were washed with PBS and resuspended in RNA lysis solution with 
1% 2-ME. Total RNA was extracted using the GenElute™ Total RNA Purification kit (Sig-
ma-Aldrich) and treated with DNase I (Invitrogen, Carlsbad, CA). Complementary DNA 
(cDNA) was synthesized from total RNA using a reaction mix containing Tris-aminome-
thane (200 mM), KCl (500 mM), MgCl2 (0.2M; Sigma-Aldrich), DTT (100mM; Invitrogen), 
random hexamers (50µM; Invitrogen), oligo(dT) 15 primer (100 µg/ml; Promega, Madi-
son, WI), dNTP mix (10 mM; Promega), RNAsin (40 U/µl; Promega) and superscript II (200 
U/µl; Invitrogen). After incubation at 42oC for 50 min and inactivation at 99oC for 3 min, 
cDNA was diluted and stored at -200C until use. For quantitative PCR, 0.2µM forward 
and reverse primer (Sigma-Aldrich), 10 µM probe (Universal Probe Library; Roche Applied 
Science, Penzberg, Germany) and diluted cDNA were added to Taqman Universal PCR 
Master Mix. Target gene expression was measured using optimal primer/probe assays 
and Taqman 7900HT (Applied Biosystems, Foster City, CA). We used the following ther-
mal cycle protocol: 2 min at 50ºC and 10 min at 95ºC followed by 40 cycles of 15 s at 95ºC 
and 1 min at 60ºC. CT values were analyzed using SDS 2.4.1 software (Applied Biosys-
tems). Expression levels of target genes were normalized using 18S rRNA as a reference. 
Primer sequences are indicated in Supplementary Table 2.
T-cell transmigration assays
CD4+CD25-/int memory T cells depleted from naive populations (CCR7+CD45RA+) were 
sorted by FACS and added at 2x105 cells/well to 3 µm pore size transwell plates (Corning, 
Amsterdam, The Netherlands). Migration of Th17 subsets towards medium or CXCL10 
(900ng/ml; R&D Systems, Abingdon, UK) was analyzed after 3 h incubation at 37°C 
using FACS. To assess transendothelial migration of Th17 subsets, migration experiments 
were performed across confluent monolayers of human brain endothelial cells (hCMEC/
D3 cell line)28 on collagen-coated 5 µm pore size transwells, as previously described.29 
In this system, 5x105 Th memory cells were added per well and migration was assessed 
after 4 h.
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Statistical analyses
Statistical analyses were carried out using Graphpad Prism Software, version 5.04. We 
used the two-tailed Mann-Whitney U test to compare two independent groups and 
the Wilcoxon matched-pairs signed rank test to compare samples of the same per-
sons. Correlations were tested using Spearman’s rank. A logistic regression model was 
used to correct for MRI measurements in the multivariable analyses. Experimental data 
are depicted as mean and standard error of the mean. P values less than 0.05 were 
considered significant.
RESULTS
Low frequencies of Th1-like Th17 and not Th17 effector cells in CIS blood associate with 
rapid MS onset
To search for pro-inflammatory Th subsets that are critically involved in early diagnosis 
of clinically definite MS (CDMS), we used PBMC at time of CIS from age- and gender-
matched patients who remained monophasic for at least 5 years (CIS-CIS, n=16) and 
from patients who experienced a second attack within 1 year (CIS-CDMS, n=16; Table 1). 
Flow cytometric analysis of CD4+ T cells showed decreased Th1-like Th17 (CCR6+CXCR3+) 
frequencies in the CIS-CDMS group compared to the CIS-CIS group (median: 5.9% vs 
11.2%, p=0.011; Fig. 1A). After correction for lesion load on MRI at baseline, using a logistic 
regression model, the association remains significant (OR: 0.78 per percent increase in 
Th1-like Th17; p=0.026). In CIS-CDMS, additional reductions in effector memory (EM) to 
central memory (CM) ratios were found for Th1-like Th17 (mean: 0.30 vs 0.50, p=0.005; 
Fig. 1B). Similar but less strong reductions were observed for Th1 (CCR6-CXCR3+; 10.0% 
vs 12.5%, p=0.070 and mean EM/CM ratio: 0.21 vs 0.29, p=0.021). Frequencies and EM/
CM ratios for Th17 (CCR6+CXCR3-) did not differ between CIS-CIS and CIS-CDMS (Fig. 
1A and B). Th subset distribution in CIS patients was not affected after stratification 
for methylprednisolone treatment in the last 3 months prior to sampling (data not 
shown). Finally, Th1-like Th17 EM/CM ratios in CIS blood inversely correlated to anti-
EBNA1 IgG titers (p=0.013; Fig. 1C) and fatigue (p=0.001; Fig. 1D), which were reported as 
independent predictive markers for early CDMS diagnosis.23, 30
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Figure 1.  Reduction of Th1-like Th17 effector cells in the blood of CIS patients with short time to CDMS
CIS patients were selected based on blood sampling within 4 months after diagnosis and time between CIS and 
CDMS. ‘CIS-CDMS’ patients were diagnosed with CDMS within 1 year (n=16; filled bars), while ‘CIS-CIS’ patients 
were not diagnosed with CDMS for at least 5 years (n=16; shaded bars). CD4+ T cells in the blood were compared 
for (A) Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CXCR3+) cell distribution, as well as (B) 
effector memory (EM; CCR7-CD45RA-) to central memory (CM; CCR7+CD45RA-) cell ratios within each of these 
subsets, as determined by flow cytometry. Th1-like Th17 effector to central memory cell ratios were correlated to 
reported predictors of early CIS to CDMS transition, anti-EBNA1 IgG blood titer (C) and fatigue severity scale (FSS; 
D). * p < 0.05; ** p < 0.01
Effector populations of highly activated Th1-like Th17 cells are reduced in blood after 
MS diagnosis
To verify that these selective differences in Th subsets are associated with MS diagno-
sis, we explored total frequencies of blood Th1 EM and Th1-like Th17 EM cells in treat-
ment-naive RRMS patients (n=18, Table 1), and age-/gender-matched healthy controls 
(HC, n=19). Strongly reduced frequencies were found for both these subsets in RRMS 
(median: 1.1% and 0.7%) compared to CIS-CIS (1.9%, p < 0.001 and 2.8%, p < 0.0001) and 
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HC (2.8%, p < 0.001 and 3.3%, p < 0.0001; Fig. 2A). These frequencies did not significantly 
differ between the RRMS and CIS-CDMS (1.0% and 1.3%) group. In RRMS, a significant 
proportion of blood Th1-like Th17 cells was positive for both CD38 and HLA-DR (Fig. 2B), 
indicating a highly activated phenotype after MS diagnosis. This was not seen for Th1 
cells (Fig. 2B). These data suggest that Th1-like Th17 effector cells are selectively activated 
in the periphery and recruited to the central nervous system during MS onset.    
Figure 2.  Th1-like Th17 effector cells are highly activated and less present in the blood after MS diagnosis 
(A) Th1 and Th1-like Th17 effector memory (EM) frequencies in CD4+ T cells from CIS-CIS (n=14) and CIS-CDMS 
(n=16) as well as RRMS (n=18) and both age- and gender-matched healthy control (HC; n=19) blood. 
(B) Highly activated fractions of blood Th1 and Th1-like Th17 cells in CIS-CIS (n=14), CIS-CDMS (n=16) and RRMS 
(n=18) patients as well as HC (n=19), as defined by co-expression of late T-cell activation markers HLA-DR and 
CD38. * p < 0.05; ** P < 0.01; *** p < 0.001; **** p < 0.0001  
Predominant expression of T-bet and RORγt, as well as IFN-γ and GM-CSF, but not IL-17A 
by activated blood Th1-like Th17 cells 
Human CCR6+ CD4+ T cells are not only strong producers of IL-17, but also express IFN-γ 
and GM-CSF.9, 27 To explore how these pro-inflammatory cytokines are co-regulated in 
our phenotypically defined Th1-like Th17 (CCR6+CXCR3+) cells, T-bet and RORγt, as well as 
IFN-γ, GM-CSF and IL-17A expression was compared to paired Th1 (CCR6-CXCR3+) and Th17 
(CCR6+CXCR3-) populations from healthy blood donors. Th1-like Th17 expressed both T-bet 
and RORγt mRNA at higher levels than Th1 (p=0.016 and p=0.004) and Th17 (p=0.008 and 
p=0.039, respectively; Fig. 3A). IFN-γ mRNA levels were similar between Th1 and Th1-like 
Th17, while GM-CSF mRNA levels in Th1-like Th17 were higher than in Th1 (p=0.008) and Th17 
(p=0.020). Th1-like Th17 cells only moderately expressed IL-17A mRNA (Fig. 3B). Differences 
in IFN-γ, GM-CSF and IL-17A expression were verified on protein level (Fig. 3C). The percen-
tage of GM-CSF-positive cells was 2- to 3-fold higher in Th1-like Th17 than in Th1 and Th17. 
IL-17A-positive cells were approximately 4-fold less present in Th1-like Th17 compared to 
Th17. At single-cell level, IFN-γ was mainly co-expressed with GM-CSF and not with IL-17A in 
Th1-like Th17 cells (Fig. 3D). These cytokine profiles were the same for Th subsets from CIS 
and RRMS blood (data not shown). TNF-α expression was comparable between Th1, Th17 
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and Th1-like Th17 subsets (Fig. 3B). CD226 was higher, while CD25 and FoxP3 were lower 
expressed by Th1-like Th17 as compared to Th17 (Fig. 3A and Supplementary Table 3), which 
supported their pro-inflammatory potential.31, 32 Th1-like Th17 cells also showed sustained 
CD161 expression (Supplementary Table 3), reflecting an ex-Th17 phenotype.33 
Figure 3.  Blood Th1-like Th17 cells predominantly express T-bet and RORγt, and are high IFN-γ and GM-CSF, but 
low IL-17A producers 
Buffy coats from 9 healthy blood donors were used to assess gene expression of TBX21, RORC and FOXP3 (A), as 
well as IFNG, CSF2, IL17A and TNFA (B) in sorted Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CXCR3+) 
memory populations. Cells were stimulated with PMA and ionomycin and mRNA levels were measured using 
quantitative PCR. (C) Flow cytometric analysis of intracellular IFN-γ, GM-CSF and IL-17A expression in PMA- and 
ionomycin-stimulated Th1, Th17 and Th1-like Th17 memory cells from the same blood donors (n=7). (D) Represen-
tative dot plots and quantification of co-expression of IFN-γ with GM-CSF and IL-17A in Th1-like Th17 memory 
cells (n=7). * p < 0.05; ** p < 0.01
A B
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Th1-like Th17 cells of MS patients are more abundant and pro-inflammatory in 
cerebrospinal fluid than in paired blood T-cell cultures
To explore the local pro-inflammatory capacity of Th1-like Th17 cells in early MS, cerebro-
spinal fluid (n=10) and paired blood (n=4) T-cell subsets from early-stage MS patients 
(Table 1) were analyzed after short-term culturing. Th1 and Th1-like Th17 were the main 
populations in the cerebrospinal fluid CD4+ T-cell pool (Fig. 4A). Proportions of Th1-like 
Th17 were higher than those of Th1 (p=0.020) and their equivalents in blood (2- to 3-fold 
increase; Fig. 4B). Similar results were obtained with EM/CM ratios, which were high for 
both subsets but most prominent in Th1-like Th17 cells in cerebrospinal fluid (Fig. 4C). Within 
the total cerebrospinal fluid T-cell pool, Th1-like Th17 cells were enriched and co-produ-
ced more IFN-γ and GM-CSF compared to CCR6- and CCR6+ CD8+ T cells, and paired blood 
counterparts (Fig. 4D to G). The percentage of IFN-γ-positive cells was increased in cere-
brospinal fluid Th1-like Th17 versus Th1 (Fig. 4E). The enrichment of Th1-like Th17 in cere-
brospinal fluid compared to blood (Fig. 4A and B) was also found in T-cell cultures from 
late-stage MS patients (n=7, p=0.016; Table 1 and Fig. 4H), suggesting that Th1-like Th17 
recruitment to the central nervous system also occurs at later stages of the disease.
Figure 4.  Prevalence of pro-inflammatory Th1-like Th17 cells in CIS and MS CSF compared to blood T-cell cultures. 
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(A-D) Presence of Th1-like Th17 (CCR6+CXCR3+) subsets in short-term cerebrospinal fluid T-cell cultures from 10 
early-stage MS patients (CIS, n=7; RRMS, n=3). Cerebrospinal fluid Th1-like Th17 were compared to Th1 cells and 
their equivalents in blood for percentages in the total CD4+ T-cell pool (A, B) and for effector memory (EM) to 
central memory (CM) ratios (C) from the same patients. Similar analyses were performed for cerebrospinal fluid 
Th1-like Th17 and both CCR6- and CCR6+ CD8+ T-cell subsets within the total T-cell pool (D). These T-cell subsets 
were separated, stimulated with PMA and ionomycin and assessed for intracellular expression of (E) IFN-γ, (F) 
GM-CSF and (G) IFN-γ with GM-CSF. For each analysis, Th1-like Th17 subsets were compared between paired 
cerebrospinal fluid and blood T-cell cultures. (H) Th1-like Th17 frequencies in T-cell cultures from paired blood and 
cerebrospinal fluid of late-stage MS patients (n=7). * p < 0.05; ** p < 0.01
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Ex vivo Th1-like Th17 cells are enriched in the central nervous system and accumulate in 
the blood after natalizumab treatment of MS patients
To confirm their recruitment to the central nervous system, we compared ex vivo Th1 
and Th1-like Th17 frequencies in single-cell suspensions of 10 brain tissues and paired 
cerebrospinal fluid and blood samples of 5 late-stage MS patients (Table 1, Fig. 5A and 
B). Th1 and Th1-like Th17 cells were overrepresented, while Th17 cells were hardly seen in 
MS brain tissues and cerebrospinal fluid, in contrast to blood. The enrichment of Th1-like 
Th17 was also found in cerebrospinal fluid, but was less in brain tissues from 2 non-
demented controls (Fig. 5B), suggesting that enhanced infiltration of Th1-like Th17 cells 
into the brain parenchyma is associated with MS.34-36 
In addition to chemokine receptors and pro-inflammatory cytokines,6, 7 adhesion molecules 
play a key role in migration of peripheral Th cells into the central nervous system, including 
VLA-4, MCAM and PSGL-1.37 Interestingly, VLA-4 but not MCAM and PSGL-1 was the most 
abundant on Th1-like Th17 cells (Supplementary Table 3). In RRMS patients (n=14), blood 
Th1-like Th17 proportions were elevated after 6 months of treatment with natalizumab 
(anti-VLA-4 monoclonal antibody; median pre- vs post-Tx: 7.7% vs 10.4%, p=0.006; Fig. 5C 
and Table 1). Th1-like Th17 cells did not show differences in EM/CM ratio (data not shown), 
but their activation state (see also Fig. 2B) was significantly reduced after natalizumab the-
rapy (Fig. 5D). Th1-like Th17 showed increased capacity to produce IFN-γ and GM-CSF in post- 
versus pre-treatment blood samples (Fig. 5E and F). These results show that the effects of 
natalizumab in MS are associated with an accumulation of Th1-like Th17 cells in the blood.
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Figure 5.  Th1-like Th17 recruitment to the central nervous system and targeting by natalizumab in MS patients.
(A) Presence of Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CXCR3+) cells in single-cell suspen-
sions from brain tissue, cerebrospinal fluid and blood of an MS patient, as determined by FACS. (B) Th1-like Th17 
frequencies in 10 brain tissues and paired cerebrospinal fluid and blood samples from 5 different MS patients 
(filled shapes). Similar analyses were performed for 2 non-demented controls (NDC; open shapes). Each shape re-
presents a different donor. For Th1-like Th17 cells in MS blood, frequencies (n=14; C), activation (n=14; D) as well as 
pro-inflammatory capacities (n=6; E and F) were determined before and 6 months after natalizumab treatment. 
T-cell activation was assessed by surface expression of both HLA-DR and CD38. To determine their pro-inflamma-
tory capacity, Th1-like Th17 memory cells were isolated from pre- and post-treatment blood, stimulated with PMA 
and ionomycin, and stained for intracellular IFN-γ and GM-CSF. * p < 0.05; ** p < 0.01      
B C D
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Predominant targeting of VLA-4high Th17.1 cells by natalizumab in MS patients who do 
not experience clinical relapses
To assess the selectivity of natalizumab effects on pro-inflammatory Th populations in MS 
patients, CCR4 was included as a surface marker in our flow cytometric panels for subdi-
vision of Th1-like Th17 into recently described pathogenic Th17.1 (IFN-γhighGM-CSFhighIL-17low) 
and Th17 double-positive (DP; IFN-γlowGM-CSFlowIL-17int) subpopulations 27, 38. Th17.1 
(CCR6+CXCR3+CCR4-) frequencies were significantly increased in RRMS blood samples 
after both 6 and 12 months of treatment (median: 5.3% and 6.1%) versus pre-treatment 
(3.7%; n=14, both p=0.0002; Table 1; Fig. 6A and B). No significant differences were found 
in Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+) and Th17 DP (CCR6+CXCR3+
CCR4+) cells (Fig. 6A and B). Importantly, this accumulation of Th17.1 was most pronounced 
in natalizumab-treated patients who were free of clinical relapses (n=9; pre-Tx, 3.8% vs 
6m post-Tx, 6.5% and 12m post-Tx, 6.8%; p=0.008 and p=0.004, respectively). As com-
pared to patients who had relapses during treatment (n=5; pre-Tx, 3.2% vs 6m post-Tx, 
4.0% and 12m post-Tx, 4.1%; Fig. 6C). The accumulation of Th17.1 cells in the blood of 
clinical responders was validated using a second cohort (Supplementary Table 1; Sup-
plementary Fig. 1A).     
In pre-treated RRMS blood, VLA-4 surface expression on Th17.1 (mean MFI: 2603) was the 
highest of all pro-inflammatory Th subsets analyzed, including Th1 (MFI: 1328, p=0.001), 
Th17 (MFI: 1255, p=0.0001) and Th17 DP (MFI: 2038, p=0.002; Fig. 6D and Supplementary 
Fig. 1B). After natalizumab treatment, VLA-4 was downregulated on all subsets analyzed, 
but this was most prominent for Th17.1 (mean reduction: 6m post-Tx, 56%, 12m post-Tx, 
58%), as compared to Th1 (6m post-Tx, 52%, p=0.038; 12m post-Tx, 54%, p=0.005), Th17 
(6m post-Tx, 37%, p=0.003; 12m post-Tx, 38%, p=0.0009) and Th17 DP (6m post-Tx, 49%, 
p=0.002; 12m post-Tx, 50%, p=0.002; Fig. 6E). This indicates that Th17.1 cells are prefe-
rentially targeted by natalizumab treatment, preventing their transmigration into the 
central nervous system of MS patients. 
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Figure 6.  Selective accumulation of Th17.1 cells in natalizumab-treated MS patients who do not experience 
clinical relapses. 
Using CCR4 as an additional marker, Th1-like Th17 cells were subdivided into Th17.1 (CCR6+CXCR3+CCR4-) and Th17 
DP (CCR6+CXCR3+CCR4+) subsets and analyzed in natalizumab-treated RRMS patients by flow cytometry (A). Th1 
(CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 and Th17 DP cells were monitored in pre- and both 6 and 12 
months post-treatment blood samples (n=14; B). Th17.1 proportions were separately evaluated in relapse-free (n=9) 
and relapsing (n=5) treatment groups (C). VLA-4 surface expression levels were determined on these Th subpopula-
tions before (D) and both 6 and 12 months after (E) natalizumab treatment. * p < 0.05; ** P < 0.01; *** p < 0.001
Pathogenic Th17.1 cells have a superior capacity to transmigrate into the central nervous 
system in early MS
To further study the central nervous system transmigration potential of Th17.1 in MS, we 
performed different in vitro transwell migration assays using total Th memory cell frac-
tions. Th17.1 was the main Th17 subpopulation migrating across transwell filters towards 
inflammatory mediator CXCL10 (Fig. 7A and B).39 No migration was observed towards 
5
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medium only (data not shown). Particularly Th17.1 cells did show spontaneous transmi-
gration across human brain endothelial layers (hCMEC/D3), which was enhanced under 
CXCL10-attracting conditions (Fig. 7C and D).
In addition, ex vivo flow cytometric analysis revealed an enrichment of Th17.1 versus 
Th17 and Th17 DP cells in cerebrospinal fluid versus paired blood samples from 4 
early-stage MS patients (3 CIS and 1 RRMS; Table 1; Fig. 7E and F). Consistently, lowered 
Th17.1 frequencies were found in the blood from 26 CIS-CDMS versus 21 CIS-CIS patients 
(p=0.019), as well as 13 RRMS patients versus 12 matched HC (p=0.031; Fig. 7G and Sup-
plementary Table 1). Both Th17.1 and Th17 DP cells were abundant in cerebrospinal fluid 
compared to blood from late-stage MS patients (Supplementary Fig. 2).    
Finally, to confirm that Th17.1 is a distinct pro-inflammatory Th17 subset, we evaluated 
the expression of key regulators of Th17 differentiation and pathogenicity. Along with 
VLA-4 (see also Fig. 6D), CD161, CD226, MDR1 (ABCB1), IL-23R, STAT4, TOSO and GZMB 
(granzyme B; all upregulated), as well as CD25 and BATF (downregulated) were discrimi-
native markers for Th17.1 (Supplementary Table 3 and Supplementary Fig. 3). The abun-
dant expression of T-bet, RORγt, IFN-γ and GM-CSF in Th17.1 cells (Supplementary Fig. 4) 
confirmed the pronounced Th1 features of this Th17 subset.27 
Collectively, these data demonstrate the propensity of Th17.1 cells to recruit to the cen-
tral nervous system and mediate disease activity in early MS.  
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Figure 7.  Enhanced central nervous system transmigration potential of Th17.1 cells and their recruitment to 
cerebrospinal fluid in early MS. 
Total Th memory cells were sorted from healthy blood and used to assess the in vitro transmigration capacities 
of Th17, Th17.1 and Th17 DP cells across transwell membranes (A and B; n=6) and monolayers of human brain 
endothelial cells (BEC; C and D, n=4) towards CXCL10. Each experiment was performed in quintuplicate. Th17 
subset distribution was assessed before (‘control’) and after migration towards medium or CXCL10 using FACS. 
(E and F) Ex vivo Th17, Th17.1 and Th17 DP frequencies of CCR6+ Th cells in paired cerebrospinal fluid and blood 
from 4 early MS patients. (G) The presence of Th17.1 cells in blood samples from 21 CIS-CIS, 26 CIS-CDMS and 13 
treatment-naive RRMS patients, as well as 12 healthy controls (HC), as determined by FACS. * p < 0.05
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DISCUSSION
In this study, we demonstrate that IFN-γ- and GM-CSF-expressing Th1-like Th17 
(CCR6+CXCR3+) cells are selectively associated with early disease activity in MS patients. 
During disease onset, highly activated and effector memory Th1-like Th17 cells are mar-
kedly reduced in the peripheral blood and represents the main pro-inflammatory T-cell 
population within cerebrospinal fluid. This local recruitment seemed to be preferentially 
targeted by natalizumab treatment to prevent subsequent MS relapses, since a Th1-like 
Th17 subpopulation termed Th17.1, and no other Th subsets, predominantly accumulated 
in the blood of relapse-free patients. The current work provides in-depth insights into 
the pro-inflammatory capacity of distinct CCR6+ Th subpopulations during the course of 
MS,9 and offers new possibilities to fine-tune currently approved T-cell directed treat-
ment for MS patients. 
The use of both CCR6 and CXCR3 as discriminating markers for Th17 cells does not only 
reflect their pro-inflammatory state, but also their capability to migrate into local inflam-
matory sites. Previous studies on Th17 cells in experimental autoimmune encephalo-
myelitis and MS primarily focused on single expression of CCR6,9 or IL-17, which is 
increased in blood and is further upregulated in cerebrospinal fluid during a relapse.17 
Here, we demonstrated that additional expression of CXCR3 subdivides human CCR6+ 
Th17 into high (CXCR3-) and low (CXCR3+) producers of IL-17A. In these IL-17low producers, 
which were overrepresented in early-stage MS cerebrospinal fluid compared to blood 
T-cell cultures, GM-CSF is the major pro-inflammatory cytokine expressed together with 
IFN-γ. This is likely caused by their elevated levels of T-bet, and not RORγt, as previously 
reported for human Th cells.11 The association of Th1-like Th17 (T-bet-dependent) and 
not Th17 (RORγt-dependent) with a short time to CDMS diagnosis is supported by the 
expression of T-bet, and not RORγt in CD4+ T cells during rapid MS onset.40 Th1-like Th17 
cells were also highly activated after MS diagnosis, which links to the important role of 
CD4+ T-cell activation in CIS progression.3 This suggests that during MS disease onset, 
the loss of T regulatory function41 results in the activation of peripheral Th1-like Th17 
subsets, which infiltrate the central nervous system to mediate local inflammation. 
Indeed, memory Th cells of relapsing MS patients were more capable of differentiating 
into Th1-like Th17 cells, albeit co-producing IFN-γ and IL-17.35 These Th cells were cultured 
in the presence of IL-23, prompting RORγt and subsequently IL-17 expression.11 In our 
CCR6- and CXCR3-based approach, we defined pro-inflammatory cytokine profiles of 
Th17 and Th1-like Th17 populations directly from the blood. This could explain why we 
identified IFN-γ/GM-CSF- and not IL-17-producing Th17 cells as the most pro-inflamma-
tory subset in early MS, and also agrees with the minimal influence of IL-17 and strong 
impact of GM-CSF on experimental autoimmune encephalomyelitis induction.13, 42, 43 For 
proper analysis of cytokine production by Th1-like Th17 cells in cerebrospinal fluid, we 
had to add IL-2 to short-term T-cell cultures, inducing GM-CSF expression.11 Th1-like Th17 
subsets co-produced more IFN-γ and GM-CSF than other T-cell subsets in cerebrospinal 
fluid and their counterparts in blood. Our finding that pro-inflammatory Th1-like Th17 
and especially Th17.1 cells were highly enriched in cerebrospinal fluid of early-stage MS 
patients is in line with their reduced frequencies in the blood (this study), and the incre-
ased cerebrospinal fluid CD4 to CD14 ratios in CIS patients with a short time to CDMS.44 
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Consistent with in situ observations in MS brain tissue,35 a small fraction of blood and 
cerebrospinal fluid Th1-like Th17 and Th17.1 cells did co-produce IFN-γ and IL-17, but this 
was considerably less than their co-production of IFN-γ and GM-CSF. Besides Th17.1, also 
Th17 DP (IL-17int) cells were enriched in cerebrospinal fluid of late-stage MS patients, sug-
gesting that local IL-17 production is mainly involved in disease progression. Nevertheless, 
the predominance of Th1-like Th17 cells in MS cerebrospinal fluid and brain tissues as 
observed in this study corresponds to more recent findings that central nervous system 
inflammation in MS is largely mediated by infiltrating IFN-γ- and not IL-17-producing 
Th cells.34, 36, 45
Th1-like Th17 cells contain several features promoting their selective intrusion into the 
central nervous system, although local Th17 plasticity cannot be completely ruled out.46 
Th1-like Th17 cells produce high levels of IFN-γ, triggering CXCL10 expression by endothe-
lial cells to favor CXCR3-mediated migration into the central nervous system,36, 47 and 
thereby MS disease activity,48 which is supported by our in vitro and ex vivo transmigra-
tion results. Additional expression of GM-CSF by this subset may further dysregulate 
the blood-brain barrier, as described for monocytes.49 Prior to their extravasation, Th17 
cells make use of distinct molecules involved in the rolling on and adhesion to endothelial 
cells, which are activated by pro-inflammatory cytokines and chemokines.37, 50, 51 One of 
these molecules is the α4β1-integrin VLA-4, which is targeted by natalizumab to cause 
a strong reduction of lymphocytes in MS cerebrospinal fluid.52 In addition to previous 
work,53 we now show that only a particular Th1-like Th17 subpopulation termed Th17.1 
accumulates in the blood from MS patients who clinically respond to natalizumab 
treatment. These selective effects may thus be useful for predicting freedom from MS 
activity,19 and understanding the potential lethal MS rebounds that occur in patients 
who have to stop this treatment due to increased risk of progressive multifocal leuko-
encephalopathy (PML).54, 55 MS rebounds are characterized by a rapid influx of pro-
inflammatory cells into the central nervous system to cause excessive inflammation, 
potentially resulting in PML-immune reconstitution inflammatory syndrome (IRIS).56 
Although not proven yet, the marked accumulation of Th17.1 in natalizumab-treated MS 
blood puts forward their transmigration into the central nervous system as a critical 
process during these complications. Out of all pro-inflammatory Th subsets defined by 
CCR6, CXCR3 and CCR4, Th17.1 revealed the strongest VLA-4 surface expression levels in 
MS blood, which explains their restricted targeting by natalizumab. Consistent with our 
results, VLA-4 levels were found to be higher on Th17 than on Th1 cells in MS patients, 
probably mediating their trafficking into the central nervous system.17 However, when 
we compared individual Th17 subpopulations, i.e. CCR6+ Th17 (CXCR3-CCR4+; IL-17high), Th17 
DP (CXCR3+CCR4+; IL-17dim) and Th17.1 (CXCR3+CCR4-; IL-17low),27 VLA-4 surface expression 
seemed to be inversely associated with their ability to produce IL-17, as also described 
for mice.57 The predominant expression of VLA-4 on Th17.1 cells closely parallels the de-
pendence of IFN-γ- and not IL-17-producing Th cells on this integrin for their entry into 
the central nervous system during experimental autoimmune encephalomyelitis.57, 58 
However, adhesion molecules other than VLA-4 must be taken into account for alterna-
tive transmigration routes of pro-inflammatory Th17 cells as well,50 especially conside-
ring the rebound effects after natalizumab discontinuation in MS. 
This cross-sectional study exemplifies that a more refined evaluation of chemokine 
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surface receptors, pro-inflammatory cytokines and adhesion molecules is warranted 
to better understand the contribution of human Th1 and Th17 to MS and other 
autoimmune and neuroinflammatory diseases. Based on CCR6/CXCR3, IFN-γ/GM-
CSF and VLA-4 expression, we identify Th1-like Th17 as a clinically relevant CD4+ T-cell 
population during disease onset and treatment in MS patients. Future work on the 
localization and antigen specificity of these subsets in human brain lesions will be 
critical to determine their local impact on myelin and axonal loss in MS. The prominent 
association of Th1-like Th17 cells, in particular Th17.1, with MS activity suggests the 
possibility for more specific T cell-targeted therapies, and pleads for further assessment 
of the use of natalizumab earlier in the disease course of MS.59             
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SUPPLEMENTARY TABLES AND FIGURES
Blood, ex vivo
Cohort HC CIS-CIS CIS-CDMS RRMS, no Tx RRMS, Nat Tx
Patients, no. 12 21a 26a 13 9b
Gender, female no. (%) 8 (67) 15 (71) 21 (81) 10 (77) 5 (56)
Age in years, median (IQR)c 33 (28-48) 35 (29-39) 33 (27-36) 45 (37-54) 28 (21-43)d
Follow-up time in years, 
median (IQR)
na 7.0 (6.1-7.3) 3.7 (2.5-5.8) na na
Disease duration in months, 
median (IQR)e
na 2.4 (1.3-3.8) 2.6 (1.4-3.4) 113 (38-130) 33 (24-57)d
≥9 lesions on T2-weighted 
images at baseline, no. (%)
na 6 (29) 13 (50.0) na na
Supplementary Table 1.  Characteristics of patients and controls in additional cohorts
a14 CIS-CIS and 16 CIS-CDMS were also included in the screening cohorts (see Table 1); b2 natalizumab-treated 
RRMS patients were also used for analysis of pro-inflammatory cytokine expression only (Table 1); cat time of 
sampling; dat time of pre-treatment sampling. RRMS according to the McDonald 2010 criteria; etime CIS diagno-
sis to sampling. 
Abbreviations: CDMS, clinically definite MS; CIS, clinically isolated syndrome; IQR, interquartile range; na, not 
applicable or available; Nat, natalizumab; RRMS, relapsing-remitting MS; Tx, treatment
Supplementary Table 2.  qPCR primer sequences
Gene Forward primer Reverse primer
ABCB1 GGAAATTTAGAAGATCTGATGTCAAAC CACTGTAATAATAGGCATACCTGGTC
BATF ACACAGAAGGCCGACACC CTTGATCTCCTTGCGTAGAGC
CSF2 TCTCAGAAATGTTTGACCTCCA GCCCTTGAGCTTGGTGAG
FCMR GAACCTTCCTGCCATCCA GAGCCATAGTCCAGTGCTCTC
FOXP3 ACCTACGCCACGCTCATC TCATTAAGTGTCCGCTGCT
GZMB CGGTGGCTTCCTGATACAA CCCCAAGGTGACATTTATGG
IFNG GGCATTTTGAAGAATTGGAAAG TTTGGATGCTCTGGTCATCTT
IL17A TGGGAAGACCTCATTGGTGT GGATTTCGTGGGATTGTGAT
IL23R CCTGGCTCTGAAGTGGAATTA GGCTATTACTGCATCCCATTG
RORC AGAAGGACAGGGAGCCAAG CAAGGGATCACTTCAATTTGTG
STAT4 CCAATGGGAGTCTCTCAGTAGAA TGTGACAGCCCTCATTTCCT
TBX21 GTCCAACAATGTGACCCAGA AAAGATATGCGTGTTGGAAGC
TNF CAGCCTCTTCTCCTTCCTGAT GCCAGAGGGCTGATTAGAGA
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Supplementary Figure 1.  (A) Validation of Th17.1 accumulation in the blood of 9 MS patients after natalizumab 
treatment. 
Frequencies of Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP 
(CCR6+CXCR3+CCR4+) cells within the CD4+ T-cell pool were compared pre- and 12m post-treatment using multico-
lor flow cytometry. (B) Representative gating and percentages of VLA-4+ cells within Th1, Th17, Th17.1 and Th17 DP 
subpopulations in pre-treatment MS blood
Supplementary Figure 2.  Flow cytometric analysis of Th17 subpopulations in paired ex vivo CSF and blood sam-
ples of 3 late-stage MS patients.
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Supplementary Figure 3.  Validation of Th17.1 as a distinct Th17 subset based on the expression of key genes 
involved in Th17 differentiation and pathogenicity. 
We sorted memory Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP (CCR6+CXCR3+CCR4+) cells 
of 7 healthy blood donors and compared the relative expression levels of ABCB1 (MDR1), IL23R, STAT4, BATF, 
FCMR (TOSO) and GZMB (granzyme B). For FCMR and GZMB expression analyses, Th subsets were activated with 
anti-CD3/CD28 abs for 24 h.
Supplementary Figure 4.  Validation of Th17.1 as a distinct Th17 subset based the expression of Th1- and 
Th17-associated pro-inflammatory cytokines and transcription factors. 
Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP (CCR6+CXCR3+CCR4+) 
cells were sorted from 7 healthy blood donors and compared for mRNA (A) and protein (B) expression of IFN-γ 
(IFNG), GM-CSF (CSF2), IL-17A (IL17A), T-bet (TBX21) and RORγt (RORC).
A
B
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ABSTRACT
Background: Cigarette smoking is a modifiable risk factor that influences the disease 
course of patients with multiple sclerosis (MS). However, in patients with a clinically 
isolated syndrome (CIS) there are conflicting results about the association between 
smoking and the risk of a subsequent MS diagnosis. The aim of this study was to deter-
mine the risk of clinically definite MS (CDMS) in smoking and non-smoking patients at 
time of a first demyelinating event. 
Methods: Two hundred and fifty patients, aged 18-50 years, were included in our 
prospective CIS cohort. At time of the first neurological symptoms, patients completed 
a questionnaire about smoking habits. Cox regression analyses were performed to 
calculate univariate and multivariable hazard ratios for CDMS diagnosis in smoking and 
non-smoking CIS patients.
Results: One hundred and fourteen (46%) CIS patients were diagnosed with CDMS 
during a mean follow-up of 58 months. In total, 79 (32%) patients smoked at time of CIS. 
Sixty-seven % of the smoking CIS patients were diagnosed with CDMS during follow-up 
compared to 36% of the non-smoking CIS patients (p<0.001). Smoking at time of CIS 
was an independent predictor for CDMS diagnosis (HR: 2.3; p=0.002). Non-smoking CIS 
patients who had a history of smoking did not have a higher risk for CDMS than those 
who had never smoked. 
Conclusions: Smoking at time of CIS was an independent risk factor for a future CDMS 
diagnosis. This is an additional argument to quit smoking at time of the first attack of 
suspected MS.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease, influenced by 
environmental factors in genetically susceptible individuals.1 This results in demyelination, 
axonal loss and neurodegeneration.1-3 The course of MS is heterogeneous in severity and 
prognosis.1 
One of the environmental factors influencing the course of MS is cigarette smoking.4 
Studies in MS patients and healthy controls consistently provide evidence that both 
active and passive smoking result in an increased risk of MS and disease progression.4-7 
Smoking does not only increase MS risk, it also shortens the time to the secondary 
progressive phase of MS (SPMS).8, 9 It has been shown that after cessation of smoking, 
negative effects slowly decrease, independent of the cumulative dose of smoking.8, 10 
Studies show that the risk of MS associated with HLA genotypes is influenced by smo-
king. This interaction leads to a much stronger effect on MS risk than the cumulative 
effect of genetic risk factors and smoking together.11, 12
In the majority of cases (85-90%) MS starts as a clinically isolated syndrome (CIS), fol-
lowed by novel episodes of neurological symptoms resulting from inflammation of the 
central nervous system (CNS). However, a CIS attack can also remain a single event.13 
Only a few studies are available in CIS patients that investigated the effect of smoking 
on subsequent MS risk. Firm conclusions in these studies are hampered by several 
methodologic issues such as low patient numbers, retrospective designs,14-16 or consi-
derable numbers of CIS patients treated with interferon-beta.17, 18 On the other hand, 
several studies in MS patients do suggest a link between smoking and MS progression.7 
Therefore, we determined the effect of smoking on clinically definite MS (CDMS) risk in 
a large prospective cohort of predominantly untreated CIS patients. It is important to 
know if smoking is associated with a future MS diagnosis, as smoking is up to now, one 
of the few modifiable risk factors for disease progression in MS. 
METHODS
Patients
Data were collected prospectively from patients with CIS at the Neurology department 
of Erasmus MC University Hospital in Rotterdam, a tertiary referral centre for patients 
with MS. Data collection was in collaboration with several regional hospitals in The 
Netherlands. Included patients had their first symptoms between May 2006 and June 
2017. Patients were aged between 18 and 50 years, with no history of previous neurolo-
gical symptoms suggestive of CNS demyelination. CIS patients were included within 6 
months following the first neurological symptoms. Patients with alternative diagnoses 
were excluded from the analyses. At baseline, a magnetic resonance imaging (MRI) scan 
and routine laboratory tests were utilized to rule out alternative diagnoses.19 Following 
inclusion, patients were reassessed at least annually at the Neurological Outpatient 
Department. 
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Questionnaire
At baseline, CIS patients completed a questionnaire to gather information about 
smoking habits, including when they first started smoking, non- or reduced-smoking 
periods and how many cigarettes were smoked within these periods. Using results of 
the questionnaire, we were able to calculate the pack-years per patient. 
Standard protocol approvals, and patient consent
This study was approved by the Medical Ethics Committee of Erasmus MC Rotterdam. 
Written informed consent was obtained from all patients.
Definitions
A relapse was defined as new symptoms or subacute worsening of existing symptoms 
after 30 days of improvement, or stable disease and no evidence of alternative diagnosis. 
Symptoms had to exist longer than 24 hours and not to be preceded by fever.20 All exacer-
bations were confirmed by neurological examination. CDMS was defined as clinical dis-
semination in space and time with two exacerbations and (para) clinical evidence of two 
separate lesions, as described by Poser et al.21 Patients who were diagnosed with CDMS 
during follow-up are referred to as CIS-CDMS and patients who remained CIS are referred 
to as CIS-CIS. Expanded Disability Status Scale (EDSS) scores were performed annually 
when patients were diagnosed with CDMS.22 EDSS performed within 3 months after a 
relapse were not used in the analyses. Follow-up was calculated by subtracting CIS date 
from the last visit date. Patients were defined as smokers when they were smoking regu-
larly at time of CIS. Non-smokers were those who did not smoke at time of CIS. Patients 
were defined as ex-smokers when they were not smoking at time of CIS, but did have a 
history of smoking in the years prior to CIS. To calculate pack-years, the number of years 
smoked was multiplied by the number of cigarettes smoked per day/20 in that period. 
Statistical analysis
Statistical analyses were done using SPSS, version 21.0 (SPSS Inc) for Windows and 
GraphPad Prism5 (GraphPad) for Windows. Nominal data comparison between groups 
was done using chi-square or Fisher’s exact test (gender, type of clinical onset, oligoclonal 
bands (OCB), ≥9 T2 lesions on baseline MRI, disease modifying therapy (DMT) at time of 
CIS, smoking at time of CIS, SPMS and alcohol use). The Kolmogorov-Smirnov test was 
performed to assess normality of data distribution. To compare continuous data we 
applied a two-tailed t-test (age at onset and follow-up time) or, when the data were 
non-parametric, a Mann-Whitney U-test (time from CIS to CDMS and pack-years). Time 
to second attack was calculated from onset of the first symptoms. Cox proportional 
hazard regression analyses were used to calculate univariate and multivariable hazard 
ratios (HR). Patients who did not have a second attack during follow-up were considered 
as censored observations. Hazard ratios were also obtained for time to EDSS 4.0 and 
time to EDSS 6.0. p values less than 0.05 were considered significant. 
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RESULTS
Patient characteristics
We included 250 patients who completed the baseline questionnaire about smoking at 
time of CIS. Of these 250 CIS patients, 114 (46%) patients had a second relapse and were 
diagnosed with CDMS during a mean follow-up time of 58.1 months (SD: 35.9).
The median time (interquartile range; IQR) from CIS to CDMS was 23.3 months (8.9-
44.3). The median time (IQR) between the first neurological symptoms and inclusion in 
the study was 1.2 months (0.3-2.9 months). 
Fifty-seven (23%) patients who were not yet diagnosed with CDMS were treated with 
DMT. The patient characteristics are shown in Table 1.
Table 1.  Patient Characteristics (CIS-CDMS vs CIS-CIS patients)
a p-value calculated between CIS-CDMS and CIS-CIS     
Abbreviations: CIS, Clinically isolated syndrome; CIS-CDMS, patients who are diagnosed with CDMS during follow-up 
after CIS defined by Poser criteria; CIS-CIS, not diagnosed with CDMS; na, not applicable; OCB, oligoclonal bands
Smokers versus non-smokers
In total, 79 of 250 (32%) patients smoked at time of CIS. Fifty-three of 79 (67%) smoking 
CIS patients were diagnosed with CDMS during follow-up compared to 61 of 171 (36%) 
in the non-smoking CIS patients (p<0.001). The number of pack-years was higher in the 
group that was diagnosed with CDMS (CIS-CDMS) during follow-up than in the group 
that remained CIS (CIS-CIS) (median (IQR) CIS-CDMS vs CIS-CIS: 2.4 (0.0-11.9) vs 0.0 
(0.0-2.7) p=0.004). (Figure 1)
CIS-patients 
(n=250)
CIS-CDMS 
(n=114)
CIS-CIS 
(n=136) p-value a
Gender, female, n (%) 189 (75.6) 92 (80.7) 97 (71.3) 0.09
Age (years), mean (SD) 33.6 (8.3) 32.6 (7.9) 34.5 (8.5) 0.07
Follow-up time (months), mean (SD) 58.1 (35.9) 72.3 (30.4) 46.3 (36.0) <0.01
Type of clinical onset, n (%)
-Optic nerve 88 (35.2) 33 (28.9) 55 (40.4) 0.06
-Spinal cord 90 (36.0) 45 (39.5) 45 (33.1) 0.30
-Other localization 72 (28.8) 36 (31.6) 36 (26.5) 0.37
OCB, (> 1 band), (%) 113 (73.9) 63 (81.8) 50 (65.8) 0.02
≥9 lesions on T2-weighted images, n (%) 96 (38.6) 53 (46.9) 43 (31.6) 0.01
DMT at time of CIS, n (%) 57 (22.8) 26 (22.8) 31 (22.8) 1.00
Smoking at time of CIS, n (%) 79 (31.6) 53 (46.5) 26 (19.1) <0.01
Pack-years at time of CIS, median (IQR) 1.0 (0.0-5.9) 2.4 (0.0-9.5)  0.0 (0.0-2.7) <0.01
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There were no differences between smokers and non-smokers in gender, localisation of 
first symptoms, age, OCB in CSF or MRI characteristics at baseline. Table 2 shows patient 
characteristics for smokers and non-smokers.
Table 2.  Patient Characteristics (smoking vs non-smoking CIS patients)
Abbreviations: CIS, Clinically isolated syndrome; OCB, oligoclonal bands
Smoking CIS patients 
(n=79)
Non-smoking Cis patients 
(n=171) p-value 
Gender, female, n (%) 58 (73.4) 131 (76.6) 0.59
Age (years), mean (SD) 33.9 (7.7) 33.5 (8.5) 0.67
Follow-up time (months), mean (SD) 60.7 (30.7) 57.0 (38.1) 0.45
Type of clinical onset, n (%)
-Optic nerve 25 (31.6) 63 (36.8) 0.42
-Spinal cord 29 (36.7) 61 (35.7) 0.87
-Other localization 25 (31.6) 47 (26.3) 0.50
OCB, (> 1 band), (%) 43 (75.4) 70 (72.9) 0.73
≥9 lesions on T2-weighted images, n (%) 33 (42.3) 63 (36.8) 0.41
DMT at time of CIS, n (%) 24 (30.4) 33 (19.3) 0.05
CDMS, n (%) 53 (67.1) 61 (35.7) <0.01
SPMS, n (%) 3 (3.8) 5 (2.9) 0.72
Alcohol use, no. of patients (%) 55 (69.6) 79 (46.2) <0.01
Figure 1.  Pack-years in CIS 
patients
Comparison of pack-years 
between CIS-CIS and CIS-CDMS 
patients. Horizontal lines and 
error bars indicate median and IQR
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Association of smoking at time of CIS with a shorter time to CDMS
Patients who smoked at time of CIS had a shorter time to CDMS diagnosis than patients 
who were not active smokers (univariate hazard ratio; HR: 2.1  p<0.001). (Figure 2) Cor-
rections were applied for multiple variables that are associated with a second attack 
(OCB in CSF, more than 9 T2 lesions, gadolinium enhancing lesions on baseline MRI, and 
optic neuritis as first symptom, no DMT before CDMS). After these adjustments, multivari-
able COX regression analysis showed smoking as an independent predictor for a second 
attack. The HR was 2.3 (p=0.002). 
In a sub-analysis we excluded the 50 CIS patients who had less than 2 years of follow-up. 
After exclusion, the results remained the same, HR: 2.0 (p<0.001). 
Fifty-seven (23%) of the patients received DMT before CDMS diagnosis. When we exclu-
ded these patients the HR was unchanged 2.0 (p=0.001). 
Figure 2.  Time from CIS to CDMS in smoking and non-smoking patients
Kaplan-Meier curve for time from CIS to CDMS for smoking and non-smoking patients at time of CIS (log-rank 
test p<0.001) 
Smoking in the past
In the group of patients that did not smoke at time of CIS (n=171), 63 (37%) patients had 
a history of smoking in the past (ex-smokers). Smoking in the past did not predict CDMS 
diagnosis in the group of non-smoking CIS patients (HR: 0.64 (p=0.12). Furthermore, in 
this non-smoking group (n=171), the number of pack-years was not correlated with time 
to CDMS (HR per pack-year: 0.96 (p=0.31)) 
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Smoking at time of CIS and disability later in the disease
In this cohort we collected EDSS data from 96 of 114 (84%) patients who were diagnosed 
with CDMS. Nineteen patients reached an EDSS of 4.0 and eight patients an EDSS of 6.0 
during follow-up. Six of these eight patients who reached an EDSS score of 6.0 or more 
were smoking at time of CIS. The HRs for both EDSS scores were not significant (HR for 
EDSS 4.0: 1.9 (p=0.18) and HR for EDSS 6.0: 4.1 (p=0.09)). However, there was a trend towards 
faster disability progression in CDMS patients who were smoking at time of CIS. 
DISCUSSION
In this prospective study of patients included after a first attack of suspected MS, we de-
termined the risk of CDMS in a cohort of 250, mostly untreated smoking and non-smoking 
CIS patients. We demonstrated that smoking at time of CIS is associated with a shorter 
time to a second clinical attack, and therefore an earlier diagnosis of CDMS. 
Smoking is a well-established risk factor for MS and disease progression after MS 
diagnosis.4, 5 This association is also found in other auto-inflammatory diseases such as 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).23, 24
Studies investigating the influence of smoking on MS risk in first attack patients have 
remained inconclusive, as described recently in a systematic review.25 Three studies were 
relatively small and used retrospective data.14-16 Other studies were large, but patients 
were treated with interferon beta immediately after CIS or two years after CIS,17, 18 Inter-
feron beta treatment could have postponed MS diagnosis.26 Therefore, the potential 
correlation between smoking and MS risk may be overshadowed by this disease-
postponing therapy. 
Compared to these studies, the present study has less confounding factors, it has a 
prospective design and only a small proportion of patients was treated with DMT before 
CDMS diagnosis.
In the multivariable analysis, we corrected our results for currently known predictors 
for CDMS diagnosis (large number of T2 lesions, contrast enhancing lesions on baseline 
MRI, unique OCB in CSF and localization of CIS) and for DMT before CDMS diagnosis.27 
After these corrections, smoking remained clearly predictive for CDMS diagnosis. There-
fore, smoking status can potentially improve prediction of a future CDMS diagnosis in 
CIS patients. Accurately predicting CDMS diagnosis is important to prevent unnecessary 
treatment of patients with low disease activity.28 
The fact that smoking in the past in current non-smoking CIS patients was not associ-
ated with CDMS suggests that the harmful effects of smoking are reversible. This sup-
ports results of earlier studies, showing that after cessation of smoking, the negative 
effect on disability progression slowly decreases, independent to the cumulative dose of 
smoking.8, 10
Our study has some limitations. Although the mean follow-up time was long (almost 
5 years), there was a wide range. To overcome this, we used a COX regression model to 
correct for follow-up time. We also performed a sub-analysis, where CIS patients with 
less than 2 years of follow-up were excluded. Excluding these patients left 200 patients 
for analysis and did not change our results. Yet, for demonstration of an association 
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between smoking at time of CIS and later disability (EDSS) a longer follow-up would be 
needed. 
Second, there is a possibility that our results are explained by potential confounding 
lifestyle factors such as body mass index (BMI) or alcohol use. It has been shown that 
obesity is a risk factor for MS.29 However, it is not likely that a high BMI explained the 
effect seen here, as obesity is more common in non-smokers.30 A Swedish study showed 
an inverse association of alcohol consumption with MS.31 We did not observe an effect 
of alcohol use on CDMS diagnosis in the regression analysis (data not shown).
Third, a follow-up MRI scan was not performed according to a fixed protocol. Instead, 
we used the classic Poser criteria that are based on clinical manifestations to define 
CDMS. Thus, we can only claim an association with clinical disease activity but not with 
lesion accrual on MRI scan. 
It is not likely that CIS patients with a second attack during follow-up had over-repor-
ted smoking at time of CIS. Even in case recall would play a serious role here, recall of 
smoking would be expectedly more strong for the question of past smoking.32 Yet, it 
was only recent smoking, more plausibly related to concurrent biological processes just 
before, during and after the first demyelinating attack, that showed an association.
The exact influence of ongoing smoking on the progression of the auto-inflammatory 
process around a first clinical attack of demyelination remains to be determined. It may 
involve several pathways, including both direct and indirect influences of tobacco toxins 
and smoke particles on T cells and antigen presenting cells.33
To conclude, we show in a large prospective cohort of CIS patients that smoking at time 
of CIS is an independent risk factor for a future CDMS diagnosis. Smoking status could 
even be a relevant parameter in predictive models on a possible MS disease course after 
CIS. Since smoking is a modifiable risk factor, our study draws attention to the relevance 
of counselling patients about smoking. Though intervention studies will be difficult to 
execute, this study may provide evidence for the argument to quit smoking for patients 
with a first attack of suspected MS.
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ABSTRACT
Background: Clinically Isolated Syndrome (CIS) is a first demyelinating event of the cen-
tral nervous system (CNS) and can be a single event. After CIS a chronic disease course 
with ongoing inflammation and relapses might occur, resulting in a diagnosis of multi-
ple sclerosis (MS). As yet, there has been no prospective exploration of whether children 
and adults with CIS have the same disease course.
Methods: Patients with CIS, whose age ranged from 1-50 years, were prospectively follo-
wed. We divided the patients in three different age groups: patients 1-10, 11-17, and 18-50 
years old. Among these groups demographic data, disease course, time to MS diagnosis 
and annualised relapse rates (ARR) were compared. 
Results: We included 383 CIS patients, of whom 218 (56.9%) were diagnosed with MS. 
Children of between 11 and 17 years old had the highest rate of MS conversion (83.5% 
versus 50.0% in the other age groups together, p<0.01) and the shortest time to MS 
diagnosis (median time 2.6 months (IQR: 0.6-6.0) vs 8.2 months (IQR: 1.9-28.2) in the 
other age groups together, p<0.01). ARR corrected for follow-up was higher in children 
<18 years old than in adults ≥18 years old with MS (mean ARR 0.65 vs 0.43, p<0.01).
Conclusion: Children with CIS tend to have a more inflammatory disease course appea-
ring from the high relapse rate in all children, and the highest rate of MS conversion 
in 11-17 year-old children. This supports early initiation of first-line disease modifying 
therapy (DMT) in children, perhaps even at first event in children at high risk for MS in 
line with current clinical practice in adults.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) that can cause a broad spectrum of neurological deficits.1 World-
wide over 2.5 million people suffer from MS, mostly young women.1 Although rare, MS 
can also occur in children.2 MS can be diagnosed when a first event of CNS demyelina-
tion, a so-called clinically isolated syndrome (CIS), is followed by a new clinical event.3-5 
In addition, MS can be diagnosed after CIS when new lesions, which fulfil MS diagnostic 
criteria for dissemination in time and space, are detected on Magnetic Resonance Ima-
ging (MRI).4,5 However, CIS can be a single event. It is unknown whether childhood-onset 
and adulthood-onset CIS and MS reflect the same disease.6 Previous studies focussed 
on MS and did not compare disease course between children and adults after onset of 
CIS.7-13 Despite existing parallels in childhood-onset and adulthood-onset MS, there are 
fundamental differences in presentation and disease course. Several studies have repor-
ted a higher relapse rate and MRI lesion load in children than in adults with MS.8,10,11,14,15 
On the other hand, progression of disability is slower in children with MS.12,13 It should 
be noted that some of the previous studies included retrospective cohorts,9,12,13,15 and 
some were conducted before the immunomodulatory treatment era in children.7-9,12,13 
Current recommendation and use of DMT in children with MS likely influenced their 
disease course and relapse rate.16 Several studies have shown initiation of first-line DMT 
in adults with CIS delays MS diagnosis and disability accumulation.17,18 In children with 
CIS it is not common practice yet to offer first-line DMT prior to MS diagnosis. Here, we 
performed a clinical prospective follow-up study of 383 patients with CIS, whose age 
ranged from 1 - 50 years, in order to report a comparison of childhood-onset versus 
adulthood-onset CIS and MS. The aim of our study was to compare clinical features at 
onset, time to MS diagnosis, relapse rate and disability. 
METHODS
Patients and definitions
Patients with CIS were included between April 2006 and August 2015, either in our pros-
pective cohort of adults with CIS (PRedicting the Outcome of a Demyelinating event, 
PROUD study),19 or in our prospective cohort study of children with a first episode of 
acquired demyelination of the CNS (PROUDkids).20 Both studies are ongoing multicentre 
observational studies conducted at Erasmus MC in Rotterdam, the Netherlands, and 
study protocols have been described previously.19,20 CIS is defined as an acute or subacute 
episode of neurological dysfunction that lasts more than 24 hours in absence of fever 
or encephalopathy.3,4,21 Patients <51 years old were included within 6 months after first 
onset. At baseline, an MRI scan was performed and routine laboratory tests were done. 
Patients with alternative diagnoses other than CIS were excluded. After baseline, patients 
were reassessed at least annually. 
MS was diagnosed in adults according to the 2010 McDonald criteria.5 Children were 
diagnosed with CIS and MS according to the diagnostic criteria from the Internatio-
nal Paediatric Multiple Sclerosis Study Group (IPMSSG), which are based on the 2010 
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Mc Donald criteria.4,5 Clinically definite multiple sclerosis (CDMS) was defined as two 
nonencephalopathic attacks with (para)clinical evidence of two separate lesions as 
described by Poser.4,22 The Expanded Disability Status Scale (EDSS) was used to define 
disability.23 EDSS scores were obtained at least 2 months after a relapse occurred and did 
not include standard cognitive assessments. Secondary progressive MS (SPMS) is defined 
as a history of gradual worsening after an initial relapsing-remitting disease course 
(RRMS), with or without exacerbations during the progressive course.24 This study was 
approved by the medical ethical committees of Erasmus MC in Rotterdam and of the 
other participating centres. Written informed consent was provided for all patients. 
Data analysis
Statistical analysis was performed using SPSS v20 (SPSS Inc., Chicago, Illinois, USA) 
and GraphPad Prism 5 (GraphPad., San Diego, USA). We divided the patients in three 
different age groups of clinical interest, based on evidence that puberty enhances CNS 
autoimmunity in females 25: i.e. pre-puberty, puberty, and adults (patients 1-10, 11-17 
and 18-50 years old). Among these groups we compared demographic data, disease 
course and time to MS diagnosis. ARR were compared between children and adults with 
MS. Because of the small number of MS patients in age group 1-10 years old (n=6), age 
groups 1-10 and 11-17 were combined for this analysis. For the comparison of continuous 
data between two groups we applied a two-tailed t-test, or when not normally distribu-
ted a Mann-Whitney U test. For analysis of multiple groups, we used one-way-ANOVA 
for normally distributed data, and Kruskal-Wallis test for not normally distributed data. 
Categorical data were analysed using the Chi-square or Fisher’s exact test. Kaplan-Meier 
survival analyses were used to analyse the time to MS diagnosis. Univariate and multi-
variable Cox proportional hazard regression models were used to obtain hazard ratios 
(HR) for MS diagnosis and EDSS 4.0 (onset of walking disability) respectively. Negative 
binomial regression, with the natural logarithm of follow-up years after MS diagnosis as 
offset, was used to analyse ARR after CIS. This offset was used to correct for the different 
follow-up times between patients. We used a generalised estimating equations (GEE) 
model to compare ARR with and without DMT. This GEE model includes the effect and 
interaction of treatment and age group and accounts for the correlation within patients. 
RESULTS
Clinical features at CIS 
We included 383 patients. Patient characteristics for the three different age groups are 
shown in table 1. Children more often presented with polyfocal clinical symptoms (31.8% 
<18 yrs vs 12.0% >18 yrs, p<0.01). Adults more often presented with isolated transverse 
myelitis (12.1% <18 yrs vs 28.6% >18 yrs, p<0.01). Children with CIS in age group 11-17 years 
had more lesions on their MRI (58.2% ≥9 T2 lesions). Lumbar puncture was performed 
less often in patients presenting with optic neuritis (ON) than in the other clinical 
presentations of CIS (55.9% vs 71.5% p<0.01). CSF OCB were less often present in 1-10 
year-old children with CIS (27.3%).
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Table 1.  patient characteristics
aDIS according to McDonald 2010 criteria bMS diagnosis according to McDonald 2010 criteria.5
P-values describe the comparison between all age groups. 
Abbreviations: CIS, clinically isolated syndrome; CDMS, clinically definite multiple sclerosis; 
DMT, disease modifying therapies; IgG, immunoglobulin G; MS multiple sclerosis; na, not applicable; 
ON, optic neuritis; OCB, oligoclonal bands; WBC, white blood cell count
Age groups 1-10 years 
(n=28)
11-17 years 
(n=79)
18-50 years 
(n=276)
Total 
(n=383) p-value
Gender, female, n (%) 16 (57.1%) 48 (60.8%) 204 (73,9%) 268 (70.0%) 0.02
Age (years), mean (SD) 6.6 (3.05) 15.2 (1.69) 34.0 (7.88) 28.1 (11.8) na
Caucasian ethnicity, n (%) 19 (67.9%) 42 (53.2%) 209 (75.7%) 270 (70.5%) 0.01  
Type of clinical onset, n (%)
-ON 10 (35.7%) 25 (30.3%) 108 (39.1%) 143 (37.3%) 0.44
-Spinal cord 2 (7.1%) 11 (13.9%) 79 (28.6%) 92 (24.0%) <0.01 
-Brainstem 0 (0.0%) 11 (13.9%) 33 (12.0%) 44 (11.5%) 0.13
-Other monofocal symptoms 6 (21.4%) 8 (10.1%) 23 (8.3%) 37 (9.7%) 0.08
-Polyfocal symptoms 10 (35.7%) 24 (30.4%) 33 (12.0%) 67 (17.5%) <0.01 
Features first MRI 
≥9 lesions on T2-weighted images, n (%) 6 (22.2%) 46 (58.2%) 99 (36.1%) 151 (39.7%) <0.01
Dissemination in spacea, n (%) 8 (28.6%) 58 (73.4%) 125 (45.8%) 191 (50.3%) <0.01
Gadolinium-enhancing lesions, n (%) (n=280) 4 (17.4%) 33 (54.1%) 85 (43.4%) 122 (43.6%) 0.02
Spinal cord MRI, n (%) 8 (28.6%) 43 (54.4%) 121 (43.8%) 172 (44.9% 0.17
Time CIS to MRI (months), median (IQR) 0.3 (0.1-0.9) 0.6 (0.2-1.6) 1.2 (0.5-2.2) 0.9 (0.3-2.0) <0.01
CSF findings 
WBC count (∙10^6/L), median (IQR) (n=216) 5.0 (2.0-16.0) 8.0 (4.3-18.8) 7.0 (3.3-12.0) 7.0 (3.0-14.8) 0.136
Positive OCB, n (%) (n=252) 6/22 (27.3%) 49/59 (83.1%) 125/171 (73.1% 180/252 (71.4%) <0.01
IgG index, median (IQR) (n=242) 0.64 (0.49-0.79) 0.95 (0.68-1.42) 0.78 (0.57-1.29) 0.81 (0.57-1.30) 0.02
Follow-up 
CDMS, n (%) 6 (21.4%) 53 (67.1%) 103 (37.3%) 162 (42.3%) <0.01
MSb, n (%) 6 (21.4%) 66 (83.5%) 146 (52.9%) 218 (56.9%) <0.01
Time CIS to CDMS (months), median (IQR) 16.5 (4.0-32.4) 9.0 (3.0-18.9) 19.0 (8.5-39.3) 15.2 (6.5-33.8) <0.01 
Time CIS to MSb (months), median (IQR) 16.4 (3.1-32.7) 2.6 (0.6-6.0) 8.2 (2.0-25.5) 4.8 (1.6-21.1) <0.01 
Follow-up (months), mean (SD) 38.3 (16.5) 38.1 (21.5) 48.5 (29.8) 45.6 (27.8) <0.01
Initiation of DMT before MS diagnosis, n (%) 1 (3.6%) 2 (2.5%) 35 (12.7%) 38 (9.9%) 0.02
Time CIS to DMT (months) median (IQR) 21.4 (7.1-33.3) 
(n=6)
6.8 (3.6-14.0) 
(n=59)
7.5 (3.8-24.5) 
(n=111)
7.2 (3.8-21.4) 
(n=176)
0.26
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Disease course and MS diagnosis
A total of 218 patients (56.9%) were diagnosed with MS during follow-up according to the 
2010 McDonald criteria in adults and according to the IPMSSG criteria in children.4,5 Children 
with CIS in age group 11-17 had the highest rate of MS conversion (83.5% versus 50.0% in 
the other age groups together p<0.01) and the shortest time to MS diagnosis (median 
time 2.6 months (IQR: 0.6-6.0) versus 8.2 months (IQR: 1.9-28.2) in the other age groups 
together, p<0.01). Children in the 11-17 year-old group also had the highest rate of CDMS 
and shortest time to CDMS diagnosis (Table 1). The time to MS diagnosis is presented in 
Figure 1. HR for future MS and CDMS diagnosis are shown in Table 2. HR did not change 
after adjustment for DMT initiation before MS diagnosis, lumbar puncture, or gadolinium 
administration. 
Figure 1.  Time from CIS to MS diagnosis in different age categories
Kaplan-Meier curves for time to MS diagnosis for patients in different age categories. (log-rank test p<0.01).
Table 2.  hazard ratios for MS and CDMS diagnosis, univariate cox regression analysis
Age group (years) No. of patients No. of events Hazard ratio (95% CI) p-value
1-10 MS 28 6 0.4 (0.2-0.8) 0.01
CDMS 28 6 0.6 (0.3-1.4) 0.24
11-17 MS 79 66 3.2 (2.4-4.3) <0.01
CDMS 79 53 3.1 (2.2-4.4) <0.01
18-50 MS 276 146 1 (ref) 1 (ref)
CDMS 276 103 1 (ref) 1 (ref)
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Annualized relapse rates corrected for follow-up were higher in children <18 years than 
in adults ≥18 years old with MS (mean ARR 0.65 vs 0.43, p<0.01). ARR between children 
and adults with MS with and without DMT are presented in Table 3. Highest ARR were 
found in 1-10 year-old children with MS (n=6): ARR without DMT 5.30 and with DMT 0.43 
(p<0.01). We found similar associations between ARR and non-Caucasian ethnicity and 
lumbar puncture in children and adults.  
Table 3.  ARR corrected for follow-up in MS patients per age group
a Presented p-values for the comparison of ARR with and without DMT within the different age groups.  
b Presented p-values for the interaction coefficient of DMT for the different age groups.
Abbreviations: ARR, annualised relapse rate; DMT, disease modifying therapies; CI, confidence interval
Disability 
Age at onset of CIS was associated with a shorter time to EDSS 4.0, HR 1.3 per 5 years 
increase in age at onset (P=0.03). After correction for type of clinical onset using a multi-
variable COX regression model, this HR did not change. Eight patients were diagnosed 
with SPMS, who had a higher age at time of CIS (Mean age of SPMS patients at CIS 42.1 
(±4.6) vs 27.8 (±11.7) in RRMS p<0.01).
DISCUSSION
The purpose of our study was to report a comparison of childhood-onset versus adult-
hood-onset CIS and MS in a large prospective cohort during the current immuno-
modulatory treatment era. The results of our study suggest a more inflammatory 
disease course, rather than a neurodegenerative disease course, in 11-17 year-old children 
with CIS, as this group had the highest rate of MS conversion and the shortest time to 
MS diagnosis, higher ARR, higher MRI lesion load and a more inflammatory CSF profile. 
Interestingly, the youngest children (1-10 years) with CIS had a relatively lower rate of 
MS conversion, lower MRI lesion load and a less inflammatory CSF profile. The latter two 
findings could be explained by our inclusion criteria since we did not include children 
with acute disseminated encephalomyelitis (ADEM). SPMS, which reflects a more 
neurodegenerative phase of MS, was found in eight patients >37 years old at onset of 
CIS. However, secondary progression in MS is age dependant and probably therefore has 
not been observed yet in our younger patients with the current follow-up.26 Furthermore, 
Age group 
(years)
Total years 
at risk 
after MS 
diagnosis
Total no. of 
relapses 
Overall ARR
(95% CI)
ARR 
without 
DMT
(95% CI)
ARR with 
DMT 
(95% CI) p-valuea
Interaction 
coefficient 
of DMT  
(95% CI) p-valueb
1-17
(n=72)
208 134 0.65 
(0.44-0.96)
2.22
(1.04-4.81)
0.48
(0.36-0.65)
<0.01 0.50
(0.28-0.92)
0.03
18-50 
(n=146)
451 193 0.43
(0.37-0.50)
0.92
(0.52-1.67)
0.40
(0.32-0.49)
<0.01 Ref. Ref.
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we found higher EDSS progression rates in adults than in children. Previous studies on 
childhood-onset versus adulthood-onset MS, already have reported a higher ARR in 
children.8,10,11 In our unique prospective study we followed children and adults already 
from onset of CIS. Overall, we found a female predominance both in patients with CIS 
and MS, except in young children diagnosed with MS before puberty, of whom four 
of six MS patients were boys. The difference in sex distribution in children diagnosed 
with MS before and after puberty and the higher rates of MS diagnoses after puberty 
suggests that sex hormones contribute to the onset of MS.2,23,25 A remarkable high rate 
of non-Caucasian ethnicities was observed in 11-17 year-old children with CIS. Higher 
rates of non-Caucasian ethnicities have been reported in childhood-onset MS and 
might reflect a higher vulnerability of developing MS at a younger age.20,27 A possible 
explanation for this might be that non-Caucasians miss certain protective genes since 
their ancestors were born in countries with a low prevalence of MS.20 
The shorter time to MS diagnosis in 11-17 versus 1-10 year-old children is partly explained 
by the current diagnostic MRI criteria which allow for an early MS diagnosis in a sub-
group of patients at first MRI, however, not in children younger than 12 years of age.4,5 
Still, we observed a high rate of CDMS and short time to CDMS diagnosis in 11-17 year-
old children. 
ARR in 1-10 year-old children with MS (n=6) was remarkable high, but the number of 
patients is too small to draw reliable conclusions. In a recently published large stu-
dy ARR did not differ in children <12 years and ≥12 years.28 The relative high rate of 
non-Caucasians (5/6) in 1-10 year-old children with MS in our cohort might contribute to 
this high ARR.29 
Early initiation of DMT in adults with CIS might have influenced their disease course. 
However, a relatively small proportion of adults (12.5%) started DMT before MS diag-
nosis. In a sub-analysis (data not shown) we found similar results when we excluded 
these patients. It is unlikely observed differences in ARR are caused by early initiation 
of DMT, since time to DMT initiation after MS was similar in children and adults, and 
pre-treatment ARR differed significantly. DMT is already offered to adults with CIS who 
are at high risk for a future MS diagnosis, but not to children with CIS. However, DMT 
especially reduces MS relapse rates and has been shown beneficial in children with 
MS.16 Therefore early initiation of first-line DMT in children with CIS at high risk for MS 
seems logical and might be considered in line with current clinical practice in adults. 
International collaboration is needed in order to define children with CIS at high risk for 
MS, and to investigate whether early initiation of DMT in 11-17 year old children is safe 
and beneficial. 
A limitation of our study is that follow-up is limited and shorter in children since our 
prospective study in adults started prior to the study in children. With current follow-up, 
however, we could already demonstrate important differences in rates of MS diagnosis 
and relapses. It would be interesting to follow our cohort in order to compare clinical 
outcome and disease progression over several decades. Another limitation of our study 
is a selection bias since we only included patients with CIS, while it is known that MS 
can present with a spectrum of acquired demyelinating events, including ADEM.4 
However, it is not expected that this influences our results much, since a diagnosis of 
MS after ADEM is uncommon with the current diagnostics criteria.4 In addition, there 
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could have been a selection in patients who were reported by physicians from other 
hospitals. We did not find a centre effect regarding demographics, MRI, CSF features or 
MS diagnosis. However, we did find a higher rate of CIS patients presenting with ON, 
included at Erasmus MC. This could be explained by referrals from the nearby Rotterdam 
Eye Hospital. Patients who were diagnosed with CDMS within 6 months after CIS who 
were not yet included in our prospective studies, could have been missed. However, we 
do not expect this includes many patients since it has been reported in another study 
that up to 30% of CIS patient were diagnosed with CDMS within 6 months30 and in our 
cohort 23% of CIS patients had CDMS within 6 months after onset of CIS. EDSS scores 
were assessed annually, therefore disability progression was not always reassessed. 
Furthermore, we do not have a standard MRI protocol, gadolinium was not administered 
to all patients at first event, and a follow-up MRI was not performed regularly, nor a 
lumbar puncture was performed in all patients. A follow-up MRI was more often performed 
in children than in adults, which influences the time to MS diagnosis. However, the 
short time to MS diagnosis in 11-17 year-old children was confirmed by the higher rate 
and shorter time to CDMS. Nevertheless, our data resemble clinical practice. 
In summary, we found a more inflammatory disease course of CIS and MS in children. 
This supports the early initiation of first-line DMT in children with MS, and perhaps 
could argue for initiation of DMT in 11-17 year-old children with CIS who are at high risk 
for a future MS diagnosis in line with current clinical practice in adults.
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ABSTRACT
Background: CSF levels of T-cell activation marker soluble CD27 (sCD27) are associated 
with subsequent disease activity after a first attack of suspected MS in adults. The 
predictive value for disease course in children with acquired demyelinating syndromes 
(ADS) is unknown.
Objectives: to assess the predictive value of sCD27 levels for clinically definite MS 
(CDMS) diagnosis in childhood ADS.
Methods: Children <18years with a first demyelinating event were prospectively inclu-
ded and followed. Soluble CD27 was determined in CSF using an ELISA. Cox regression 
analyses were used to calculate hazard ratios (HR) for CDMS. 
Results: A total of 94 ADS children were included (ADS with encephalopathy (ADS+) 
n=33 and ADS without encephalopathy (ADS-) n=61). Twenty-nine of 61 ADS- children 
(48%) were diagnosed with CDMS during follow-up. At baseline, sCD27 levels were 
higher in patients with a future CDMS diagnosis (n=29) than in monophasic ADS+ 
(n=30), monophasic ADS- (n=28) and relapsing non-MS patients (n=7) (p<0.001). In ADS- 
patients, sCD27 was associated with CDMS (HR 1.8 per 100 U/mL increase in sCD27 levels, 
p=0.031), after adjustments for age, oligoclonal bands and presence of dissemination in 
space on baseline MRI.
Conclusion: CSF sCD27 levels at first attack of demyelination is associated with CDMS 
diagnosis in children. This makes sCD27 a potential clinically relevant quantitative marker 
when performing routine CSF diagnostics.
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INTRODUCTION
Clinical manifestations of acute onset inflammatory demyelinating disease of the 
central nervous system (CNS) in children are termed acquired demyelinating syndromes 
(ADS).1, 2 ADS encompasses for example optic neuritis (ON), transverse myelitis (TM) as 
well as other presentations that localise to monofocal or polyfocal locations in the CNS, 
such as acute disseminated encephalomyelitis (ADEM). Up to one third of the children 
with ADS receive a later diagnosis of multiple sclerosis (MS).1, 3, 4 5 At the time of a first 
attack, it can be a challenge to determine the disease course of these patients. Early 
identification of children who will have an active disease course is important and can 
have therapeutic implications.6 
Soluble CD27 (sCD27) is a soluble form of CD27 secreted by activated T-cells after activa-
tion via the T-cell receptor, and is introduced as a potential biomarker for T-cell medi-
ated inflammation.7 CD27 and sCD27 have a role in maturation, activation and prolife-
ration of T and B cells.8, 9 High sCD27 levels are reported in autoimmune diseases like 
rheumatoid arthritis, systemic lupus erythematosus and MS.10-12 Bielekova et al, validated 
CSF sCD27 as a biomarker for intrathecal T-cell activation in MS, using an extensive and 
validated battery of biomarkers for CNS inflammation.13 Serum sCD27 does not discrimi-
nate between healthy individuals and MS patients.14 In a recent study, high sCD27 levels 
in CSF associate with MS diagnosis and disease course in adult patients with clinically 
isolated syndromes.15 
These observations in adults have not yet been validated in the paediatric population 
with CNS demyelination. It is shown that children with MS tend to have a more inflam-
matory disease course than adults.16, 17 Therefore,we hypothesized that the predictive 
value of sCD27 levels for a second attack of MS will be equal or even higher in children 
than in adults. Furthermore, ADS with encephalopathy (ADEM) are known to have 
extensive intracerebral inflammation on MRI scans and may have severe clinical presen-
tations.18 The levels of sCD27 might therefore differ between ADS subtypes.  
Here we examined whether sCD27 levels at first attack in children differ between ADS sub-
types and assessed the predictive value of sCD27 for a second attack of MS in paediatric ADS 
patients. 
METHODS 
Study participants
Patients <18 years were included in the Dutch prospective and multicentre study for 
children with acquired demyelinating syndromes (ADS) (PROUD-kids study).2 All patients 
with a lumbar puncture and baseline MRI, performed for routine diagnostics <6 months 
after onset of first symptoms, were included between June 2006 and February 2017. 
Patients with alternative diagnosis were excluded. Patients were assessed at baseline 
and reassessed regularly. Patients were instructed to contact the hospital in case of 
suspected exacerbation. 
8
136
Chapter 8
Definitions 
Acquired demyelinating syndromes in children encompass the first attack of demyelina-
tion in the central nervous system, including patients presenting with encephalopathy 
(ADEM, defined as ADS+) and ADS without encephalopathy (defined as ADS-).2 3 CDMS 
was defined as two non-encephalopathic attacks, based on the clinical criteria proposed 
by the International Paediatric MS study group for paediatric MS diagnosis.3 Relapsing 
patients who have a distinct clinical phenotype other than CDMS were also included in 
this study, such as ADEM followed by relapsing optic neuritis (ADEM-ON),19 anti-aquaporin 
4 antibody (AQP4-ab) positive and negative relapsing disease.3, 20,21 
A relapse was defined as acute worsening of existing symptoms or new symptoms after 
30 days of improvement or stable disease and no evidence of an alternative diagnosis. 
The symptoms should exist for more than 24 hours and not be preceded by fever.22 Exa-
cerbations were confirmed by neurological examination. 
Follow-up duration was calculated by subtracting the date of first symptoms from 
the last visit date. Disability was expressed by the Expanded Disability Status Scale 
(EDSS).23 
CSF samples and sCD27 ELISA
CSF samples were centrifuged for 10 minutes at 3000 rpm to separate the supernatant 
from cells and cellular components. After centrifugation, all samples were stored in 
-80 degrees Celsius until use.24 Routine diagnostics of CSF included oligoclonal bands 
(OCBs), IgG index, cell count and total protein. Soluble CD27 levels were measured in 
duplo using the available commercial ELISA kit (Pelikine compact human sCD27 kit) 
manufactured by Sanquin in Amsterdam, the Netherlands.7 The manufacturer’s instruc-
tions were followed when performing the sCD27 ELISA. Levels of sCD27 were expressed 
by U/mL by reference to a standard curve supplied with the ELISA kit. The clinical diag-
nosis was blinded for the analysts who performed the ELISA. The detection limit of the 
ELISA was 6 U/mL.
Standard protocol approvals, registrations and patient consents
The PROUD-kids study was approved by the Erasmus MC ethical committee and by the 
ethical committees of the other participating centres. Written informed consent was 
obtained from patients and/or their families. 
Statistical analysis 
Statistical analyses were performed using SPSS 24.0. Kolmogorov-Smirnov test was 
used to assess the normality of the data. Figures are made in Graphpad Prism5. Soluble 
CD27 levels were not normally distributed, and were therefore log transformed to attain 
normally distributed data. Due to log-transformation, geometric means were calcu-
lated. For group comparisons, Student’s t-test and Mann-Whitney U test were used for 
continuous variables when appropriate. Student’s t-test was performed to compare the 
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sCD27 levels in different ADS subgroups. Chi-square and Fisher exact test were used for 
categorical data. Correlation analyses were done for two continuous variables. 
Cox proportional hazard regression models were used to calculate univariate and 
multivariable hazard ratios (HR) in the ADS- group, with CDMS set as endpoint. The Cox 
proportional hazard assumption was tested by including a time dependent covariate in 
the model. Known predictors for MS diagnosis such as age of onset, OCB and fulfilling 
dissemination in space (DIS) at baseline MRI are used for adjustments in the multivariable 
analysis for sCD27 levels. 
Annualised relapse rate (ARR) for CDMS patients was compared between groups with 
high and low levels of sCD27 using a binomial regression model with the natural loga-
rithm of number of follow-up years after a second clinical attack as offset. This offset 
corrects for the difference in follow-up duration between patients. The data were over-
dispersed and therefore the Poisson regression model was not suitable for our data set. 
P-value of <0.05 was considered significant. 
RESULTS
Patients
A total of 94 children with a first attack of ADS were included in this study. Of these 
children, 33 presented with ADS+ and 61 with ADS-. The median age for ADS+ was 4.5 
years (IQR 2.6-6.3) and for ADS- patients 14.5 years (IQR 11.3-16.0). During follow-up, 
30/33 (91%) of the ADS+ patients remained monophasic. Three ADS+ patients (9%) had 
a relapsing disease and fulfilled the criteria for ADEM-ON. No patient presenting with 
ADS+ was diagnosed with CDMS. Within the ADS- patients, 33/61 (54%) had a second 
attack. Of these 33 relapsing patients, 29/33 (88%) children were diagnosed with a 
second attack fulfilling the criteria for CDMS and the other 4/33 (12%) were diagnosed 
with a relapsing demyelinating disorder other than MS (2 AQP4-ab positive and 2 AQP4-ab 
negative patients). The median time to CDMS was 10.3 months (IQR 4.3-15.7 months). 
The median follow-up duration for all included patients was 2.5 years (IQR 1.4-4.9 years).
The following flowchart (figure 1) illustrates the presenting phenotypes (ADS+ and ADS-) 
and diagnoses during follow-up. 
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Figure 1.  Flowchart of included ADS patients
Patients presented as ADS without encephalopathy (ADS-) and ADS with encephalopathy (ADS+; ADEM). The 
disease course during follow-up are shown dividing patients in monophasic ADS-, monophasic ADS+, CDMS and 
relapsing non-MS. The relapsing non-MS patients included 3 ADEM followed by optic neuritis, 2 AQP4 positive 
NMOSD and 2 patients with AQP4 negative NMOSD. 
Abbreviations: ADS, acquired demyelinating syndromes; ADS-, ADS without encephalopathy, ADS+, ADS with 
encephalopathy; ADEM, acute disseminated encephalomyelitis; AQP4, anti-aquaporin 4 antibodies; CDMS, 
clinically definite MS
The median time between onset of symptoms and CSF sampling was 2.2 weeks (IQR 
0.7-5.9). No correlation was found between the levels of sCD27 and time between first 
symptoms and CSF sampling in the total group and in all groups separately. Twenty-four 
of 94 patients (26%) received acute treatment (intravenous corticosteroids) before CSF 
sampling. No difference in sCD27 was found in patients who did or did not receive 
intravenous corticosteroids. No patients were on disease modifying therapy (DMT) or 
oral steroids before CSF sampling. Patient characteristics are shown in Table 1.
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Soluble CD27 levels in subgroups of ADS  
Soluble CD27 levels at first attack of ADS were higher in patients with a future second 
attack of MS (n=29) than in ADS-patients who remained monophasic (n=28) (geometric 
means 65 U/mL; 95% CI 47-89 vs 13 U/mL; 95% CI 9-18, p<0.001). Patients with monophasic 
ADS+ (n=30) did not differ in sCD27 levels from monophasic ADS- patients (n=28) (geome-
tric mean 18 U/mL; 95% CI 11-30 vs 13 U/mL; 95% CI 9-18), but did differ from ADS- patients 
with future CDMS diagnosis (geometric mean 13 U/mL; 95% CI 9-18 vs 65 U/mL; 95% CI 48-
89; p<0.001). Patients with a relapsing non-MS disease course (n=7; 4 patients with ADS- 
onset and 3 with ADS+ onset) had lower sCD27 levels at onset than patients with a future 
CDMS diagnosis (geometric mean 18 U/mL; 95% CI 8-42 vs 65 U/mL; 95% CI 48-89 U/mL; 
p=0.001), but did not differ from monophasic ADS+ and monophasic ADS- patients. 
Figure 2.  Comparison of CSF sCD27 levels in ADS at time of first demyelinating event
Comparison of CSF soluble CD27 levels between patients with ADS+ (ADEM), monophasic ADS-, CDMS and relap-
sing non-MS patients. The relapsing non-MS patients included 3 ADEM followed by optic neuritis, 2 AQP4 positive 
NMOSD and 2 patients with AQP4 negative NMOSD. 
Horizontal lines with error bars indicate geometric means with 95% CI. 
Abbreviations: ADS, acquired demyelinating syndromes; ADS-, ADS without encephalopathy; ADS+, ADS with 
encephalopathy; ADEM, acute disseminated encephalomyelitis; CDMS, clinically definite MS
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These results are displayed in Figure 2. No differences were found in sCD27 levels 
between anti-MOG positive (n=13) and anti-MOG negative (n=81) patients (data not 
shown). 
Fourteen of the 59 ADS- patients (24%) (after excluding the 2 AQP4 positive patients) 
fulfilled MS diagnosis at baseline by fulfilling the IPMSSG 2012 criteria for MS on first 
MRI.3 The sCD27 levels of these 14 children are significantly higher than ADS- patients 
who did not fulfil the criteria at baseline (geometric mean 78 U/mL; 95% CI 53-115 vs 20 
U/mL; 95% CI 15-30, p<0.001). 
Of the 28 monophasic ADS– patients, 10 patients showed sCD27 levels that exceed the 
upper bound of the 95% confidence interval of the geometric mean (13 U/mL; 95% CI 
9-18), as shown in Figure 2. Of these patients, 8/10 fulfilled the diagnosis of MS by follow-up 
MRI scans, but did not experience a second attack during follow-up. The sCD27 geome-
tric mean of these 8 patients was higher than the other 20 monophasic ADS- patients 
(geometric mean 35 U/mL; 95% CI 27-45 vs 9 U/mL; 95% CI 6-12; p<0.001), but lower than 
the patients with future CDMS diagnosis (geometric mean 35 U/mL; 95% CI 27-45 vs 65 
U/mL; 95% CI 48-89 U/mL; p=0.04). 
A subgroup analysis (n=59) was performed after excluding patients with <2 years of 
follow-up (patients with CDMS n=20). This did not change our observation that sCD27 
levels are elevated in patients with a future second attack of MS compared to the three 
other subgroups (geometric mean 61 U/mL, 95% CI 42-89 vs 15 U/mL, 95% CI 10-22; 
p<0.001). 
Soluble CD27 correlates with CSF and MRI parameters
Patients with unique OCBs in CSF had higher sCD27 levels compared to patients without 
OCB (geometric means 42 U/mL; 95% CI 30-60 vs 17 U/mL; 95% CI 12-23, p<0.001). 
Soluble CD27 levels were positively correlated with IgG index (Spearman rho 0.695, 
p<0.001) as well as white blood cell count (Spearman rho 0.444, p<0.001). 
Patients fulfilling DIS on baseline MRI (n=50) showed higher sCD27 levels than patients 
without DIS (geometric mean 35 U/mL; 95% CI 26-46 vs 16 U/mL; 95% CI 11-24, p=0.003). 
A total of 72 patients (77%) received gadolinium when the first MRI was performed. The 
sCD27 levels were significantly higher in children who showed contrast enhancement  
(n=31, 58%) than patients without contrast enhancement (geometric mean 49 U/mL; 
95% CI 34-71 vs 19 U/mL; 95% CI 12-28, p=0.001). 
For the analyses depicted above, all patients were analysed. Exclusion of patients with 
ADS+ (ADEM) and relapsing non-MS from the analysis (thus only including patients 
with monophasic ADS- and CDMS), did not alter the results. Results are shown in 
Figure 3.
High levels of sCD27 at first attack in ADS- patients are independently associated with a 
shorter time to CDMS.  
As described above, all patients with a second attack of MS had an ADS- presentation. 
No patient with ADS+ was diagnosed with CDMS. Therefore, in the following analyses 
ADS+ patients were excluded as well as the relapsing non-MS patients with AQP4-ab. 
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Figure 3.  Comparison of sCD27 levels with CSF and MRI parameters 
Comparing CSF and MRI parameters with the levels of sCD27 in ADS patients.
Horizontal lines with error bars indicate geometric means with 95% CI. 
Abbreviations: ADS, acquired demyelinating syndromes; OCB, oligoclonal bands; DIS, dissemination in space 
A Kaplan Meier curve was obtained after dichotomizing the sCD27 levels, using the median 
of the included ADS- patients (n=59); median sCD27 36.0 U/ml. Six of 29 patients in the 
low sCD27 group were diagnosed with CDMS (21%) versus 23/30 (79%) in the high level 
group. Figure 4 shows the Kaplan Meier curve for time to CDMS diagnosis (log-rank test, 
p=0.006). 
The univariate HR for CDMS was 2.8 (95% CI 1.7-4.6) per 100 U/mL increase in sCD27 
levels (p<0.001). In the multivariable COX regression analyses, we corrected for age of 
onset, OCB and dissemination in space (DIS). After these corrections, sCD27 was inde-
pendently associated with time to CDMS diagnosis with an HR of 1.8 (95% CI 1.0-3.3) per 
100 U/mL increase in sCD27 levels (p=0.031).
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Eight of 29 patients (28%) who received MS diagnosis based on MRI received DMT before 
CDMS and this might have postponed the second attack. We performed a sub-analysis 
using the COX-regression analysis where we excluded these patients, resulting in the 
same HR for the univariate (2.8, 95% CI 1.7-4.9; p<0.001) and multivariable analyses after 
adjusting for age of onset, OCB and DIS (1.8, 95% CI 0.96-3.4; p=0.061).
Figure 4.  Kaplan Meier curve for time to CDMS diagnosis in ADS without encephalopathy 
Kaplan Meier curve for time to CDMS diagnosis. All ADS- patients were stratified into two groups by the median 
CSF sCD27 level of all CIS patients; median 36 U/mL. 
Abbreviations: ADS, acquired demyelinating syndromes; ADS-, ADS without encephalopathy; CDMS, clinically 
definite MS
Annualised relapse rate and disability
In patients who were diagnosed with CDMS, we used a negative binomial regression 
model for analyzing the ARR. The median of sCD27 levels in CDMS patients (n=29; 
71 U/mL) was used to stratify patients into two groups with either high or low sCD27 
levels. There was no difference found in ARR between high and low level group after 
correcting for follow-up duration. No correlation was found between sCD27 levels and 
EDSS score during follow-up.
144
Chapter 8
DISCUSSION
Here we show that the T-cell activation marker sCD27 in CSF at first attack in paediatric 
ADS differs among ADS subtypes. Soluble CD27 levels in patients with a future diagnosis of 
CDMS were higher than in monophasic ADS+, monophasic ADS- and relapsing non-
MS patients. There was no difference between the latter three groups. We analyzed 
ADS+ patients separately from ADS- patients as MS diagnoses after ADS+ is extremely 
low and also in our cohort no patients with ADS+ were diagnosed with CDMS during 
follow-up. Soluble CD27 was associated with a shorter time to CDMS diagnosis indepen-
dently of known relevant clinical parameters such as MRI and CSF characteristics. 
An interesting observation was that 80% of the monophasic ADS- patients, whose 
sCD27 levels exceeded the 95% CI intervals of the whole monophasic ADS- group, fulfilled 
the IPMSSG diagnostic criteria for MS based on follow-up MRI. The sCD27 levels of this 
group were higher than monophasic ADS- and somewhat lower than patients with 
CDMS diagnosis. This may be related to the fact that these patients (who are diagnosed 
with MS by MRI alone) have a less active clinical disease course, compared to CDMS 
patients with higher levels of sCD27.
In line with van der Vuurst de Vries et al, we observed higher soluble CD27 levels in 
patients with a future CDMS diagnosis than in monophasic ADS patients without en-
cephalopathy (including clinically isolated syndromes).15 The levels were even higher in 
children than in adults with MS (geometric mean 65 U/ml; 95% CI 48-89 versus 42 U/mL; 
95% CI 29-51 respectively).15 Our data not only validates the conclusion of van der Vuurst 
de Vries et al, but is also congruent with previous observations that paediatric MS 
patients have a more inflammatory disease course compared to adults. 16, 25-30 
The higher levels in patients with a future CDMS diagnosis most likely correspond to a 
higher intrathecal T-cell activation and higher inflammatory activity. The correlation we 
found between sCD27, OCB and IgG index is in line with previous adult studies. 13-15 In vitro, 
a functional role of sCD27 on stimulation and differentiation of B-cells is described earlier.31, 32 
However, the exact role for sCD27 on IgG production remains to be investigated.
In adult MS patients, a higher ARR was found in patients with high sCD27 levels at 
time of clinically isolated syndrome.15 One would expect also a higher relapse rate in 
paediatric MS patients with high sCD27 levels at time of the first attack, however, no 
association with ARR was found. This finding might be explained by a ceiling effect, as 
the overall relapse rate in our paediatric MS cohort is high.16 
No association was found with EDSS, which is little surprising given the slower disease 
progression in paediatric MS.27, 33 Longer follow-up duration will be needed to investigate 
a possible relationship between sCD27 levels and chronic disease progression. 
There were a few limitations of this study. First, the follow-up duration varied between 
patients. We addressed this problem by correcting for follow-up duration in the survival 
analyses. We also performed a sub-analysis in which we excluded patients with less 
than two years of follow-up. This did not alter the conclusions. Second, we did not 
perform a follow-up MRI on a regular basis. However, we aimed to assess the value of 
sCD27 levels on the clinical disease course and therefore chose CDMS as a study endpoint in-
stead of the McDonald criteria. In addition, the use of DMTs may have delayed a second 
attack and could have influenced the results of the survival analyses. Therefore we per-
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formed sub-analyses after excluding patients with ADS- who used DMT before CDMS 
diagnosis. After excluding these patients, the follow-up analysis was not significant 
(p=0.061), however, there was still a clear trend and the univariate analysis remained sig-
nificant. Lastly, patients who remained monophasic had a shorter time to CSF sampling 
compared to patients who were diagnosed with CDMS during follow-up. This may have 
been caused by the difference in severity of the presenting symptoms and the differential 
diagnosis at onset, for example in ADEM, where acute non-demyelinating pathology 
needs to be ruled out. Yet, we found no correlation between the time to CSF sampling 
and the levels of sCD27, making it unlikely that this influenced our results. 
In summary, we show that CSF sCD27 in children with ADS at time of the first attack is 
associated with a future CDMS diagnosis, independently of MRI and CSF parameters. 
This result is in line with the earlier finding in adult CIS patients that higher sCD27 was 
associated with subsequent MS diagnosis.14 Therefore we can conclude that sCD27 is a 
potential clinically relevant quantitative marker when performing routine CSF diagnostics 
not only in adults but also in children with ADS. The next step will be validation of these 
findings in international cohorts.  
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ABSTRACT  
Background: A promising biomarker for axonal damage early in the disease course of 
multiple sclerosis (MS) is neurofilament light chain (NfL). It is unknown whether NfL has 
the same predictive value for MS diagnosis in children as in adults. 
Objective: To explore the predictive value of NfL levels in CSF for MS diagnosis in paediatric 
and adult CIS patients.
Methods: A total of 88 adult and 65 paediatric patients with a first attack of demyelination 
were included and followed (mean follow-up time in adults: 62.8 months (SD±38.7) and 
43.8 months (SD±27.1) in children). Thirty control patients were also included. Lumbar 
puncture was done within 6 months after onset of symptoms. NfL was determined in 
CSF using ELISA. COX regression analyses were used to calculate hazard ratios (HR) for 
clinically definite MS (CDMS) diagnosis. 
Results: After adjustments for age, oligoclonal bands, and asymptomatic T2-lesions 
on baseline MRI, increased NfL levels in both paediatric and adult CIS patients were 
associated with a shorter time to CDMS diagnosis (children HR 3.7; p=0.007, adults HR 
2.1; p=0.032). For CIS patients with a future CDMS diagnosis, children showed higher NfL 
levels than adults (geometric mean 4888 vs 2156 pg/mL; p=0.007).
Conclusion: CSF NfL levels are associated with CDMS diagnosis in children and adults 
with CIS. This makes NfL a promising predictive marker for disease course with potential 
value in clinical practice. 
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INTRODUCTION
Childhood-onset multiple sclerosis (MS) occurs in 3-5% of all MS patients.1, 2 Although 
children with MS have a more inflammatory disease course with a higher relapse rate 
than adult patients,3-5 clinical follow-up studies suggest that disability progression 
is slower in children than in adults.4, 6, 7 However, impairment of age-expected brain 
growth was seen early in the disease course of paediatric MS patients.8 This indicates 
that not only neuroinflammation but also neurodegeneration occurs early in child-
hood-onset MS. 
Axonal damage is considered one of the major causes for persisting neurological disabi-
lity in MS.9 A promising biomarker for axonal damage is neurofilament light chain (NfL). 
Neurofilament light chain is an element of the neuron cytoskeleton, and is released in 
the extracellular space after neuronal cell death.10 In healthy individuals, NfL levels in-
crease with age, which reflects neurodegeneration and is part of the physiological aging 
process.11 
High NfL levels in CSF in adults with clinically isolated syndrome (CIS) have been repor-
ted as an independent risk factor for MS diagnosis.12 Furthermore, NfL levels have been 
associated with brain volume changes in adult CIS patients.12 However, whether NfL is 
also increased at disease onset in children is still unknown.
The primary purpose of this prospective study was to investigate whether NfL levels can 
predict diagnosis of clinically definite MS (CDMS) in children with CIS. Our second aim 
was to compare NfL levels in CSF at time of a first demyelinating event between children 
and adults. Finally, we examined the association between NfL and signs of axonal loss 
on magnetic resonance imaging (MRI). 
METHODS
Study participants 
Children and adults were included in either our prospective cohort of adult patients 
with CIS (PRedicting the OUtcome of a Demyelinating event, PROUD study) or in our 
prospective cohort of children with acquired demyelinating syndromes (ADS) (PROUD-
kids study).13, 14 Both studies are ongoing multicentre studies initiated by Erasmus MC in 
Rotterdam, The Netherlands, which is a tertiary referral centre for adult and paediatric 
MS patients (MS Centre ErasMS, and National Paediatric MS Centre). 
All patients were included between February 2002 and December 2015 within 6 months 
after a first event of demyelination of the central nervous system (CNS). Adult patients 
were younger than 50 years of age, and paediatric patients were younger than 18 years. 
No patients had a history of previous neurological symptoms suggestive for CNS 
demyelination. Patients with alternative diagnoses were excluded from analyses. 
The included patients underwent a baseline brain MRI and routine laboratory tests to 
rule out other possible diagnoses. A lumbar puncture (LP) was performed and extra CSF 
was collected and stored at –80°C until use. 
Patients were assessed at baseline and were reassessed regularly. At baseline instructions 
were given to the patients to contact the hospital in case of suspected exacerbation. 
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Cerebrospinal fluid of adult control samples (n=30) was obtained in the Erasmus MC 
from patients with neurological symptoms but no objective clinical or paraclinical 
findings to define a specific neurological disease (symptomatic controls). 15 
Standard protocol approvals and patient consents
The study protocol was approved by the Medical Ethics Committee of Erasmus MC 
Rotterdam and of the other participating centres. Written informed consent was ob-
tained from all patients and/or their families. 
Definitions
CIS was defined as a first attack of demyelination in the CNS without encephalopathy.16 
Clinically definite MS (CDMS) was defined by the Poser criteria as two non-encephalopathic 
attacks with clinical evidence of two separate lesions.17 ADS in children encompass the 
first attack of demyelination, including CIS and acute disseminated encephalomyelitis 
(ADEM).14 Patients presenting with other ADS subtypes than CIS or ADEM were excluded 
from the analyses. Children were diagnosed with CIS, ADEM and CDMS according to 
the diagnostic criteria proposed by the International Paediatric Multiple Sclerosis Study 
Group.13 CDMS was used as the primary outcome. Patients who remained CIS during 
follow-up are referred to as CIS-CIS and patients who were diagnosed with CDMS during 
follow-up are referred to as CIS-CDMS. In both children and adults, an exacerbation 
is defined as sub-acute worsening of existing symptoms, or new symptoms after at 
least 30 days of improvement or stable disease. Symptoms should exist for more than 
24 hours, not be preceded by fever, and not be caused by an alternative diagnosis.18 All 
exacerbations were confirmed by neurological examination. 
Expanded Disability Status Scale (EDSS) was used to assess disability.19 When patients 
were diagnosed with CDMS an EDSS was done annually. EDSS scores performed within 
3 months after an exacerbation were not considered. Follow-up was calculated by 
subtracting the date of first symptoms from the last visit date. Baseline MRI scans were 
performed at 1.5 Tesla scanners and reviewed blindly. Available T1-, axial T2-, axial and/or 
sagittal fluid attenuated inversion recovery (FLAIR)- images were used. The MRIs were 
scored on ≥9 T2 lesions, dissemination in space and time, and asymptomatic T2 lesions. 
The presence of T1-hypointense lesions on baseline MRI were assessed in CDMS patients. 
T1-hypointense lesions were defined as non-enhancing lesions being hypointense rela-
tive to cortical grey matter.20 Patients who did not receive gadolinium were excluded for 
the analysis of T1-hypointense lesions.
CSF sampling and NfL ELISA
Routine CSF diagnostics including IgG index, oligoclonal bands (OCB), cell count and 
total protein were performed. The remaining CSF was immediately centrifuged for 10 
minutes at 3000 rpm to separate the supernatant from cells and cellular elements. 
After centrifugation, samples were aliquoted and stored at –80°C until use.
CSF analyses for OCBs were performed in local laboratories using isoelectric focusing.21 
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OCB status was regarded as positive if there were ≥2 unique bands in CSF compared to 
serum. IgG index above 0.66 was considered as elevated. 
Neurofilament light chain levels in CSF were measured batch-wise in two rounds, 
according to the manufacturer’s instructions, using a stable commercially available 
solid phase sandwich ELISA (UmanDiagnostics, Umea, Sweden).22 NfL concentrations 
(picogram per millilitre (pg/mL)) were calculated using a standard curve according to 
manufacturer’s instructions. All samples were tested double blind and measured in 
duplicate. The detection limit of the ELISA was 150 pg/mL. 
Data analysis
We used SPSS software, version 21.0 (SPSS Inc) and GraphPad Prism5 to perform statistical 
analyses. After log transformation, NfL levels showed a parametric distribution in both 
children and adult samples. Therefore we calculated geometric means for NFL levels. 
Group comparisons for continuous data were performed using 2-tailed t test for normally 
distributed variables (NfL, age at onset, follow-up time) and Mann-Whitney U test was 
used for non-parametric data (time between CIS and LP). We used one-way ANOVA 
and post-hoc Bonferroni correction for parametric data to analyse differences between 
multiple groups. Chi-square or Fisher exact test were performed for categorical variables 
(gender, type of clinical onset, OCB, elevated IgG index, asymptomatic T2 lesions, ≥9 
T2-lesions, and disease modifying therapies (DMT) after CIS and before CDMS). Spear-
man rank correlation was used for correlation analyses between non-parametric conti-
nues variables. Time to CDMS diagnosis was determined by subtracting the date of the 
first symptoms from the date of diagnosis. COX proportional hazard regression analyses 
were used to calculate univariate and multivariable hazard ratios (HR) for time to CDMS 
diagnosis. Known predictors for MS diagnosis were used in the multivariable analyses 
(OCB, asymptomatic T2-lesions). Patients who were not diagnosed with CDMS during 
follow-up were considered as censored observations. We used the median of NfL levels 
to establish cut-off values for high and low levels of NfL in children and adults separately. 
p-values less than 0.05 were considered significant. 
RESULTS
Patients characteristics
A total of 65 children with a first demyelinating event of the CNS, 88 adult patients 
with CIS, and 30 age and gender matched adult control individuals were included in this 
study. 
Of the 65 children, 24 presented with ADEM and 41 with CIS. Twenty-five of 41 (61%) 
children with CIS were diagnosed with CDMS during a mean follow-up time of 38.4 
months (SD: 21.0). The mean follow-up time in adult CIS patients was 68.2 months (SD: 
39.3) in this period 43 (49%) patients were diagnosed with CDMS. 
The median time (interquartile range; IQR) from CIS to CDMS in adult patients was 36.4 
months (14.4-48.9) and in children 10.8 months (5.0-15.7). 
154
Chapter 9
The time between CIS and LP was not significantly different between children and adult 
patients. No patients were receiving DMT at time of LP.
Sixteen adult patients (18%) and 14 (34%) children who were not yet diagnosed with 
CDMS received DMT (glatiramer acetate (n=11), interferon (n=19), natalizumab (n=1)). 
The patient characteristics for adults and children are shown in Table 1 and Table 2.
Adults
Controls 
(n=30)
CIS-patients 
(n=88)
CIS-CDMS 
(n=43)
CIS-CIS 
(n=45) p-valuea
Female sex, n (%) 20 (66.7) 59 (67.0) 34 (79.1) 25 (55.6) 0.02
Ageb (years), mean (SD) 33.4 (±9.5) 31.2 (±7.2) 31.9 (±7.1) 33.6 (±7.3) 0.28
Follow-up time (months), mean (SD) na 62.8 (±38.7) 89.0 (±36.8) 48.3 (±30.7) <0.01 
Type of clinical onset, n (%)
-Optic nerve na 41 (46.6) 21 (48.8) 20 (44.4) 0.68
-Spinal cord na 23 (26.1) 11 (25.6) 12 (26.7) 0.91
-Other localization na 24 (27.3) 11 (25.6) 13 (28.9) 0.73
OCB, (≥2 bands), n (%) na 63/83 (75.9) 36/41 (87.8) 27/42 (64.3) 0.01 
Elevated IgG index (cut-off: 0.66), n (%) na 44/85 (51.8) 22/41 (53.7) 22/44 (50.0) 0.74
Time CIS to LP (weeks), median (IQR) na 6.1 (2.7-13.2) 6.0 (2.9-12.6) 6.7 (2.6-14.1) 0.97
≥9 lesions on T2-weighted images, n (%) na 27 (30.7) 18 (41.9 9 (20.0) 0.03
Asymptomatic T2-lesions, n (%) na 76 (86.4) 38 (88.4) 38 (84.4) 0.59
MS based on first MRIc, n (%) na 16 (18.2) 11 (25.6) 5 (11.1) 0.08
DMT before CDMS diagnosis, n (%) na 16 (18.2) 12 (27.9) 4 (8.9) 0.02
Time between CIS and start DMT 
(months), median (IQR)
na 27.8 (9.7-43.1) 29.5 (9.9-46.6) 14.4 (5.9-29.0) 0.25
Table 1.  Patient characteristics (adults)
a p value calculated between CIS-CDMS and CIS-CIS   
b For patients with CIS: age at CIS, for Controls: age at lumbar puncture 
c Dissemination in space and time at baseline based on McDonald 2010 criteria
Abbreviations: CIS, Clinically isolated syndrome; CIS-CDMS, patients who are diagnosed with CDMS during follow-up 
after CIS defined by Poser criteria; CIS-CIS, not diagnosed with CDMS; na, not applicable; DMT, disease 
modifying therapy; OCB, oligoclonal bands; Ig, Immunoglobulin; LP, lumbar puncture.
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Table 2.  Patient characteristics (children)
a p value calculated between CIS-CDMS and CIS-CIS   
b Dissemination in space and time at baseline based on McDonald 2010 criteria 
Abbreviations: CIS, Clinically isolated syndrome; CIS-CDMS, patients who are diagnosed with CDMS during 
follow-up after CIS defined by Poser criteria; CIS-CIS, not diagnosed with CDMS; na, not applicable; DMT, disease 
modifying therapy; OCB, oligoclonal bands; Ig, Immunoglobulin; LP, lumbar puncture.
NfL levels at time of the first demyelinating event per clinical subgroup 
Patients (children and adults) at time of a first attack of demyelination showed higher 
NfL levels than control individuals; geometric mean 2040 vs 444 pg/mL; p<0.001. In 
Figure 1, NfL levels from controls, adult, and paediatric patients are shown.
In adult patients, NfL levels at time of CIS were higher in the group that was diagnosed 
with CDMS (CIS-CDMS, n=43 (49%)) compared to the group that remained CIS during 
follow-up (CIS-CIS); geometric mean 2156 vs 1342 pg/mL; p=0.012. (Figure 2)
In children, we compared NfL levels between CIS-CIS, CIS-CDMS, and ADEM patients. NfL 
levels at time of CIS in paediatric CIS-CDMS patients (n=25; 61%) were higher than in 
paediatric CIS-CIS patients; geometric mean 4888 vs 967 pg/mL; p=0.01. Children with 
ADEM did not differ in NfL levels from CIS-CIS and CIS-CDMS children; geometric mean 
2683 pg/mL (Figure 2). There was no correlation between time from onset of symptoms 
to LP and NfL levels in both children and adults. 
9
Children
ADS-patients 
(n=65)
ADEM 
(n=24)
CIS-CDMS 
(n=25)
CIS-CIS 
(n=16) p-value a
Female sex, n (%) 38 (58.8) 16 (66.7) 16 (64.0) 6 (37.5) 0.10
Age (years), median (IQR) 12.5 (5.4-15.5) 4.1 (2.6-7.2) 15.0 (13.8-16.0) 14.2 (9.0-16.4) 0.52
Follow-up time (months), mean (SD) 43.8 (±27.1) 53.1 (±33.7) 44.1 (±22.3) 29.5 (±15.5) 0.03
Type of clinical onset, n (%)
-Optic nerve 11 (16.9) 0 (0.0) 5 (20.0) 6 (37.5) 0.22
-Spinal cord 11 (16.9) 0 (0.0) 6 (24.0) 5 (31.2) 0.61
-Other localization 7 (10.8) 0 (0.0) 4 (16.0) 3 (18.8) 1.00
-Polyfocal without encephalopathy 12 (18.4) 0 (0.0) 10 (40.0) 2 (12.5) 0.08
-Polyfocal with encephalopathy 24 (36.9) 24 (100.0) 0 (0.0) 0 (0.0) 1.00
OCB, (≥2 bands), (%) 28/54 (51.9) 0/17 (0.0) 21/23 (91.3) 7/14 (50.0) 0.01
Elevated IgG index (cut-off: 0.66), n (%) 33/50 (66.0) 4/12 (33.3) 22/23 (95.7) 7/15 (46.7) <0.01
Time first symptoms to LP (weeks), 
median (IQR)
2.3 (0.8-7.6) 1.6 (0.6-2.6) 6.0 (1.9-12.8) 1.8 (0.6-7.8) 0.10
≥9 lesions on T2-weighted images, n (%) 27 (41.5) 6 (25.0) 6 (64.0) 5 (31.2) 0.04
Asymptomatic T2-lesions, n (%) 55 (8.6) 22 (91.7) 24 (96.0) 9 (56.2) 0.003
MS based on first MRIb, n (%) 10 (15.4) na 9 (36.0) 1 (6.2) 0.03
DMT before CDMS diagnosis, n (%) 14/41 (34.1) na 9 (36.0) 5 (31.3) 0.75
Time between CIS and start DMT 
(months), median (IQR)
6.4 (3.3-12.1) na 6.3 (1.7-14.8) 6.5 (3.5-10.4) 0.72
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Figure 1.  CSF NfL levels in Controls vs 
Adults vs Children 
CIS and ADEM patients are included in 
children. 
Horizontal lines with error bars indicate 
geometric mean with 95% CI. 
Abbreviations: NfL, Neurofilament light 
chain; pg/mL, picogram/millilitre
NfL levels compared between children and adult
Next, we compared NfL levels between children and adult patients at time of CIS. In the 
CIS-CDMS group, NfL levels were higher in children compared to adults; geometric mean 
4888 vs 2156 pg/mL; p=0.007. NfL levels were not different between adults and children 
in the CIS-CIS groups (Figure 2).
Figure 2.  NfL 
levels in clinical 
subgroups of adults 
and children 
Horizontal lines 
with error bars 
indicate geometric 
mean with 95% CI. 
Abbreviations: 
NfL, Neurofilament 
light chain; ns, not 
significant; pg/mL, 
picogram/millilitre
157
High NfL levels are associated with CDMS in children and adults with CIS
9
Association of NfL levels with time to CDMS diagnosis in children and adults with CIS
To analyse time to CDMS diagnosis, we used median CSF NfL levels in CIS patients as 
cut-off. This resulted in a cut-off of 1802 pg/mL for adults and 2537 pg/mL for children. 
These cut-offs were used to divide CIS patients (ADEM excluded) into groups with high 
and low NfL levels, and were subsequently used in the COX regression analysis.
The univariate COX regression analysis showed a HR for CDMS diagnosis of 2.1; 
p=0.024 in adults and 3.8 in children with CIS; p=0.003. Kaplan-Meier curves are 
shown in Figure 3A/B. 
In a multivariable COX regression analysis, we corrected for clinically relevant parameters; 
the presence of asymptomatic T2 lesions on the baseline MRI and OCB. We also corrected 
for age at onset, based on correlation with NfL levels in control individuals (spearman rho 
0.59, p=0.001). The HR in the multivariable COX regression analysis for high NfL levels 
was 2.1 in adults (p=0.032) and 3.7 in children (p=0.007). (Table 3)
Figure 3.  Time from CIS to CDMS in CIS patients with high and low CSF NfL levels 
A. Adults (log-rank test p=0.02). 
B. Children (log-rank test p=0.001). Kaplan-Meier curves showing time to CDMS diagnosis for CIS patients (ADEM 
excluded) with either high or low CSF NfL levels. 
Abbreviations: CDMS, Clinically definite multiple sclerosis; NfL, Neurofilament light chain; pg/mL, picogram/
millilitre
Sixteen (18%) adult CIS patients and 14 (34%) children received DMT before CDMS diag-
nosis. This could have postponed the second attack. The HR in children increased after 
excluding patients who received DMT before CDMS diagnosis. In adults the univariate 
HR did not change, and the HR in the multivariable analysis showed a trend towards 
significance.
When we add DMT before CDMS diagnosis into the COX regression model, the HRs did 
not change.  
Thirteen (11%) adults and nine (22%) children were treated with methylprednisolone 
A B
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within three months before LP. When we corrected for this in the COX regression model, 
the results did not change. 
In another sub-analysis, we excluded CIS-CIS patients who had less than 2 years follow-up 
(children: n=5, adults: n=10). After this exclusion, HRs were not altered in adults and 
increased in children. Table 3 shows the univariate and multivariable HRs including 
those of the subanalyses. 
Table 3.  Cox regression (univariate and multivariable) hazard ratios for CDMS diagnosis in adults 
and children with CIS
Hazard ratios for CDMS diagnosis in subgroups for adults and children with CIS (ADEM excluded) 
Multivariable analyses: corrected for presence of asymptomatic T2 lesions on baseline MRI, presence of OCB and 
age of onset
Abbreviations: HR, hazard ratio; CI, confidence interval; DMT, disease modifying treatment; CDMS, clinically definite 
multiple sclerosis; FU, follow-up; CIS, clinically isolated syndrome. 
Association of CSF NfL levels with disability 
We did not find a correlation between CSF NfL levels and EDSS scores after CDMS 
diagnosis. We collected EDSS data from 55/68 (81%) patients who were diagnosed with 
CDMS. Only 6 patients (4 adults and 2 children) reached an EDSS of 3.0 or more. 
Association of CSF NfL levels with signs of axonal damage on MRI
CSF NfL levels were increased in CDMS patients showing T1-hypointense lesions on 
baseline MRI (adults 20/39, 51%; children 15/23, 65%). We found this in adults (geome-
tric mean 3188 vs 1588 pg/mL; p=0.001) and in children (geometric mean 8920 vs 1668; 
p=0.001). (Figure 4A/B)
Univariate analysis 
HR (95% CI)
P-value Multivariable analysis 
HR (95% CI)
P-value
Adults
Total group (n=88) 2.1 (1.1-3.9) 0.024 2.1 (1.1-4.1) 0.032
After excluding patients with DMT 
before CDMS diagnosis (n=72)
2.2 (1.1-4.7) 0.035 2.2 (1.0-4.9) 0.061
After excluding CIS-CIS patients 
with FU <2 years (n=78)
2.0 (1.1-3.8) 0.027 2.1 (1.1-4.1) 0.034
Children 
Total group (n=41) 3.8 (1.6-9.2) 0.003 3.7 (1.4-9.3) 0.007
After excluding patients with DMT 
before CDMS diagnosis (n=27)
19.8 (2.5-155.5) 0.005 13.7 (1.6-114.3) 0.015
After excluding CIS-CIS patients 
with FU <2 years (n=36)
3.8 (1.6-9.2) 0.003 4.2 (1.6-11.3) 0.004
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Figure 4.  CSF NfL levels in CIS-CDMS adults and children with and without T1-hypointense lesions on baseline MRI 
A. Adults: T1-hypointense lesions vs no T1-hypointense lesions on baseline MRI. 
B. Children: T1-hypointense lesions vs no T1-hypointense lesions on baseline MRI. 
Horizontal lines with error bars indicate geometric mean with 95% CI. 
Abbreviations: NfL, Neurofilament light chain; pg/mL, picogram/millilitre; CDMS, Clinically definite multiple 
sclerosis
DISCUSSION
In this prospective study, we demonstrate that CSF NfL levels in children and adults with 
a first attack of suspected MS are predictive for CDMS diagnosis. Furthermore at time of 
CIS, CSF NfL levels in patients with a future CDMS diagnosis are higher in children than 
in adult patients. This underlines that not only inflammation is more severe in children3-5 
but that children also have more axonal damage early in the disease course of MS than 
adult patients.8 
To our knowledge, we are the first to show that CSF NfL levels are associated with a 
subsequent diagnosis of CDMS in children with CIS. In addition, the results validate the 
predictive value of CSF NfL levels for CDMS diagnosis in adult CIS patients.12, 23 Both in 
adults and children, these findings were independent of known predictive factors for 
CDMS, i.e. asymptomatic T2 lesions on baseline MRI and unique OCBs in CSF. Moreover, 
CSF NfL levels predicted a second attack even better than these currently used markers. 
It is essential to improve currently available routes to prediction to prevent unnecessary 
treatment of patients with low clinical disease activity, especially because these im-
munomodulatory therapies can have serious side effects. Recently, other potential CSF 
biomarkers for a future MS diagnosis have been identified.24, 25 Our findings draw further 
attention to the relevance of including CSF analyses as part of routine diagnostics. 
9
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Since NfL is considered a biomarker for axonal damage, neurodegeneration, and 
brain atrophy,26, 27 we reasoned that its presence in CSF could be associated with T1-
hypointense lesions on MRI, which are signs of axonal loss.28 In children with CIS, these 
T1-hypointense lesions have been reported to be highly predictive for MS diagnosis.20 
Here, we demonstrate that children and adult CIS patients with T1-hypointense lesions 
on baseline MRI have higher NfL levels than patients without these lesions. 
CSF NfL levels in children with ADEM were not significantly different from levels in 
patients who remained CIS or who were eventually diagnosed with CDMS. Nevertheless, 
these levels were high in ADEM patients (geometric mean 2683 pg/mL), indicating con-
siderable axonal damage. Studies have reported cognitive impairment and persistent 
motor dysfunction in children with ADEM.29, 30 Moreover, it has been shown that subsequent 
white matter maturation and age-expected brain growth is disturbed not only in pae-
diatric MS, but also in monophasic ADS, including ADEM.31, 32 These findings support the 
occurrence of damage during the acute phase with a lasting impact. Which stresses the 
importance of adequate follow-up and support after the acute event.
NfL levels have been reported to be also increased in serum of adult CIS and MS patients,33, 34
but the predictive value in CIS patients for MS diagnosis of this marker seems limited 
to CSF.12 As we here aimed to assess and compare prediction in both children and adults 
with CIS, we restricted in this study to CSF samples.
There are some limitations in this study. First, the range of follow-up is rather wide. We 
did correct for this in the COX regression analyses, and we also performed a sub-analysis 
after excluding CIS-CIS patients with a follow-up less than 2 years, which did not change our 
findings. Second, in both the adult and paediatric study, we did not perform a follow-up 
MRI on a regular basis. Therefore, the Poser criteria were used instead of the McDonald 
2010 criteria. In this way, we could show an effect on clinical disease activity (second 
attack) instead of disease activity measured with MRI. Third, in order to prove an association 
of CSF NfL levels with EDSS, we will need a longer follow-up period since disability occurs 
later in the disease course especially in children.6 Fourth, we did not have access 
to advanced imaging techniques for quantification of neurodegeneration (e.g. T1-
hypointense lesion volumes, total brain volume and brain tissue integrity). However, 
we used the presence of T1-hypointense lesions as an MRI marker for axonal damage,28 
because it is easily assessable. Furthermore, we did not include paediatric controls 
since we did not receive ethical permission to collect paediatric control CSF samples, 
which made the collection of this rare material not possible. Yet, control groups in other 
paediatric studies indicate low physiological levels of NfL, in the same range as the 
adult controls in the present study.35, 36  
Last, although our sample size was relatively small due to limited availability of CSF, 
we were still able to correct our results for other predictive factors for MS diagnosis. 
Our findings in children were also compatible to those in adults, further stressing the 
robustness of the observations.
In conclusion, we show that high levels of CSF NfL are associated with CDMS diagno-
sis independently of known predictive factors (i.e. asymptomatic T2 lesions and OCB) 
in both children and adults. CSF NfL levels at time of a first demyelinating event are 
higher in children than in adults with a future CDMS diagnosis. In addition, this marker 
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for axonal damage, is associated with MRI signs of neurodegeneration in both groups. 
Given that therapeutic interventions might delay disease progression and accumulation 
of disability,37, 38 it is essential to accurately predict MS diagnosis, not the least in the 
paediatric population. Hence, NfL in CSF is a promising predictive marker for the disease 
course in both adults and children with a first demyelinating event, with a potential 
value in future clinical practice. 
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Chapter 10
Patients who have a first attack of multiple sclerosis (MS), also called clinically isolated 
syndrome or CIS, face a precarious future. Not all patients will be diagnosed with MS 
and the disease course after MS diagnosis is highly heterogeneous.1 Being able to ade-
quately counsel these patients about their long-term prognosis is important, especially 
since MS affects mostly young patients in the most productive years of their lives.2    
This thesis focuses on the disease course after a first attack of demyelination, both in 
adults with CIS and children with childhood-onset acquired demyelinating syndromes 
(ADS), a rare variant within the spectrum of demyelination.3 We focused on defining 
prognostic factors, both clinical markers and biomarkers, for a better prediction of 
disease course after a first attack of demyelination, not only for predicting MS diagno-
sis but also for predicting disease course after MS diagnosis. The studies in this paper 
are executed within two prospective patient cohorts. One cohort consists of adult CIS 
patients and the other cohort consists of paediatric ADS patients, giving the unique 
opportunity to compare the disease course of children and adults after a first attack of 
demyelination. All patients were included at time of the first attack of demyelination 
and after that followed prospectively. This chapter discusses the key findings of the 
studies described in this thesis and directions for future research.
Diagnosing MS at time of the first attack
The majority of CIS patients will experience a second relapse. However, more than one 
third remains monophasic.4 Fifty percent of the patients in our cohort of adult CIS 
patients with a mean follow-up time of 5.5 years had a second relapse.
The first generally recognized criteria for MS were described by Allison and Millar in 
1954,5 followed by multiple revisions.6 Poser et al. described criteria for clinically definite 
MS (CDMS) in 1983, these were purely based on two clinical manifestations of demye-
lination in two different neurological localizations at two different timepoints.7 Since 
2001, MRI findings are included in the diagnostic criteria.8 Not only clinical dissemina-
tion in space (DIS) and time (DIT) but also DIS and DIT on the MRI scan can now lead to 
an MS diagnosis. After this first version of the McDonald MRI criteria, multiple revisions 
are implemented.8-11 The criteria have been simplified over time and allow a faster MS 
diagnosis. 
Since the 2010 criteria, a diagnosis of MS could be made based on a single CIS attack 
with no subsequent clinical relapses. Therefore this patient group comes even closer 
to the group with radiologically isolated syndrome (RIS). Because DMT can delay MS 
diagnosis in CIS patients, the discussion comes closer to whether high risk RIS patients 
should also be treated with immunomodulating therapies. 
The latest revisions in 2017 include presence of unique oligoclonal bands (OCB) in 
cerebrospinal fluid (CSF) as a substitute for DIT on MRI.11 This means that a CIS patient 
can be diagnosed with MS when the MRI meets criteria for DIS and OCB are present 
in CSF. Furthermore, not only asymptomatic but also symptomatic lesions can be used 
to meet criteria for DIS and DIT. One could imagine that these simplifications of the 
criteria could lead to a higher number of MS diagnosis in patients who will not have 
a future second attack. Accurate diagnostic criteria are essential to select patients for 
early treatment with immunomodulating therapies. Early treatment has been shown 
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beneficial for disease outcome.12-14 However, these therapies have adverse effects, and 
treating patients who will remain clinically monophasic should be prevented.
In chapter 2, we applied the latest diagnostic criteria to a cohort of 229 CIS patients with 
a mean follow-up time of 5.4 years. We compared the performance of the new 2017 
criteria to the former 2010 criteria in predicting CDMS diagnosis according to the Poser 
criteria.7 The most important finding was that with the new criteria twice as many 
patients could be diagnosed with MS at time of the first attack (97 vs 46 patients). The 
2017 criteria were more sensitive than the 2010 criteria (68% vs 36%), but specificity de-
creased from 85% to 61%. These results imply that the 2017 criteria will probably lead to 
a higher number of MS diagnoses in patients with a less active disease course. To allow 
earlier initiation of disease modifying therapies (DMT), a high sensitivity of diagnostic 
criteria is essential. But a decrease in specificity can lead to erroneous diagnoses and 
unnecessary treatment of patients with a benign disease course. Unnecessary treat-
ment should be avoided, most importantly, because these therapies can have serious 
adverse effects.15, 16 In 63% of the patients who were diagnosed with MS based on the 
2017 criteria at baseline (and not based on the 2010 criteria) MS diagnosis was made 
based on DIS and OCB in CSF and no DIT on the baseline MRI. Forty-seven percent of 
this group was not diagnosed with CDMS during follow-up. The reduction of specificity 
seems to be mostly caused by the inclusion of OCB to the criteria. 
In our CIS cohort, follow-up MRI scans were not performed uniformly according to a 
strict protocol, therefore we could not demonstrate if the new criteria at baseline were 
better in predicting MS diagnosis based on new lesions on a follow-up MRI scan. However, 
one could argue whether predicting activity on MRI or predicting clinical disease activity 
is more relevant for further treatment decisions. 
Validation of these criteria in other cohorts of CIS patients is essential to test their accu-
racy in clinical practice.
Clinical prognostic factors in patients with CIS
Fatigue is a common symptom in MS patients, more than 75% of these patients report 
fatigue.17, 18 Our study group showed earlier that fatigue was already present early in the 
disease course, at time of the first attack.19 The same study showed that fatigue was an 
independent predictor for a subsequent CDMS diagnosis, unrelated to anatomical loca-
lization of the first attack. This implicates that fatigue in MS patients may not be related 
to the attack itself but probably to MS related pathophysiological processes as inflam-
mation, demyelination and axonal loss.20, 21 However, fatigue in MS patients can also be 
the result of MS-related symptoms such as sleep deprivation, MS-related neuro-psychiatric 
disorders, or effect of medication.20, 21 Yet, several studies indicated an independent rela-
tion between inflammation and fatigue.22, 23 
In chapter 3, we explored the long-term course of fatigue after CIS. First, we validated 
our earlier finding that patients with a future CDMS diagnosis had already a higher 
fatigue score (FSS)24 at time of the first attack than patients who remained monophasic 
during a mean follow-up of 4.3 years. Next, we showed that after CDMS diagnosis the 
FSS increased even more. Fatigue seems to exist early in the disease course of MS, 
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probably will remain present during the further follow-up and increases after CDMS 
diagnosis. Other studies in MS patients also suggested a persistency of fatigue over 
time.17, 25, 26 However, the follow-up time in these studies was short with a maximum of 3 
years. Furthermore, these studies evaluated fatigue years after MS diagnosis. Our study 
shows that the majority of MS patients have to cope with disabling fatigue, which exists 
already very early in the disease course, therefore fatigue deserves proper attention in the 
standard care for MS patients already in the most early stages of the disease. 
Cigarette smoking has been shown to influence the disease course of MS patients.27 In 
chapter 6, we demonstrated that smoking at time of CIS was an independent predictive 
factor for a second attack during follow-up (HR: 2.3; p<0.01). We expected this outcome 
since earlier studies have shown the influence of smoking on disability and the time to 
secondary progressive MS (SPMS). In addition, there is an increased risk of MS for people 
who smoke in the general population.27, 28 However, earlier studies remained inconclusive 
in respect to the predictive value of smoking in CIS patients.29 These earlier studies had 
small sample sizes and used retrospective data.30, 31 Other studies included patients 
who were treated with interferon beta immediately after CIS or two years after CIS.32, 33 
Treatment with interferon beta could have postponed a second attack and may have 
overshadowed the potential correlation between smoking and CDMS diagnosis. 
Interestingly, our data showed that smoking in the past in current non-smoking 
patients was not associated with CDMS. This finding suggests that the harmful effects 
of smoking are reversible. This is in line with earlier studies, showing that the negative 
effects on disability progression decrease after cessation of smoking.34, 35 These results 
were independently of the cumulative dose of smoking. The pathophysiological mecha-
nism of the influence of smoking on MS remains to be determined. Direct and indirect 
influences of tobacco toxins and smoke particles on T cells and antigen presenting cells 
may be part of this mechanism.36
Since smoking is a modifiable risk-factor for MS, counselling patients about smoking is 
of great importance, especially because the negative effects of smoking seem to reduce 
after cessation of smoking. Smoking status could also be a relevant parameter in predic-
tive models for MS in CIS patients. 
Children versus adults
Multiple sclerosis with a childhood-onset is rare. Around 3-5% of MS patients have their 
first attack during childhood, and only <1% under the age of 12.3, 37 Diagnosing paediatric 
MS is challenging because of the rarity of this disease in children and the more extensive 
differential diagnosis for childhood-onset MS.38 
Although children have a higher number of relapses, more severe relapses,39 and more 
lesions on brain MRI,40, 41 time to reach disability endpoints is longer in children than 
in adult patients with MS.42, 43 Yet, because the start of the disease in children is at a 
younger age, paediatric patients reach these disability endpoints earlier in life than 
adult MS patients. These results are based on retrospective studies or studies conducted 
before the immunomodulating treatment era in children. The second part of this thesis 
focusses on children versus adults.
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In chapter 7, we compared disease course after CIS between three age groups (1-10 
years, 11-17 years, and 18-50 years). Patients were included in two prospective patient 
cohorts with paediatric and adult patients followed after a first attack of demyelination. 
This study included a total of 383 CIS patients. We observed, in line with the studies 
mentioned before,39-41 that children with CIS tend to have a more inflammatory disease 
course than adult patients with CIS. Children aged between 11 and 17 years were more 
often diagnosed with MS and had a shorter time between CIS and MS diagnosis than 
patients in the other age groups. Patients in this age group also had more T2 lesions on 
the baseline MRI scan and a more inflammatory CSF profile. The secondary progressive 
phase of MS was reached for eight patients who were all older than 37 years of age 
at onset of CIS.44 Since SPMS is age dependent,45, 46 the patients with a younger age at 
disease onset probably did not reach this progressive phase yet. For both children and 
adults, there was a female predominance, except for the youngest age group before 
puberty (1-10 years), in this young group more boys than girls were diagnosed with MS. 
This difference in sex distribution before and after puberty and the total increase in MS 
diagnoses after puberty implies a role for sex hormones in the onset of MS. This role for 
female and male sex hormones is also suggested in other studies.47, 48  
Furthermore, we found, in line with other literature, a higher rate of non-Caucasian CIS 
patients in the paediatric group than in the adult group.49, 50 Non-Caucasian ethnicity 
seems to lead to a higher vulnerability for developing MS at a younger age, this could be 
due to a lack of protective genes, since their ancestors were born in countries with a low 
MS prevalence. 
After MS diagnosis, paediatric MS patients had a higher annualized relapse rate (ARR) 
than patients with adulthood-onset MS. However, after the start of DMT treatment, the 
ARR was comparable between adults and children. This change in ARR after administration 
of DMT and the more inflammatory disease course in children supports early initiation 
of DMT in children with MS, even at time of CIS in children who are at high risk for MS 
diagnosis in the age group 11-17 years. This is in line with current clinical practice in adult 
CIS and MS patients. However, data about long term adverse effects of DMT in children 
are limited. It is crucial to investigate whether early initiation of DMT in children is safe 
and beneficial, since childhood-onset MS is rare, international collaboration is needed. 
As described above, disability progression is slower in paediatric than in adult patients 
with MS.42, 43, 51 However, neurodegeneration plays also a role in early childhood-onset 
MS, It has been shown that age-expected brain growth was impaired early in the disease 
course in paediatric MS patients.52 One of the major causes for persisting neurological 
disability in MS is axonal damage.53 A well-established biomarker for this process is 
neurofilament light chain (NfL), an element of the neuron cytoskeleton.54 NfL is released 
in the extracellular space after neuronal cell death. NfL increases with age in healthy 
individuals, reflecting neurodegeneration as part of the physiological aging process.55 In 
adult CIS patients, NfL levels are shown to be associated with a future MS diagnosis.56, 57 
In chapter 9, we show that this is also the case for paediatric CIS patients. NfL levels in 
CSF at time of the first attack predicted a second attack (CDMS) both in children and 
adults with CIS. NfL levels were even higher in children than in adults, implying that 
early in the disease course, children have not only signs of more inflammation but also 
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seem to have more axonal damage than adults.40, 41 NfL levels predicted a second attack 
even better than currently used markers such as asymptomatic T2 lesions on MRI and 
unique OCBs in CSF. These findings suggest an important role for CSF analyses as part 
of the routine diagnostic process. Furthermore, we found in children and adults with 
a future CDMS diagnosis, a correlation between NfL levels and T1 hypo-intense lesions 
on baseline MRI, another sign of axonal loss. These T1 hypo-intense lesions are highly 
predictive for MS diagnosis in children.58 We did not find an association between NfL 
levels at time of the first attack and disability later in the disease course. In order to 
prove such an association, a longer follow-up time is probably needed, since disability 
occurs late in the disease course, especially in children.42, 43 
The results of the above described studies show that the disease course after CIS in 
children is not only more inflammatory than in adults but they also show that signs of 
neurodegeneration are present already early in the disease course. Initiating treatment 
(DMT) to prevent further relapses with possible residual damage seems logical. Predic-
ting who will have an active disease course is crucial, especially in this young patient 
group, since these children have a long time of treatment ahead and long-term damage 
of these therapies started in childhood is not studied very well. Markers such as NfL 
could possible help in selecting patients who will have an active disease course. 
T cell activation in CIS and ADS
A biomarker that could possibly help in the early selection of patients with an active 
disease course is the immunological marker soluble CD27 (sCD27). Soluble CD27 is 
released by activated T cells, after activation via the T-cell receptor/CD3 complex,59 as 
shown in figure 1.
Figure 1.  sCD27 release after T cell stimulation 
via the T-cell receptor/CD3 complex
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A clear association has been found between sCD27 and the presence of intrathecal 
T cells.60 This T-cell activation marker seems to be directly related to the core 
immunopathology of MS.61, 62 It has been shown that sCD27 is higher in CSF from MS 
patients than from control individuals.60, 63, 64
In chapter 4, we show that high CSF levels of sCD27 in adults with CIS are independently 
associated with a future MS diagnosis. Furthermore, we found a higher attack frequency 
in patients with high sCD27 levels at baseline than patients with low sCD27 levels. 
CD27 and sCD27 induce activation and proliferation of T and B cells.65, 66 There is some 
evidence that sCD27 could play a role in the IgG production by B cells. An in vitro study 
showed that memory B cells could be stimulated to differentiate into IgG-secreting 
plasma cells by binding of sCD27 to the CD27 ligand CD70.67 This functional role of 
sCD27 could explain the strong correlation that we and others found between sCD27 
and IgG index.60, 63 
Our finding that sCD27 predicts a future MS diagnosis in adults with CIS is validated 
in a cohort of children with ADS in chapter 8. We show that children with a first attack 
of demyelination and a future CDMS diagnosis have higher sCD27 levels than patients 
with a first attack of demyelination with encephalopathy, relapsing non-MS patients 
and monophasic paediatric CIS patients. In accordance with our findings in adults, 
sCD27 levels are predictive for a second attack in paediatric CIS patients. This validation 
strengthens the conclusions from both studies. Notable is that sCD27 levels are higher 
in children than in adults with a future MS diagnosis, which reflects the more inflam-
matory disease course in children compared to adults, as is also shown in chapter 7.39-41 
Both in adults and children, we did not see an association between sCD27 and disability 
later in the disease. This is not surprising since most disability occurs late in the disease 
course this is not surprising. As mentioned before, disability progression in paediatric 
MS is slower than in adults.42 In children we did not find a correlation between sCD27 
and ARR, this is in contrast with our findings in adults where ARR did correlate with 
sCD27. An explanation for this inconsistent finding could be a ceiling effect, since the 
relapse rate in children is overall high.39
Soluble CD27 seems an activation marker directly related to the immunopathology of 
MS. Both in adults and paediatric patients with a first attack of demyelination, sCD27 
could be a useful quantitative marker for disease activity when performing routine CSF 
diagnostics. 
T helper 17 (Th17) cells (CCR6+) express IL-17 and are shown to be critical regulators of 
MS disease activity.68 CCR6 and IL-17 are considered as key determinants for trans-
migrating across the blood-brain barrier.69 Th17 cells are functionally highly heterogeneous. 
Depending on the pro-inflammatory milieu, Th17 cells consist of sub-populations that 
express not only CCR6 and IL-17 but also other distinct surface markers (CXCR3, CCR4) 
and pro-inflammatory cytokines (IFN-y, GM-CSF).68, 70 Especially GM-CSF is considered as 
an important mediator in MS onset.71
In chapter 5, we showed that Th1-like Th17 cells (CCR6+CXCR3+), a subpopulation of Th17 
cells expressing IL-17 but also both IFN-y and GM-CSF,72 were selectively associated with 
early disease activity in CIS and MS patients. Effector memory Th1-like Th17 cells were 
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more abundant in blood from CIS patients who remained CIS for at least 5 years (CIS-
CIS) than in CIS patients who converted to CDMS within 1 year (CIS-CDMS). This is not 
the case for Th17 (CCR6+, CXCR3-) cells. Th1-like Th17 frequencies in CIS-CDMS patients at 
time of CIS are comparable with the frequencies in blood from untreated MS patients. 
Interestingly, this same subset was more abundant in CSF of CIS and early MS patients 
and had a higher production of the pro-inflammatory cytokines IFN-Y and GM-CSF than 
their paired peripheral blood equivalents. This implies a local recruitment of this highly 
activated subset in the CSF of early MS patients. Furthermore, Th17.1 cells (a subpopu-
lation of Th1-like Th17 cells, CCR6+CXCR3+CCR4-) express the highest VLA-4 levels and 
selectively accumulate in blood from patients who were relapse free while treated with 
natalizumab. There was no accumulation of Th17.1 cells in blood from MS patients trea-
ted with natalizumab who experienced relapses. 
In summary, we show evidence for the recruitment of highly pro-inflammatory specific 
Th17 subsets into the CSF during disease onset. Th1-like Th17 subpopulations, in parti-
cular Th17.1 cells, probably play an important role in clinical disease activity in patients 
with MS. This data could be of value for developing more specific T cell-targeted thera-
pies. However, to determine their local impact in the MS brain, localization and revea-
ling the antigen specificity of these subsets in brain lesions is the first step.
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Main findings
 The revised 2017 McDonald criteria for MS double the number of MS diagnoses at baseline 
 Including OCB as a substitute for ‘dissemination in time’ in the McDonald 2017 criteria has 
the highest impact on the decrease in specificity
 Fatigue is validated as an independent predictor for CDMS diagnosis in CIS patients
 Fatigue, present at time of CIS, will probably remain present during the further follow-up 
and increases after CDMS diagnosis
 Cigarette smoking at time of CIS is an independent predictor for CDMS diagnosis 
 Past smoking in currently non-smoking CIS patients is not associated with CDMS diagnosis
 Children with CIS have a more inflammatory disease course, with a higher relapse rate 
than adult CIS patients
 Children with CIS between 11-17 years of age are more often and earlier diagnosed with 
MS, have more T2 lesions on baseline MRI and have a more inflammatory CSF profile than 
patients in other age groups
 The female predominance is not seen in the youngest age group, before puberty 
 (1-10 years of age) 
 High CSF NfL levels predict a future MS diagnosis both in adult and paediatric CIS patients 
 NfL levels correlate with T1 hypo-intense lesions on baseline MRI, a sign of axonal loss, in 
children and adults with a future CDMS diagnosis
 sCD27 is an independent predictor for MS diagnosis in adult and paediatric CIS patients
 Adult CIS patients with high sCD27 levels at baseline have a higher attack frequency 
during follow-up than patients with low sCD27 levels 
 Th1-like Th17 cells are more abundant in peripheral blood of CIS patients who remain 
monophasic during follow-up than in CIS patients with a short time to CDMS diagnosis
 Th1-like Th17 subpopulations, in particular Th17.1 cells, are recruited to the CSF during 
disease onset of MS
 Th17.1 cells have the highest VLA-4 expression and selectively accumulate in blood from 
relapse free natalizumab treated patients
Clinical implications
 The McDonald 2017 criteria probably lead to a higher number of MS diagnoses in patients 
with a less active disease course
 Fatigue deserves proper attention throughout the disease course of MS
 Patients with CIS and MS should quit smoking
 Early initiation of DMT should be considered in paediatric CIS patients who are at high 
risk for developing MS 
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FUTURE PERSPECTIVES
Multiple markers are identified for predicting disease course after a first attack of 
demyelination. MRI is, up to now, the best tool to predict disease course. In the new 
diagnostic criteria, MRI remains the most important component.11 However, the search 
for markers in blood and CSF to reveal new biomarkers for predicting disease course and 
providing a more individualized care is crucial and ongoing.73 These markers could also 
be helpful in gaining more insight into the pathogenesis of MS. 
Since the predictive value of NfL in CSF has been shown in multiple CIS cohort including 
ours, this marker may be a good candidate to be incorporated in following versions of 
the MS criteria.  
Our findings on the recruitment of the highly pro-inflammatory Th1-like Th17 subsets in 
CSF of early MS patients and the association of these subsets and relapses while treated 
with Natalizumab could be of value for selecting patients for whom another therapy 
would be more effective. Furthermore these findings could help in developing more spe-
cific T cell-targeted therapies. However, first the local impact of these subsets on the MS 
brain and the antigen specificity of these subsets in brain lesions should be revealed.
The two prospective patient cohorts with adult CIS patients and paediatric ADS patients 
have been followed for up to 10 years now, and becoming more valuable as follow-up 
grows. Especially for revealing factors that predict disability and time to the secondary 
progressive phase of MS, a long follow-up time is required. Therefore it is of great im-
portance to keep following the patients in these prospective cohorts in the future. 
International collaboration is of great value to increase patient numbers, especially 
when studying such a rare entity as childhood-onset ADS. For genetic and proteomic 
studies, large sample sizes are required. These studies could help in finding new protein 
markers or genes which are associated with MS diagnosis in MS or ADS patients. It is 
crucial that the data collection is uniform, this is important to be able to pool the data 
and to draw reliable conclusions. There are guidelines available for standardised collec-
ting samples and reporting results.74, 75 Another reason why international collaboration 
is interesting is the possibility to investigating environmental factors, which may vary in 
different parts of the world. 
A relatively new topic in MS research is the gut microbiome. The gut microbiome is 
defined as the complex balance between the microbial populations in the gastrointes-
tinal tract and the immune system.76 Alterations of this microbiome may lead to dysregu-
lation of immune responses not only in the gut but also in the central nervous system. 
In experimental autoimmune encephalomyelitis, a mouse model for MS, certain intes-
tinal bacterial populations led to a more pro inflammatory condition that may result in 
developing autoimmune diseases. Whereas other intestinal bacterial populations have 
been shown to protect against inflammation in the CNS.77 Known risk factors for MS are 
smoking, vitamin D insufficiency, differences in diet and alcohol use. These risk factors 
also influence the gut microbiome.76 There is growing evidence of differences in the 
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microbiota between MS patients and controls.78 A recent study showed that transgenic 
mice transplanted with the microbiota derived from a monozygotic twin with MS had a 
higher incidence of MS-like autoimmunity than the mice who received a faeces trans-
plant from the healthy twin.79 It will be of great value to examine the microbiome early 
in the disease course, in therapy naïve CIS patients. This might lead to more diagnostic 
and prognostic markers. Exploring the microbiome in those untreated patients will 
help in understanding the pathogenesis of MS, and may contribute to develop lower 
risk therapeutic management in the future. In both the PROUD study in adults and the 
PROUD-kids study in paediatric patients, we started collecting faecal samples to study 
the microbiota in these two patient cohorts. 
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Chapter 11
SUMMARY
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS), affecting genetically susceptible individuals, influenced by environmental factors. 
In 85% of cases, the disease presents itself with clinical relapses as a result of demyeli-
nation in different parts of the CNS. Because the course of MS is highly heterogeneous, 
prediction factors at time of the first attack (CIS) are needed. The need for reliable prog-
nostic factors is even more urgent since there is a growing number of disease modifying 
therapies (DMT) available for MS. Early initiation of these therapies is favourable for the 
prevention of future relapses and disability.
The studies described in this thesis are executed within two prospective cohorts of 
adult and paediatric patients followed after a first attack of demyelination. We aimed to 
find prognostic factors for the disease course after a first attack of demyelination both 
in children and adults. 
Chapter 1 gives a short introduction on MS and describes currently known and used 
clinical, imaging and biological factors for the prediction of disease course.
The first part of this thesis focused on the disease course after CIS in adult patients. 
In 2017, the International Panel on Diagnosis of Multiple Sclerosis proposed new revi-
sions to the McDonald criteria for MS. The most important change was that with the 
new criteria dissemination in time (DIT) could be realized when unique oligoclonal 
bands (OCB) were found in the cerebrospinal fluid (CSF), this could replace DIT on MRI. 
The other change was that not only asymptomatic but also symptomatic lesions on 
MRI could contribute to DIT and dissemination in space (DIS). In chapter 2, we validated 
these criteria in 229 adult CIS patients. With these new criteria twice as many MS diag-
noses could be made at time of the first attack (97 (54%) vs 46 (26%); p<0.01). We found 
a higher sensitivity for a second attack using the new 2017 criteria than when using the 
former 2010 criteria (68% vs 36%; p<0.01). However, the specificity was lower for the 
new criteria (61% vs 85%; p<0.01). These data imply that the McDonald 2017 criteria will 
lead to a higher number of MS diagnoses in patients with a less active disease course. 
Fatigue is one of the most reported and disabling symptoms for MS patients. Chapter 3 
evaluates the long-term course of fatigue after CIS. First, we validated our previous 
finding that fatigue at time of CIS predicts a future CDMS diagnosis after adjustments 
for sex, age, ethnicity, localization of symptoms, gadolinium enhancement at baseline 
MRI, and DMT before CDMS diagnosis in 235 CIS patients (hazard ratio (HR) 2.6; p<0.01). 
After that, we showed that the fatigue scores (FSS) increased by 0.86 units after CDMS 
diagnosis (p=0.01). We demonstrated that fatigue started early in the disease course, 
already at time of CIS, and increased after a second attack. 
In chapter 4, we investigated whether the T-cell activation marker soluble CD27 (sCD27) 
measured in CSF from CIS patients predicts MS diagnosis and a high relapse rate. First 
we showed higher level of CSF sCD27 in 77 patients with CIS than in 30 control indivi-
duals. We showed that within the CIS group, high sCD27 levels were predictive for MS 
diagnosis independently of MRI and CSF measurements (HR 2.4 per 100 U/mL increase 
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of sCD27; p<0.01). Interestingly, within the group that experienced a second attack, we 
observed that patients with high sCD27 levels at time of CIS had a 5.5 times higher annua-
lized relapse rate (ARR) during follow-up after the second attack compared to patients 
with low sCD27 levels at time of CIS (ARR 0.33 vs 0.06; p=0.02). Soluble CD27 levels were 
also associated with IgG index, unique OCB in CSF, ≥9 T2 lesions and subclinical T2 lesions 
on baseline MRI. 
In chapter 5, we performed an extensive study, in different patient groups, on Th1-like 
Th17 cells (CCR6+CXCR3+), which is a subpopulation of T helper 17 cells (CCR6+), a key me-
diator in MS disease activity. We found that Th1-like Th17 cells, expressing IL-17 but also 
IFN-γ and GM-CSF, were decreased in peripheral blood from CIS patients who converted 
to CDMS within one year (CIS-CDMS) compared to CIS patients who remained monophasic 
for at least 5 years (CIS-CIS) (6% vs 11%; p=0.01). For Th1 (CCR6-CXCR3+) and Th17 (CCR6+ 
CXCR3-) cells this reduction was not seen. A reduced effector memory (EM) to central 
memory (CM) ratio was found for the Th1-like Th17 subset in CIS-CDMS patients (0.3 vs 
0.5; p<0.01). This ratio correlated with anti-EBNA1 IgG titres (p=0.01) and fatigue scores 
(FSS) (p<0.01), markers that are shown to be predictive for an early MS diagnosis. 
In blood from patients who were already diagnosed with MS, we found strongly redu-
ced frequencies of Th1-like Th17 effector memory (EM) cells compared to CIS-CIS and 
healthy controls (0.7% vs 2.8% vs 3.3%; p<0.01). In MS patients, a higher proportion of 
Th1-like Th17 cells was positive for the activation markers CD38 and HLA-DR. This was 
not seen for Th1 cells. This pleads for a selective activation of Th1-like Th17 effector cells 
in blood from patients with MS.
After that, we analysed paired CSF and blood samples from CIS and early MS patients. 
We found that the Th1-like Th17 proportion in CSF was 2- to 3-fold higher and produced 
more IFN-γ and GM-CSF than the paired blood Th17-like Th17 cells. Ex vivo experiments 
confirmed the local enrichment of Th1-like Th17 cells in the CNS, this subset was enriched 
in brain tissue from late-stage MS patients and not in brain tissue from non-demented 
controls. Next, we studied the migration of peripheral T helper subpopulations into the 
CNS. VLA-4 was the most abundant adhesion molecule on Th1-like Th17 cells, especially 
on the Th17.1 subset (CCR6+CXCR3+CCR4-). This specific subset accumulated selectively 
in blood of natalizumab (an anti-VLA-4 monoclonal antibody) treated patients. We saw 
this only in natalizumab-treated patients who remained free of relapses (relapse-free 
patients: pre-treatment 3.8% vs post-treatment 6.8%; p<0.01, patients with relapses: 
pre-treatment 3.2% vs post-treatment 4.0%). And downregulation of VLA-4 by natalizu-
mab was most prominent on Th17.1 cells. In vitro trans-well migration assays confirmed 
that Th17.1 was the main Th17 subpopulation migrating across human brain endothe-
lial layers towards the inflammatory mediator CXCL10. Furthermore, Th17.1 cells were 
enriched in CSF from CIS and early MS patients compared to paired blood samples. Also 
lower Th17.1 frequencies were seen in blood from CIS-CDMS vs CIS-CIS patients (p=0.02). 
These data demonstrate the ability of Th1-like Th17 cells, in particular Th17.1 cells to 
migrate to the CNS and influence disease activity in early MS.  
Cigarette smoking is shown to be a risk factor that influences disease course of MS 
patients. However, there are conflicting results for the predictive value of smoking for 
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MS diagnosis in CIS patients. In chapter 6, we studied the association between smoking 
at time of CIS and a subsequent CDMS diagnosis in 250 CIS patients. We found a higher 
rate of CDMS diagnoses in CIS patients who smoked at time of CIS than in non-smoking 
CIS patients (67% vs 36%; p<0.01). And smoking at time of CIS was an independent pre-
dictor for CDMS diagnosis (HR: 2.3; p<0.01). Interestingly, non-smoking CIS patients who 
had a history of smoking did not have a higher risk of CDMS than CIS patients who had 
never smoked, suggesting that the harmful effects of smoking are reversible.
Part 2 focused on the disease course after CIS in paediatric versus adult patients. 
In chapter 7, we compared disease course and clinical features at disease onset between 
107 children and 276 adults who were followed after CIS. We divided the total group 
in three age groups (1-10, 11-17, 18-50 years). Lesion load on MRI was highest in the 
11-17-year-old children. Children presented more often with polyfocal clinical symptoms 
than adults (32% vs 12%; p<0.01). We saw the highest rate of MS and CDMS conversion 
in the 11-17-year-old CIS group (84% vs 50%; p<0.01). This group also had the shortest 
time to MS diagnosis (HR: 3.2, 95%; p<0.01). Annualized relapse rates were evaluated in 
patients who were diagnosed with MS using a negative binomial regression model with 
log link. Without DMT, paediatric patients showed a higher ARR than adults (2.22 vs 0.91; 
p<0.01). However, after DMT administration ARR was the same for paediatric and adult 
MS patients (0.48 vs 0.40). These data showed a more inflammatory disease course in 
children after CIS than in adults, this argues for early initiation of DMT in 11-17-year-old 
children in line with current clinical practice in adult CIS patients. 
Based on our earlier finding in adult patients with CIS that high sCD27 levels were pre-
dictive for a future MS diagnosis, we evaluated this T-cell activation marker in 94 children 
with ADS in chapter 8. We found the same result as we found in adults described earlier 
in this thesis. High CSF sCD27 levels in paediatric ADS patients without encephalopathy 
were associated with a future CDMS diagnosis (HR 2.8 per 100U/mL increase in sCD27 
levels; p<0.01). Children with ADS and encephalopathy did not differ in sCD27 levels 
from monophasic ADS patients without encephalopathy. However, ADS patients with 
encephalopathy had lower levels sCD27 than ADS patients without encephalopathy 
who were diagnosed with CDMS during follow-up. Also in children, sCD27 levels were 
associated with OCB and IgG index. 
It has been shown that neurofilament light chain (NfL), a marker for axonal damage, in 
CSF is predictive for MS diagnosis in adult CIS patients. In children, this was not studied 
yet. Therefore we investigated the predictive value of NfL in CSF from 65 paediatric and 
88 adult CIS patients. In chapter 9, we first validated that high NfL levels were associated 
with CDMS diagnosis in adult patients with CIS (HR: 2.1; p=0.03). After that we demon-
strated that NfL was also an independent predictor for CDMS diagnosis in paediatric 
CIS patients (HR: 3.7; p<0.01). Moreover, in the group with a future CDMS diagnosis, 
children had higher NfL levels than adults at time of CIS (4888 vs 2156pg/mL; p<0.01). 
We also showed that patients with a future CDMS diagnosis and T1-hypointense lesions 
on baseline MRI, which is a sign for axonal damage, had higher NfL levels than patients 
without T1-hypointense lesions, in both adults and children (adults: 3188 vs 1588pg/mL; 
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p<0.01, children: 8920 vs 1668pg/mL; p<0.01). These results imply that children not only 
have a more inflammatory disease course than adults, as shown earlier in this thesis, 
but also that this young patient group has signs of neurodegeneration already early in 
the disease course. 
Chapter 10 discusses the main findings of this thesis and recommendations for future 
research.
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SAMENVATTING
Multiple sclerose (MS) is een chronische ontstekingsziekte van het centrale zenuwstelsel 
(CZS). Zowel genetische als omgevingsfactoren zijn van invloed op het ontstaan van 
MS. MS start bij 85% van de patiënten met klinische aanvallen als gevolg van demyelini-
satie van de zenuwen in verschillende delen van het CZS. Omdat het ziektebeloop van 
MS-patiënten erg heterogeen in ernst en prognose is, zijn er op het moment van de 
eerste aanval (CIS) factoren nodig die het ziektebeloop kunnen voorspellen. Betrouwbare 
prognostische factoren zijn erg belangrijk vanwege het groeiende aantal beschikbare 
immunomodulerende therapieën (IMT) voor MS-patiënten. Vroeg in het ziekteproces 
starten met deze therapieën voorkomt latere MS aanvallen en invaliditeit. 
De studies die beschreven worden in dit proefschrift zijn uitgevoerd binnen twee pros-
pectieve cohorten van volwassenen en kinderen die gevolgd zijn na een eerste aanval 
van demyelinisatie. Het doel van deze studies is om prognostische factoren te vinden 
die het ziektebeloop na een eerste aanval van demyelinisatie in volwassenen en kinderen 
kunnen voorspellen. 
Hoofdstuk 1 geeft een korte introductie over MS en beschrijft klinische en biologische 
factoren die nu bekend zijn en gebruikt worden voor het voorspellen van het 
ziektebeloop. 
Het eerste deel van dit proefschrift gaat over het ziektebeloop na CIS bij volwassen 
patiënten. In 2017 heeft ‘the International Panel on Diagnosis of Multiple Sclerosis’ een 
voorstel gedaan voor nieuwe revisies van de McDonald criteria voor MS. De belangrijkste 
verandering in de nieuwe criteria is dat als er unieke oligoclonale banden (OCB) worden 
gevonden in de liquor er niet meer aan spreiding in tijd (DIT) hoeft te worden voldaan. De 
andere belangrijke verandering is dat niet alleen asymptomatische maar ook symptoma-
tische afwijkingen op de MRI-scan kunnen bijdragen aan DIT en spreiding in plaats (DIS). 
In hoofdstuk 2 hebben we deze nieuwe criteria toegepast op een cohort van 229 volwas-
sen CIS-patiënten. Met deze nieuwe criteria konden twee keer zoveel MS-diagnoses
worden gesteld op het moment van de eerste aanval (97 (54%) vs 46 (26%); p<0.01). 
Wanneer we de nieuwe 2017 criteria gebruikten vonden we een hogere sensitiviteit 
voor een tweede aanval dan wanneer we de oude 2010 criteria gebruikten (68% vs 36%; 
p<0.01). De specificiteit was echter lager voor de nieuwe criteria (61% vs 85%; p<0.01). 
Deze data laten zien dat de McDonald 2017 criteria leiden tot een hoger aantal MS-
diagnoses bij patiënten met een minder actief ziektebeloop. 
Vermoeidheid is een van de meest gerapporteerde en invaliderende symptomen voor 
MS-patiënten. Hoofdstuk 3 evalueert het langetermijn beloop van vermoeidheid na 
CIS. Eerst hebben we onze eerdere bevinding bevestigd, namelijk dat vermoeidheid op 
het moment van CIS voorspellend is voor een toekomstige CDMS-diagnose. Dit was 
ook het geval na correctie voor geslacht, leeftijd, etniciteit, locatie van de symptomen, 
contrast-aankleuring op de eerste MRI en IMT voor CDMS-diagnose (hazard ratio (HR) 
2.6; p<0.01). Hierna hebben we laten zien dat de vermoeidheids-score (FSS) 0.86 punten 
hoger was na CDMS-diagnose (p=0.01). Vermoeidheid was al vroeg in het ziektebeloop, 
op het moment van CIS, aanwezig en werd erger na een tweede aanval. 
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In hoofdstuk 4 hebben we onderzocht of de T-cel activatie marker soluble CD27 (sCD27) 
gemeten in liquor van CIS-patiënten voorspellend is voor MS-diagnose en voor een 
verhoogde aanvalsfrequentie. We vonden dat binnen de CIS-groep, hoge sCD27 waarden 
voorspelden voor MS-diagnose, onafhankelijk van MRI en liquor metingen (HR 2.4 per 
100 U/mL verhoging van sCD27; p<0.01). Interessant was, dat binnen de groep die een 
tweede aanval had gekregen, patiënten met hoge sCD27 waarden op het moment van 
CIS een 5.5 keer hogere jaarlijkse aanvalsfrequentie (ARR) hadden tijdens follow-up, 
vergeleken met patiënten met lage sCD27 waarden op het moment van CIS (ARR 0.33 
vs 0.06; p=0.02). Soluble CD27 waarden waren ook geassocieerd met IgG index, unieke 
OCB in liquor, ≥9 T2 afwijkingen en subklinische T2 afwijkingen op de eerste MRI-scan. 
In hoofdstuk 5 hebben we een uitgebreide studie binnen verschillende patiëntengroepen 
gedaan naar Th1-like-Th17 cellen (CCR6+CXCR3+), een subpopulatie van T-helper 17 (Th17) 
cellen (CCR6+). Deze cellen spelen een belangrijke rol in ziekteactiviteit bij MS-patiënten. 
We vonden dat Th1-like Th17 cellen, die niet alleen IL-17 maar ook IFN-γ en GM-CSF tot 
expressie brengen, minder aanwezig waren in bloed van CIS-patiënten die binnen een 
jaar gediagnostiseerd werden met CDMS (CIS-CDMS) dan in bloed van CIS-patiënten die 
tenminste 5 jaar lang CIS bleven (CIS-CIS) (6% vs 11%; p=0.01). Voor Th1 (CCR6-CXCR3+) 
en Th17 (CCR6+ CXCR3-) cellen zagen we deze verlaagde frequentie niet. Ook vonden we 
een verlaagde effector memory (EM) / central memory (CM) ratio voor de Th1-like Th17 
subset in CIS-CDMS patiënten (0.3 vs 0.5; p<0.01). Deze ratio correleerde met de anti-EBNA1 
IgG-titer (p=0.01) en de vermoeidheids-score (FSS) (p<0.01), dit zijn beide markers die 
geassocieerd zijn met een vroege MS-diagnose. 
In bloed van patiënten die al met MS gediagnostiseerd waren, vonden we sterk verlaagde 
frequenties van Th1-like Th17 EM cellen vergeleken met CIS-CIS patiënten en gezonde 
controles (0.7% vs 2.8% vs 3.3%; p<0.01). Daarnaast was een groter deel van de Th1-like 
Th17 cellen positief voor de activatie markers CD38 en HLA-DR. Dit zagen we niet voor 
Th1 cellen. Dit pleit voor een selectieve activatie van Th1-like Th17 effector-cellen in bloed 
van patiënten met MS. 
Hierna hebben we gepaarde liquor en bloed samples van CIS en vroege MS-patiënten 
geanalyseerd. Hierin vonden we dat het deel Th1-like Th17 cellen in liquor 2 tot 3 keer 
hoger was dan in bloed en dat deze cellen in liquor meer IFN-γ and GM-CSF produceerden 
dan gepaarde bloed Th1-like Th17 cellen. Ex vivo experimenten bevestigden de lokale ver-
hoging van Th1-like Th17 cellen in het CZS: deze subset was verhoogd in hersenweefsel van 
MS-patiënten. Dit was niet het geval in hersenweefsel van controles. 
Hierna bestudeerden we de migratie van perifere T-helper subpopulaties naar het CZS. 
VLA-4 was het adhesiemolecuul dat het meest tot expressie kwam op de Th1-like Th17 
cellen, in het bijzonder op de Th17.1 subset (CCR6+CXCR3+CCR4-). Deze specifieke subset 
hoopte selectief op in het bloed van met natalizumab (een anti-VLA-4 monoclonale 
antistof) behandelde patiënten. We zagen deze ophoping in bloed alleen in natalizu-
mab-behandelde patiënten die vrij van aanvallen bleven tijdens de behandelperiode 
(aanvalsvrije patiënten: voor behandeling 3.8% vs na behandeling 6.8%; p<0.01, patiën-
ten met aanvallen: voor behandeling 3.2% vs na behandeling 4.0%). Vermindering van 
VLA-4 expressie door natalizumab werd vooral gezien in de Th17.1 cellen. 
In vitro trans-well migratie analyses lieten zien dat Th17.1 inderdaad de Th17 subpopulatie 
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was die het meest migreerde door menselijke brein endotheelcel-lagen richting de 
inflammatoire cytokine CXCL10. Daarnaast waren Th17.1 cellen verhoogd in liquor van 
CIS en vroege MS-patiënten in vergelijking met gepaard bloed. Ook zagen we verlaagde 
Th17.1 frequenties in bloed van CIS-CDMS vs CIS-CIS patiënten (p=0.02). Deze data laat 
het vermogen van Th1-like Th17 cellen, met name de Th17.1 subset, zien om op te hopen 
in het CZS en ziekteactiviteit te beïnvloeden in vroege MS-patiënten.
Het roken van sigaretten is in eerdere studies aangetoond als risicofactor die het ziekte-
beloop van MS-patiënten beïnvloedt. Er zijn echter tegenstrijdige resultaten wat betreft 
de voorspellende waarde van roken voor MS-diagnose in CIS-patiënten. In hoofdstuk 6 
is de associatie tussen roken op het moment van CIS en een toekomstige CDMS-diagnose 
onderzocht in 250 CIS-patiënten. Er was een hoger aantal CDMS-diagnoses in CIS-
patiënten die rookten vergeleken met CIS-patiënten die niet rookten (67% vs 36%; 
p<0.01). Ook was roken op het moment van CIS een onafhankelijke voorspeller voor 
CDMS-diagnose (HR: 2.3; p<0.01). Daarbij was het interessant dat niet rokende CIS-
patiënten die in het verleden wel gerookt hadden, geen hoger risico op CDMS hadden 
in vergelijking met CIS-patiënten die nog nooit gerookt hadden. Dit wijst erop dat de 
schadelijke effecten van roken reversibel lijken te zijn. 
Het tweede deel van dit proefschrift gaat over het ziektebeloop na CIS bij kinderen 
versus volwassenen. 
Hoofdstuk 7 vergelijkt het ziektebeloop en de klinische parameters op het moment 
van de eerste neurologische uitval tussen 107 kinderen en 276 volwassenen met CIS. De 
gehele groep is verdeeld in 3 leeftijdscategorieën (1-10, 11-17, 18-50 jaar). Het aantal witte 
stof afwijkingen op de MRI was het grootst in de kinderen van 11-17 jaar. Ook presenteerden 
kinderen zich vaker met polyfocale-symptomen vergeleken met volwassenen (32% vs 
12%; p<0.01). Kinderen in de leeftijd 11-17 jaar werden het meest gediagnostiseerd met 
MS tijdens follow-up (84% vs 50%; p<0.01). Ook was de tijd tot MS-diagnose voor deze 
groep het kortst (HR: 3.2, 95%; p<0.01). We hebben de jaarlijkse aanvalsfrequenties 
binnen de patiënten die gediagnostiseerd waren met MS onderzocht. Binnen de groep 
patiënten zonder IMT hadden kinderen de hoogste aanvalsfrequentie vergeleken met 
volwassenen (2.22 vs 0.91; p<0.01). Maar in de groep die behandeld werd met IMT was 
de aanvalsfrequentie tussen kinderen en volwassenen gelijk (0.48 vs 0.40). Deze data 
wijzen erop dat kinderen een meer inflammatoir ziektebeloop hebben dan volwassenen, 
dit is een argument voor het vroeg starten met IMT bij kinderen van 11-17 jaar. Dit is in 
overeenstemming met het huidige beleid in volwassen patiënten met CIS. 
Gebaseerd op onze eerdere bevinding in volwassen CIS-patiënten dat hoge sCD27 
waarden voorspellend waren voor een toekomstige MS-diagnose, hebben we deze T-cel 
activatie marker ook bekeken bij 94 kinderen met een eerste aanval van demyelinisatie 
(ADS). In hoofdstuk 8 beschrijven we dat hoge sCD27 waarden in liquor van kinderen 
met ADS zonder encefalopathie geassocieerd zijn met een toekomstige CDMS-diagnose 
(HR 2.8 per 100 U/mL verhoging van sCD27; p<0.01). Deze resultaten kwamen overeen 
met wat we ook in volwassenen vonden, zoals eerder beschreven in dit proefschrift. 
De sCD27 waarden van kinderen met ADS en encefalopathie waren hetzelfde als voor 
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monofasische ADS patiënten zonder encefalopathie. ADS patiënten met encefalopathie 
hadden lagere sCD27 waarden vergeleken met ADS patiënten zonder encefalopathie die 
tijdens follow-up gediagnostiseerd werden met CDMS. Ook bij kinderen waren sCD27 
waarden geassocieerd met de IgG index en unieke OCB in liquor. 
Uit eerdere studies bleek dat neurofilament light chain (NfL), een marker voor axonale 
schade, in liquor voorspellend is voor MS-diagnose bij volwassenen met CIS. In kinderen 
was dit nog niet eerder onderzocht. Daarom hebben we de voorspellende waarde van 
NfL in liquor van 65 kinderen en 88 volwassenen met CIS bekeken. In hoofdstuk 9 hebben 
we eerst gevalideerd dat hoge NfL waarden in liquor geassocieerd zijn met CDMS-
diagnose in volwassen CIS-patiënten (HR 2.1; p=0.03). Hierna hebben we laten zien dat 
NfL een onafhankelijke voorspeller voor CDMS-diagnose is in kinderen met CIS (HR: 
3.7; p<0.01). Daarnaast zagen we dat binnen de groep die werd gediagnostiseerd met 
CDMS, kinderen op het moment van CIS hogere NfL waarden hadden dan volwassenen 
(4888 vs 2156pg/mL; p<0.01). Ook lieten we zien dat binnen de patiënten met een toe-
komstige CDMS-diagnose, de patiënten met T1-hypointense afwijkingen op de eerste 
MRI-scan (een teken voor axonale schade) bij zowel volwassenen als kinderen hogere 
NfL waarden hadden dan de patiënten zonder deze afwijkingen (volwassenen: 3188 vs 
1588pg/mL; p<0.01, kinderen: 8920 vs 1668pg/mL; p<0.01). Dit wijst erop dat kinderen 
niet alleen een meer inflammatoir ziektebeloop hebben dan volwassenen, zoals eerder 
in dit proefschrift beschreven, maar dat deze jonge patiëntengroep ook al vroeg in het 
ziektebeloop tekenen van neurodegeneratie vertoont.
In hoofdstuk 10 worden de belangrijkste bevindingen van dit proefschrift bediscussieerd 
en worden er aanbevelingen gedaan voor toekomstig onderzoek.
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Jeanette, en Andy, dank voor de goede samenwerking, het opwerken en bewaren van 
onze samples en zeker ook voor al het droogijs dat ik door de jaren heen heb geleend. 
Collega’s van het MS centrum: Dorine, Beatrijs, Yu Yi, Julia, Daniëlle, Tessel, Naghmeh, 
Immy, Arlette, Katelijn, Louk, Rinze, Sarita, Hanne, Jacqueline, Josje, Wendy, Yvonne, Leonieke, 
Mascha, Sjoukje. Ik ben blij en trots dat ik van deze groep deel uitmaak. Dankjulliewel voor 
de goede samenwerking en (zeker even belangrijk) dank voor alle gezelligheid.
Een paar mensen wil ik in het bijzonder bedanken. Dorine, ik kan me geen betere super-
visor wensen. Ik ken niemand anders die het zo druk heeft en toch zo benaderbaar is. Ik 
waardeer je behulpzaamheid, geduld en nauwkeurigheid enorm. Dankjewel voor alles. 
Beatrijs, toen Dorine vertelde dat jij me ging superviseren moet ik toegeven dat ik een 
beetje teleurgesteld was en dat ik dacht dat je sowieso niet aan Dorine zou kunnen 
tippen. Maar ik had het mis. Ook jij stond altijd voor me klaar en ook jou kon ik altijd 
bellen met vragen. Heel veel dank daarvoor. 
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Josje, dankjewel voor je oprechte interesse en dat je me af en toe een hart onder de 
riem steekt. De honderden handtekeningen die je van me nodig had zal ik alleen niet 
gaan missen. 
Tessel, Ik heb met veel plezier de PROUD studie van je overgenomen, dankjewel voor de 
gezelligheid op de nodige culturele uitstapjes tijdens congressen en natuurlijk dankjewel 
voor je nuttige aanvullingen op mijn manuscript. 
Julia, wat was ik blij dat jij er was toen ik 4 jaar geleden begon. Je hebt gezorgd dat ik niet 
in het diepe viel, je stond altijd voor me klaar als ik weer is ergens onzeker over was of een 
vraag had. Dankjewel voor al je hulp op de poli, je kritische blik op mijn manuscripten en 
je fijne gezelschap tijdens congressen en op de 22ste. 
Daniëlle, kamergenootje, hardloopmaatje en zeker ook borrelmaatje op congressen, dank 
voor al je goede raad en gezelligheid. Ik vind het heel fijn dat ik je dadelijk weer vaker ga 
zien in de kliniek.
Lieve Yu Yi, het was zo fijn om mijn hele promotietijd lang iemand te hebben met wie ik 
alles kon bespreken. Dankjewel voor je vele baksels, de Chinese fondues bij jou thuis en 
alle koffie- en wijnmomentjes om elkaar moed in te spreken. Ik ben jaloers op je vermogen 
om alles altijd tip top te organiseren. Maar ik ben ook blij dat ik je af en toe met je beide 
benen op de grond kon zetten als je soms te hard van stapel liep en iets te veel ging lijken 
op dat kleine meisje van vroeger dat 3 uur per dag piano speelde. Jou zo ‘streng’ toe-
spreken hielp mij te relativeren. Dus dankjewel daarvoor. Dankjewel dat je mijn paranimf 
wilt zijn en dat je op deze bijzondere dag, net als tijdens onze hele promotietijd, naast me 
wil staan.
Collega’s bij de immunologie en virologie: Marvin, Jamie, Liza, Malou, Annet, Marie-José, 
Steven en Gijs. Als Yu Yi of ik weer is veel te laat kwamen aanzetten met bloedsamples 
waren jullie altijd bereid deze nog op te werken. Ik besef dat dat soms totaal niet gelegen 
kwam, dus heel veel dank daarvoor. Veel dank ook voor de gezelligheid tijdens de MS 
onderzoeksdagen, borrels en sportieve evenementen, zoals het traplopen en fietsen. 
Marvin en Jamie, dankjulliewel voor de enorme hoeveelheid werk die jullie hebben 
verricht voor het T-cel paper, en met zeer goed resultaat. Malou, dankjewel voor de 
gezellige journalclub-etentjes met Daniëlle, Julia en Yu Yi, waar je de tijd nam om aan 
ons ‘onwetende dokters’ de wondere wereld van de immunologie simpel uit te leggen. 
Marvin en Gijs, dank voor de gezelligheid, discussies en borrels op congressen.  
Mijn kamergenootjes op de 22ste, dat zijn er nogal wat door de jaren heen: Laurike, 
Harmke, Marienke, Yu Yi, Louk, Agnes, Daniëlle B, Bianca, Esther, Christine, Daniëlle v P, 
Carina, Joyce, Sonja, Jeroen, Farren, Christa, Amaia, Marieke, Naziha, Alex, Merel, Krista, 
Melissa, Kim. Lunchen, liters koffie en thee, heel veel kletsen, taart eten tijdens 
brandoefeningen, nog meer taart eten, uit eten, borrels, foute (apres-ski) muziek op 
vrijdag om 4 uur, en feestjes. Het is een beetje een kippenhok met zoveel vrouwen op 
een kamer, maar ik vind persoonlijk niks mis met een goed kippenhok. Ik heb genoten 
van mijn tijd met jullie op de kamer.
Laurike, Harmke en Daniëlle, dankjulliewel voor de heerlijke klaverjasavondjes; ondanks 
dat het klaverjasspel aan het uitsterven is, zullen wij deze traditie nog lang in stand 
houden. E
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Epilogue
Agnes, Marienke en Daniëlle, jullie waren hele fijne tafelgenoten, dank voor alle goede 
gesprekken en ik heb genoten van onze dagelijkse lunchmomenten. Lieve Daniëlle, de 
afgelopen jaren hebben we veel lief en leed gedeeld, ik ben ontzettend blij dat jij mijn 
paranimf wilt zijn.
Ook de andere arts-assistenten en neurologen bedankt voor de goede vrijdagmiddag 
borrels, tennistoernooien, assistentenuitjes en de jaarlijkse Babinski-reisjes.
Lieve (schoon) familie en vrienden, ik wil jullie bedanken voor de interesse die jullie 
toonden in mijn onderzoek maar vooral ook voor de nodige afleiding. Sophie, je bent 
mijn liefste zusje maar ook mijn beste vriendin. Ik kan me niet voorstellen dat dat ooit 
zal veranderen. Papa en mama, dank jullie wel voor jullie onvoorwaardelijke steun bij 
alles wat ik doe. En papa, ik ben vereerd dat jij de kaft van mijn boekje hebt getekend en 
ook wil ik je heel erg bedanken voor het opmaken van mijn proefschrift.
Lieve Mart, als ik het af en toe allemaal niet overzie ben jij er altijd om me te helpen 
relativeren, je nuchtere kijk op de wereld heeft me, vooral de laatste maanden, enorm 
geholpen. Ik wil je ook bedanken voor het lezen van mijn manuscript en je hulp bij het 
bedenken van een goede titel. Ik bewonder je creativiteit, en bijna onuitputtelijke 
energie. Ik kijk uit naar de rest van ons leven samen.
207
LIST OF ABBREVIATIONS
ADEM Acute disseminated encephalomyelitis
ADEM-ON ADEM followed by relapsing optic neuritis
ADS Acquired demyelinating syndromes
ADS+ ADS with encephalopathy
ADS- ADS without encephalopathy
AID Autoimmune disease
AIDS Acquired immunodeficiency syndrome 
AUC Area under the curve
AQP4 Aquaporin-4
ARR Annualized relapse rate
BMI Body mass index
CCR C-C chemokine receptor
CD Cluster of differentiation
CDMS Clinically definite multiple sclerosis
CHI3L1 Chitinase 3 like 1
CI Confidence interval
CIS Clinically isolated syndrome
CM Central memory
CNS Central nervous system
CSF Cerebrospinal fluid
CXCR CXC chemokine receptor 
DIS Dissemination in Space
DIT Dissemination in Time
DMT  Disease modifying therapy
DNA Deoxyribonucleic acid
DP Double positive
EAE Experimental autoimmune encephalomyelitis
EDSS Expanded disability severity scale
EBV Epstein-Barr virus
ELISA Enzyme-Linked Immuno Sorbent Assay
EM Effector memory
FACS Fluorescence activated cell sorting
FCS Fetal calf serum
FLAIR Fluid-attenuated inversion recovery
FN False negative
FP False positive
FSS Fatigue severity scale
FU Follow-up
GEE Generalized estimating equations
GM-CSF granulocyte macrophage colony-stimulating factor
GWAS Genomic-wide association study
HADS Hospital Anxiety and Depression Scale
HC Healthy control
HR Hazard ratio
HLA Human leukocyte antigen
IFN Interferon
IgG Immunoglobulin G Ep
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IL  Interleukin
IPMSSG  International Pediatric Multiple Sclerosis Study Group
IQR  Inter quartile range
IRIS  Immune reconstitution inflammatory syndrome
KFLC  Kappa free light chains
LFLC  Lambda free light chains
LP  Lumbar puncture
MC  Medical centre
MFI  Median fluorescent intensity
MRI  Magnetic resonance imaging
MS  Multiple sclerosis
N  Number of patients
NA  Not applicable
NfL  Neurofilament light chain
NS  Not significant
NMO  Neuromyelitis optica
NMOSD  Neuromyelitis optica spectrum disorders
NPV  Negative predictive value
OCB  Oligoclonal bands
OCT  Optical coherence tomography
ON  Optic neuritis
OND  Other neurological diseases
OR  Odds ratio
pg  picogram
PML  Progressive multifocal leukoencephalopathy
PPMS  Primary progressive multiple sclerosis
PPV  Positive predictive value
PDW  Proton-density-weighted
PROUD  PRedicting the OUtcome of a Demyelinating event
PROUDkids PRedicting the OUtcome of a Demyelinating event in children
RA  Rheumatoid arthritis
RIS  Radiologically isolated syndrome
RNFL  Retinal nerve fibre layer
ROC  Receiver operating curve
RR  Relative risk
RRMS  Relapsing remitting multiple sclerosis
SC  Symptomatic control
sCD27  Soluble CD27
SD  Standard deviation
SE  Spin-echo
SLE  Systemic lupus erythematosus
Th  T helper 
TM  Transverse myelitis
TN  True negative
TP  True positive
SPMS  Secundary progressive multiple sclerosis
VEP  Visual evoked potential
VLA-4  Very late antigen-4
WBC  White blood cell count
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